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Abstract 
This work aims to demonstrate the use of oral-fluid methods in evaluating the 
effectiveness of a vaccination programme at the individual (vaccine conversion) and 
population levels (herd immunity and virus transmission and origin) within a developing 
country context. The setting for this work was Ethiopia- a country beset with huge 
economic, social and logistical difficulties in vaccine programme implementation. The 
study comprises the following: First, the development and evaluation of highly sensitive 
measles specific IgG/IgM ELISAs using oral-fluid, second, the application of these 
assays to evaluate routine and campaign measles vaccination programmes, and third 
genotyping of measles virus strains circulating in the country, again using oral-fluid 
samples. 
Paired blood and oral fluid samples were obtained from787 individuals of all ages from 
rural Ethiopia for evaluation of the measles enhanced IgG antibody capture (GAC) 
enzyme linked immunosorbent assay (ELISA). Relative to serum, oral fluid assay 
sensitivity and specificity were: 97.4% and 91.1% for measles IgG. This work is the 
development and evaluation of a new method that has contributed scientifically to 
vaccination programme evaluation and refinement. 
Pre- and post-vaccine antibody determined in 296 children attending for routine measles 
immunization in Addis Ababa suggested the average vaccination age at which 92.6% 
(200/216) seroconversion rate attained was about nine and half months. Oral-fluid based 
testing show 87.3% (185/212) seroconversion rate for IgM antibody compared to the 
92.6% serconversion rate for serum. This work included the development and use of an 
oral-fluid enhanced MACELISA as a useful substitute to serum in evaluating vaccine 
seroconversion. 
RT-PCR was performed for oral-fluid and serum samples collected from outbreaks and 
sporadic measles cases across the country to study the molecular genotype characteristics 
of the strains. Sequence analysis of outbreaks and sporadic case samples revealed that the 
viruses of the D4, D8 and B3 genotypes were found in the country. This study also 
demonstrates the practicality of integrating oral-fluid based genotyping into measles 
surveillance efforts. 
Pre-campaign survey work carried out in Assella town by collecting oral-fluid samples 
from 1928 children aged 9-59 months visiting vaccination stations, and post-campaign 
survey work undertaken by cluster-based random sampling of 750 oral fluid samples 
from eligible individuals aged between 9 months to <20 years clearly show (i) a shortfall 
in measles 'immunity 'in the target age group (9-59 months), and (ii) a significant deficit 
in 'immunity' in those too old to have received the vaccine. This work demonstrates for 
the first time the merit of oral-fluid sampling in evaluating a measles vaccine campaign. 
The main achievements summarized above, give weight towards the practicality of using 
oral fluid in evaluating and refining immunization programmes in the developing country 
setting. It waits to be seen if the non-invasive technology will gain wider support in the 
measles control activities. 
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INTRODUCTION 
1. OVERVIEW 
The burden of measles is estimated to be 30 million cases and nearly one million related 
deaths each year (WHO, 1999). In Ethiopia, the Ministry of Health (MOH) estimated 
55,000 children under 5years of age die from measles and its complications every year 
(MOH, 1998). 
Key strategies for the local elimination/total eradication of measles as a disease are as 
follows. The spread of measles infection through a population requires that a chain of 
infectives should be maintained. Protection against this spread of infection can be taken 
at two points. First, the route from suscepibles to recovereds can be short-circuited by the 
establishment of immunization (Hinman, 1966; Spink, 1978). Second is to interrupt the 
mixing of infectives and susceptibles with protective barriers (e. g. isolation) (Curtin, 
1985). The greatest potential is with vaccination. 
Acquired immunity after measles illness is permanent. Live attenuated measles virus, 
when administered at recommended ages, produces about 85% immunity after one dose 
and greater than 90% immunity after two doses (Hull et al., 1983; Strebel, 1998; Cutts et 
al., 1999). Vaccine-induced immunity is long lasting and protective to all the diverse 
geographic origin strains. Widespread vaccination has resulted in interruption of measles 
virus transmission in a number of countries. For instance, the Gambia in 1968-69, the 
English speaking Caribbean islands, Cuba, Chile, the USA over short periods in 1993, 
1995, and 1996 (de Quadros et al., 1988; Bellini and Rota, 1998). Similar achievements 
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were obtained in England and Wales through 1995-2000 (Ramsay et al., 2003). The 
success of recent mass vaccination campaigns in these countries has suggested that global 
eradication of measles may be possible. Reaching this goal will require continued 
commitment to increase vaccination coverage levels with a co-coordinated global effort. 
WHO targeted measles elimination by the year 2000 in the American region, by 2007 in 
the European region and by 2010 in the eastern Mediterranean region (CDC, 1999). The 
WHO current policy to the region of Africa is adopting a strategy aiming to raise routine 
vaccine coverage to at least 80% and using supplemental campaigns in non-polio- 
reservoir countries by 2003 (WHO-Afro, 2000). 
Laboratory investigation will play a critical role in monitoring the success of measles 
control strategies and as we shall see this role will require the development of more 
sensitive diagnostic methods suitable for diagnosis and surveillance, genetic analysis of 
measles strains and a technology which is transferable worldwide. 
Measles diagnosis relies increasingly on serological tests (Arista et al., 1995). Serum 
based diagnosis can be made by virus isolation, by demonstration of a significant increase 
in specific immunoglobulin G (IgG) titers, or by the detection of anti-measles virus (MV) 
IgM antibodies by using radio-immunoassays (RIA), enzyme-linked immunosorbent 
assays (ELISAs) and direct or indirect fluorescence-antibody techniques (Perry et al., 
1993; Arista et al., 1995; Samuel et al., 1998; Lee et al., 1999; Nigatu et al., 1999). 
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The effectiveness of an immunization programme can be evaluated though serological 
survey methods. The need for techniques that obviate the requirement for blood sampling 
promotes the application of oral-fluid based methods to the evaluation of the 
immunization programs. Oral-fluid based testing has an advantage of convenience, 
avoidance of inadvertent transmission of blood-borne pathogens, ease of use in paediatric 
and geriatric populations; as well as the potential for blood-free home and work place 
collection of patient samples. 
To facilitate the use of oral fluid in measles diagnosis an IgG and IgM capture ELISA has 
been developed (Chapter 2,3). Demonstration of the utility of oral fluid in 
epidemiological studies and measles vaccination evaluation utilizing these methods is 
described in this thesis (Chapter 3,6). The use of molecular epidemiology in the 
control/elimination of measles infection by monitoring the virus circulation is also 
undertaken in this research work (Chapter 4,5). 
H. OBJECTIVES OF THE STUDY 
Of the "ten elements of surveillance" summarized by WHO (1968) at least in six of them 
viza viz, morbidity reporting, epidemic reporting, laboratory investigations, individual 
case investigations, epidemic field investigations and surveys, the laboratory has a role in 
providing serological results for measles surveillance. This indicates that the general 
advantages of measles surveillance data depend in large part on laboratory results. The 
requirement of blood specimens for laboratory results can limit the yield of data for 
measles surveillance. In this respect we need another source of human biological material 
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for measles surveillance, which is inexpensive and simple to collect, acceptable to donor 
and collector and provides accurate representation of serological status. 
Oral fluid has been explored as a source of human biological material for surveillance of 
viral diseases (Parry et al., 1987). It has clear advantages over venipuncture in 
surveillance and epidemiology of viral diseases. In the UK, oral-fluid sampling and 
screening has been used for the surveillance of measles, mumps and rubella (MMR) since 
1994 (Ramsay et al., 2003). This has permitted the impact of MMR vaccination 
programme to be monitored and evaluated in a way which may not have been possible 
through blood collection alone. 
Measles serological surveys could play a role in the evaluation of immunization 
programmes (Babad et al., 1995; Cox et al., 1998). Immuno-serological cross-sectional 
measles surveys have particular importance to determine immunization programme 
strategy in relation to age groups, geographic areas, socioeconomic groups and risk 
population groups. Follow-up serological measurements in measles immunized persons 
has importance to determine the proportion developing immune responses, quality and 
extent of response, duration of response and level of protection against measles infection. 
Periodic measles serological surveys have advantage to identify groups who are not 
receiving measles vaccines or who have inadequate responses. The importance of 
seroepidemiology for such purposes is paramount although the necessity for venipuncture 
reduces the ease and acceptability of this method. New methods that obviate the 
requirement for blood sampling could further encourage the application of measles 
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serological surveys for the evaluation of measles immunization programme. To achieve 
the aforementioned roles at better performance this thesis work was undertaken for 
measles vaccination programme evaluation and surveillance based on oral-fluid 
collection and screening methods. The purpose of this thesis is, therefore, to explore the 
development and evaluation of oral fluid as a diagnostic specimen for measles virus with 
particular reference to the developing country setting. The technologies developed (see 
A2, appendix attached to Chapter 2) have increased the level of sensitivity and specificity 
where salivary examination for measles IgG and IgM is practical and convenient. Using 
PCR technology we found oral-fluid from measles cases to be useful in the molecular 
characterization of measles virus. Success of the measles vaccination programme can be 
assessed using oral fluid specimens as markers of sero-conversion. 
The thesis specifically aims to achieve the following: - 
1. The development of a GACELISA for the detection of measles specific IgG in oral- 
fluid, with performance (sensitivity and specificity) that makes it suitable for 
replacement of serum assays, particularly for estimating population immunity. 
2. The development of a MACELISA for the detection of measles specific IgM in oral- 
fluid, suitable in performance to replace serum assays. 
3. Demonstration of the use of these assays in the estimation of measles antibody 
(immunity) prevalence in the vaccine-targeted population and in monitoring the 
outcome of a measles vaccination programme (routine and campaign) in a developing 
country setting. 
4. Demonstrate the utility of oral fluid to study the molecular epidemiology of measles 
virus in a developing country in a period of accelerated measles control. 
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Community surveys of measles specific IgG/IgM are useful to guide the design of 
measles control programmes. For example these help in (a) defining levels of immunity 
to measles pre- and post-vaccination efforts, i. e. assessing the effectiveness of the 
vaccination programme, (b) identifying age groups in which a significant susceptible 
proportion remain, (c) assessing sero-conversion rates following vaccination. Analysis of 
the genetic characteristics of wild-type measles helps to elucidate the origin and 
transmission pathways of measles virus (Rota et al., 1996). The genetic data when 
analysed with other epidemiological data provides a means to assess the efficacy of 
measles control programmes. For such molecular studies measles RNA can be detected 
by RT-PCR from isolates, oral fluid, blood, throat-swabs, urine collected from acute 
cases. There have been no systematic studies made to evaluate the relative sensitivity of 
these different samples. The primary role of this study is in the demonstration of the use 
of oral fluid as a clinical specimen for detecting IgG/IgM antibody for evaluating measles 
control strategies and the virus genome for molecular epidemiological studies. 
The thesis has 7 chapters. Chapter 1 reviews the literature on issues of measles virus and 
immunization strategies. This is followed in Chapter 2 by description of the development 
of a GACELISA for the detection of measles specific IgG in oral fluid. Chapter 3 
presents a study of pre- and post-vaccine status of measles antibody in infants using 
serum and oral-fluid testing: an evaluation of routine immunization in Addis Ababa, 
Ethiopia. The basis for this evaluation is in part a novel enhanced MACELISA for the 
detection of measles specific IgM in oral fluid. An analysis of measles viruses circulating 
in Ethiopia during 1998-9, in which a new genotype is identified, is presented in Chapter 
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4. In Chapter 5 the serological and molecular characterization of measles virus outbreaks 
reported in Ethiopia during 2000 - 2002 is presented. Results of an evaluation of a 
measles immunization campaign using oral-fluid antibody surveys are presented in 
Chapter 6. Chapter 7 presents some future developments and applications of measles oral 
fluid methods. It has two parts (1) future technical developments (2) future wider 
applications of oral-fluid methods. 
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CHAPTER 1 
LITERATURE REVIEW 
1. MEASLES VIRUS 
1.1.1 Classification and morphology 
The position of the measles virus is presented in the Seventh Report of the International 
Committee on Taxonomy of Viruses (ICTV) (van Regenmortel et al., 2000). A basic 
division is made between families whose member viruses have deoxyribonucleic acid 
(DNA) or ribonucleic acid (RNA) as their genetic material. The Paramyxoviridae is an 
RNA family that the measles virus belongs. The measles virus is not distinguishable from 
other members of the paramyxovirus family by electron microscopy (Cliff et al., 1993). 
Measles virions are spherical, enveloped particles with a helical nuleocapsid (Norrby, 
1964). The diameter of the pleomorphic particles varies between 100 and 250 nm. The 
envelope carries surface projections (peplomers) with a length of 9-15nm. There are two 
different peplomers, which have distinct morphologies: the haemagglutinin (H) 
peplomers appear conical, whereas the fusion (F) peplomers are shaped like dumbbells 
with ends of unequal size. On the inside surface of the envelope is the matrix (M) protein, 
which is thought to interact with the peplomers and with the nucleocapsid and to play a 
key role in virus maturation. Purified matrix (M) protein appears as short, tubular 
structures with a width of 8 nm. The nuleocapsid has a helical structure with a diameter 
of 17-18 nm. The nucleocapsid is packed within the envelope in the form of a 
symmetrical coil of undefined nature. 
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1.1.2 Measles clinical features 
Figure 1.1. Time course (as day 0 is assumed the onset date of rash) of clinical events in 
measles disease (temperature given in °F, where 38 °C = 100.4 °F). (Source: Modified 
from Cliff et al, 1993) 
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The incubation period is usually 10 days (and can range from 7 to 18 days) from 
exposure to onset of fever. This is the period of maximum respiratory transmission to 
susceptible individuals. Prodromal fever, conjunctivitis, coryza, cough and Koplik spots 
on the buccal mucosa characterize the disease. A characteristic red rash (maculo-papular 
erythematous rash) appears on the third to seventh day, beginning on the face, becoming 
generalized and lasting four to seven days. The period of communicability continues for 4 
to 5 days after rash onset, although the patient is then less infectious. The time course of 
clinical events in measles disease is shown in Figure I. I. 
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1.1.3 Natural infection 
Measles virus enters through the respiratory tract and is carried by lymphocytes to the 
regional lymph nodes. It then spreads from cell to cell and is transported by wandering 
macrophages or lymphocytes to the reticulo-endothelial system. Activated thymus- 
dependent lymphocytes form a line of sensitized cells capable of reacting with measles 
antigen. T-cells then react with the infected cells liberating virus into the extra-cellular 
fluids where it stimulates B-lymphocytes to produce antibody. Once released from cells 
virus is disseminated by the blood stream to the skin, mucous membranes and other 
tissues where it proliferates. Large numbers of thymus-dependent immunocytes follow 
and give rise to a delayed-hypersensitivity reaction manifesting as the clinical syndrome 
of measles. 
1.1.4 The immune response to measles infection 
Cell-mediated immune responses appear to be important in both the pathology and 
recovery from measles disease. It is required to clear measles virus infection. However, 
both humoral and cell-mediated immunity appear to be capable of preventing infection in 
normal individuals exposed to the virus. Measles-specific immune suppression begins 
with the onset of clinical disease, before the rash, and continues for many weeks after 
apparent recovery. Antibodies are first detectable when the rash appears. The life-long 
protection results from natural infection in large, relatively dense populations (Black, 
1966). IgM antibodies are produced initially, followed by IgG and IgA in serum and 
secretions. IgM antibodies peak at 7-10 days after rash onset and fall rapidly, rarely being 
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detected more than 8 weeks after rash onset (Pederson et al., 1996; Bouche et al., 1998). 
The presence of IgM is generally accepted as evidence of primary measles infection (by 
wild or vaccine virus). IgG antibody peaks about 2 weeks following rash onset and 
subsequently declines, but is detectable for years after infection. 
1.1.5 Growth in cell cultures 
This review is based on my present work experience at CPHL (see Chapter 2) with 
reference to other studies cited in the text. While humans are the only hosts, measles can 
be propagated in vitro in cell cultures and lines. Virus can be isolated successfully from 
respiratory secretions and blood during the prodromal phase up to about the first or 
second day of rash using human kidney cell cultures (Enders and Peebles, 1954). 
Available reports show that human embryo kidney and monkey kidney were equally 
sensitive for the primary isolation of measles virus (Matumoto, 1966). The virus can also 
readily be isolated from blood and respiratory secretions obtained during the catarrhal 
prodrome and on the first day of the rash if inoculated into primary cultures of human or 
monkey renal cells (Enders et al., 1957; Enders, 1962). After adaptation to these cells, 
conversion to growth in continuous cell lines seems to be reasonably easy. It can 
successfully be propagated in a wide variety of cells which include human amnion, dog 
kidney, bovine kidney, conjuctival cells, human liver, and chick embryo (Bech, 1958; 
Mutai, 1959; Gendelman et al., 1984). Measles virus grows in continuous line cells of 
human origin such as FL, AV-2, HEP-2, KB, and HeLa, and also the simian cell lines 
BSC-1 and MS (Dekking and McCarthy, 1956; Black et al., 1956; Kohn and Yassky, 
1962). Recent works show success of the method of isolation of the virus from clinical 
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specimens (primary isolation) using an Epstein-Barr virus-transformed marmoset B 
lymphoblastoid cell line, B95a (Kobune et al., 1990). 
Multiplication of MV produces characteristic changes in cell cultures. The main features 
being development of multi-nucleated cells or syncytia, formation of cytoplasmic and 
intranuclear inclusion bodies, and vacuolization of cytoplasm with slow destruction of the 
cell sheet. In HEp-2 or FL cell cultures inoculated with more than one virus particle per 
cell, intracellular virus is first detected after 12 to 18 hours and increases until 24 to 48 
hours (Bellini and Rota, 1995). Virus release into the fluid medium begins at about 30 
hours and increases until 36 to 48 hours. After a plateau of several days, both titers 
decline. With a small inoculums or inoculation at the time of implanting the cells, the 
phase of growth and decline of infective virus are somewhat prolonged. 
1.1.6 Differential diagnosis 
The non-specific nature of the prodromal signs and the existence of mild cases make 
clinical signs unreliable as the sole diagnostic criteria of measles disease. Misdiagnosis of 
measles is, for example, more common among young infants, and outbreak associated 
cases are more likely to be laboratory confirmed than sporadic cases (Ramsay and 
Emond, 1978; Ramsay et al., 2003). Measles may resemble infections with rubella, 
dengue fever, ECHO, coxsackie, parvovirus B19 and herpes virus 6 viruses, as well as 
some bacterial and rickettsial diseases (Nur et al., 1999). Moreover, there are other 
conditions that may present in a similar form, including Kawasaki's disease, toxic shock 
and drug reactions. Selection of appropriate testing algorithms will depend upon the 
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prevalence of these conditions in countries, and the availability of adequate laboratory 
services. Countries in the elimination phase with successful measles immunization 
programmes are finding that a high percentage of suspected measles cases are due to 
rubella (WHO, 1999). As measles and rubella may be coincidentally eradicated with use 
of MMR vaccine, testing negative measles serum samples for rubella will provide useful 
information for rubella surveillance. 
1.1.7 Immunological detection of measles infections 
Measles virus can be detected from various clinical samples by using serological 
methods, cell cultures techniques or molecular techniques. Samples that can be collected 
at different stages of the measles infection for virus isolation and serological tests are 
outlined in Table 1.1. 
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Table I. I. Samples for laboratory diagnosis of measles virus infections*. 
Virus disease Samples for virus Samples for serology Remarks 
isolation for detection of 
antigen 
Acute measles Blood (leukocytes), Acute and convalescent Period of infectivity; 
throat secretions serum prodromal stage until 1- 
(saliva/oral-fluid), 2 days after rash; 
conjunctival secretions, antibody rises occur at 
urine; skin biopsies appearance of rash; in 
tropical measles, 
possibly prolonged virus 
excretion also in stools 
Measles pneumonia Blood (leukocytes), Acute and convalescent Frequently no rash; 
throat secretions, serum prolonged period of 
conjunctival secretions, infectivity 
urine 
Acute measles Brain specimen (biopsy Serum and CSF In most cases, no 
encephalitis or autopsy specimen), infectious virus is 
cells in CSF detectable; occasional 
local production of 
antibodies in the CNS 
SSPE Brain specimen (biopsy Serum and CSF Virus antigen detected 
or autopsy specimen), in CSF cell; virus 
cells in CSF, lymph isolation requires 
node biopsy (? ) propagation of explants 
cultures and 
cocultivation with 
susceptible cells; hyper- 
immune antibody 
response; local 
production of antibodies 
in the CNS 
* Source : Modified from Norrby E and Oxman MN. Measles virus. In: Fields BN et al., eds. Virology, 
Second edition. New York: Raven Press, Ltd. 1990, pp. 1033, Table 5. 
The following is a summary of identification methods available for laboratory diagnosis 
of measles infection. 
1.1.7.1 Serological assays 
Measles infection is diagnosed serologically by 1), detecting measles specific IgM 
antibodies; or 2), quantifying measles specific immunoglobulins in order to demonstrate a 
significant rise in IgG between paired acute and convalescent sera. 
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1.1.7.1.1 Measles Specific IgM Antibodies 
IgM produced on primary vaccination declines more rapidly than IgM produced in 
response to the wild virus. Vaccine and wild virus IgM cannot be distinguished by 
serological tests. A vaccination history is therefore essential for interpretation of test 
results. The following methods are commonly used to detect measles-specific IgM. 
" IgM capture ELISA, requires only one blood sample for case confirmation. Assays 
show 97% sensitivity compared with the plaque reduction neutralization test (PRNT) 
in detecting infection in vaccinated infants (Erdman et al., 1991). In clinically 
confirmed cases, the sensitivity and specificity of capture assays were 91.8% and 
98.2% respectively, while the positive and negative predictive values were 98.2% and 
92.0% respectively (Arista et al., 1995). Capture ELISA assays are considered 
superior to indirect assays, since they do not require the removal of IgG antibodies. 
Several capture IgM ELISA kits are commercially available. 
" 1gM indirect ELISA, requires only one blood sample for case confirmation. In 
clinically confirmed cases, the sensitivity and specificity of indirect assays were 
90.3% and 98.2% respectively, while the positive and negative predictive values were 
98.2% and 90.5% respectively (Arista et al., 1995). Indirect ELISA assays are the 
most widely used. However, this type of assay requires a specific step to remove IgG 
antibodies. Problems with the incomplete removal of the IgG can lead to inaccurate 
results. 
" Serologic tests are effective in identifying cases of SSPE (Table 1.1). Patients with 
this disease have serum antibody titers, which are 10-100 times higher than those seen 
35 
in late convalescent-phase sera. There is pronounced local production of oligoclonal 
measles virus antibodies in the CNS (Vandvik et al., 1973). 
1.1.7.1.2 Measles Specific IgG Antibodies 
" Several capture and indirect IgG ELISA kits are commercially available. 
9 Recently newer capture ELISA methods specific for IgG and IgM of measles virus 
that have about 97% sensitivity and about 90% specificity have been developed at 
CPHL, London, UK, and CDC, Atlanta, USA, for detecting measles infection using 
oral fluid (Helfand et al., 1996; Nigatu et al., 1999). 
1.1.7.1.3 Quantification of Measles-specific immunoglobulins 
" Virus neutralization, the plaque reduction neutralization test (PRNT), requires two 
serum samples, acute and convalescent, and shows 100% sensitivity in confirming 
clinical measles. Single titers of greater than 120 are consistent with 100% protection 
against clinical measles (Chen et al., 1990; Ratnam et al., 1995; Lee MS et al., 1999). 
0 Haemagglutination inhibition (HI) requires two serum samples, acute and 
convalescent, and shows 98% sensitivity in detecting antibody increase in vaccinated 
students and 100% sensitivity in vaccinated infants (Kalter et al., 1991). 
Generally complement fixation methods and radio-immunoassays (RIA) have been 
developed as the most useful method in the past employed with diagnosis of measles. 
(Perry et al., 1993). 
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1.1.7.2 Virus isolation 
The growth of measles virus in cell culture is mentioned previously in detail. The virus 
can be cultured with difficulty from urine, nasopharyngeal or oral-fluid specimens or 
peripheral blood lymphocytes during the prodrome and rash stages of the disease (Table 
1.1). Thereafter virus excretion declines rapidly. Detection and identification of the virus 
in cell culture may take several weeks. Possession of a measles virus isolates permits 
genomic analysis and comparison with other strains from different locations and years, 
providing information on its origin and transmission history. 
1.1.7.3 Reverse transcription polymerase chain reaction (RT-PCR) 
Amplification of measles RNA after reverse transcription (RT-PCR) is done in 
specialized laboratories and can be use for measles surveillance programmes. 
II. MOLECULAR BIOLOGY OF MEASLES VIRUS 
11.1.1. Genomic structure 
The measles negative-sense non-segmented (single-stranded) RNA genome consists of 
six transcription units (Figurel. 2), which generates the mRNAs for six structural and two 
non-structural proteins (Barrett et al., 1991). Three structural proteins are complexed with 
viral RNA, and the other three structural proteins participate in the formation of the virus 
envelope (Table 1.2). The major internal component is the phosphorylated N 
(nucleocapsid) protein. This has a molecular weight (MW) of approximately 60 kd. The 
other internal virion components are the L (large protein or polymerase) and P 
(phosphoprotein) which are present only in limited quantities. The P protein shows a high 
degree of sensitivity to proteolytic enzymes. The envelope components consist of the M 
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(matrix) protein and the H (haemagglutinin) and F (fusion) peplomers. The M protein has 
MW of 36-37 kd, with some size variation in different virus strains (Wechsler, 1982). 
The glycosylated H protein has MW of 79 kd. The F protein is synthesized in a precursor 
form as a glycoprotein with MW of 55-60 kd (Graves et al., 1978; Ogura et al., 1988). 
The mRNA for the P-protein also encodes, in an overlapping reading frame, the non- 
structural C protein and V protein (Bellini et al., 1985). The functional importance of 
these structural proteins is mentioned in Table 1.2. Research shows Baculovirus 
expression of the nucleoprotein genes of measles virus and utility of the recombinant 
protein in diagnostic enzyme immunoassays (Hummel et at., 1992). The in-house 
Microimmune measles specific IgG and IgM oral-fluid capture assays developed at 
CPHL demonstrated the importance of nucleoproteins in immunological assays. The IgG 
assay was used to undertake the work mentioned in Chapter 6. 
The entire measles virus genome has been sequenced and it contains about 15,900 
nucleotides (Rota et al., 1995), but the exact number varies between virus strains and 
even between viruses of the same strain with different passage histories. Sequence of the 
nucleotide genome shows genetic hetrogeneity for the N, F, H, M, P and L genes (Taylor 
et al., 1991; Baczko et al., 1991; Komase et al., 1995; Rima B et al., 1995a; 1995b). The 
highest degree of variation is found in the C terminus of the N and H genes (Taylor et al., 
1991). The sequence of the C-terminal 151 amino acids of the N protein analyzed in 18 
MV strains show up to 7.2% divergence in the nucleotide sequence and 10.6% 
divergence in the amino acid sequence between the most unrelated strains (Taylor et al., 
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1991). Compared to the H and N genes, the F, M, and L genes of the wild-type MVs are 
relatively conserved (Komase et al., 1995; Rota et al., 1992). 
Table 1.2. Structural components of the measles virus 
Component MW (kd) Virion location Function 
N-nucleoprotein 60 Dominating internal Protects viral RNA 
protein 
P-polymerase(phospho) 72 Internal; associated with Probably part of 
protein N transcription complex 
L-large protein 180-200 Internal; associated with Part of the transcription 
N complex 
M-matrix 36-37 Inside virion envelop Assembly of virions 
H-haemagglutinin 79 Transmembranous Adsorption to nucleated 
envelope glycoprotein cells and erythrocytes 
F-fusion factor 41(F1) and 18-20(F2) Transmembranous Cleaved protein; active 
envelope glycoprotein in fusion of cells, 
haemolysis, and virus 
entry 
11.1.2. Genetic diversity of MV and geographical distribution of genotypes 
MV is serologically monotypic (Rota et al., 1994). However, genetic heterogeneity exists 
among MVs and provides a basis for the study of their molecular epidemiology. 
Sequencing of the MV nucleoprotein (N) and haemagglutinin (H) genes is used to assign 
MVs to one of eight clades, designated A to H. Clades B, C, D and G are further 
subdivided into genotypes B1, B2 and B3, C1 and C2, D1 to D8, G1 and G2, respectively 
(Chibo et al., 2000). Clades are used to indicate the relationship between the various 
gentypes. The genotype designations are the operational taxonomic units. A unified 
nomenclature guideline for MV strains and a definition of their genotypes has been 
proposed by WHO (WHO, 1998; 2001). 
The virus is distributed worldwide, and molecular genotyping procedures have been able 
to demonstrate significant differences between isolates from different locations (Bellini 
39 
and Rota, 1998). The following table shows the geographical distribution of measles 
virus genotypes. 
Table 1.3. Measles virus genotype distribution worldwide (Source: Rota et al., 1994; Bellini and 
Rota, 1998; WHO, 1998; 2001; Chibo et al., 2000 etc. ) 
Genotype Discription 
A vaccines, pre-vaccine and recent wts 
B1 Africa, USA 
B2 Africa, USA 
B3 Nigeria, Ghana, Sudan, Congo, Gambia, Cameroon, USA 
CI Japan 1984, Germany 1992 
C2 Morocco, Western and Central Europe, USA, Brazil, UK, Australia 
D1 Australia, UK 1974, INACTIVE* 
D2 South Africa, Zambia 
D3 Japan, Philippines 
D4 South Africa, USA, Pakistan, Iran, India, Ethiopia, Australia, Russia 
D5 Malaysia, Australia, Japan, Thailand 
D6 Western and Central Europe, USA, Brazil, UK, Argentina, Chile, Turkey 
D7 Australia (Victoria), Europe, Germany 
D8 South Asia, Middle East, Balkans, Ethiopia 
D9 Venezuela, Indonesia (West Java) 
E Germany 1971, INACTIVE* 
F Spain 1965, INACTIVE* 
GI USA 1983, INACTIVE* 
G2 Indonesia, Malaysia, Thailand 
G3 East Timor, Indonesia 
H1 China, USA, UK, Australia, Korea, Mongolia 
H2 Vietnam 
*= Circulation terminated 
11.1.3. Molecular amplification techniques used for the detection and quantification 
of measles virus 
The development of molecular amplification procedures has enabled the specific 
detection of measles RNA and its genomic sequences (Figure 1.2). These techniques have 
been used to determine infection of a person from samples of different source (see Table 
1.1). Brain tissues from patients have been used for PCR in detecting subacute 
scelerosing panencephalitis (SSPE) associated cases (Godec et al., 1990). Peripheral 
40 
blood mononuclear cells have also been used in PCR for looking at infection of 
monocytes during acute measles cases (Esolen, 1993). Nasopharyngeal aspirates (NPA) 
were used in PCR for detection of measles virus (Shimizu, 1993). Recently sera and 
plasma specimens have been used for molecular identification of distinct haemagglutinin 
measles virus and for detection of virus infection in patients (Nakayama et al., 1995). 
Clinical samples such as CSF, NPA, throat swab, oral fluid and urine have also been used 
at CPHL for detecting measles virus RNA by PCR (Jin, 1996). These marked 
developments have been enables to determine truly infected measles cases, particularly 
when serological results are indeterminate and to study biological variation of different 
strains. This enables to gain wider acceptance promises in the future (see Chapter 7). 
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Figure 1.2. Structure and genomic organization of measles virus and proteins encoded by 
its genes. Eight gene products are indicated; N (nucleocapsid), P (phosphoprotein), C 
(nonstructural), V (nonstructural), M (matrix), F(fusion), H (hacmagglutinin), and L 
(large or polymerase). The number of amino acids in different proteins is shown under 
the boxes. Regions indicated by explosion stars are the virus genome amplified for first 
and second round PCR. (upper). Cross-sectional part of the measles virion (lower). (Data 
derived mainly from Alkhatih and Briedis, 1986; Bellini et al, 1985; Bellini et al, 1986; 
Blumberg et al., 1988; Buchland et al., 1987; Gerald et al., 1986; Richardson et al., 1986; 
Roýzcnhlatt cat al.. 1985). 
5' 
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III. MEASLES VACCINES AND IMMUNIZATION 
The development of live attenuated measles virus vaccines began soon after the isolation 
of the virus by Enders and Peebles (1954). By the end of 1950s, Enders and colleagues 
had developed the Edmonston B strain of live attenuated measles vaccine by subjecting 
the virus to passage in different cell cultures (Enders, 1962). The Edmonston B vaccine 
was frequently found associated with rash and fever greater than 39.5 °C (Krugman et at., 
1962). To alleviate this problem gamma globulin was often administered simultaneously 
to reduce the occurrence of high fever and rash. In the early to mid 1960s a formalin- 
inactivated measles vaccine derived from the Edmonston strain was used. Administration 
was normally given as three doses of inactivated virus at monthly intervals (Krugman et 
al., 1965). Use of inactivated vaccine was stopped in 1967, when it was realized that 
immunity was short-lived, and that recipients were at risk of atypical measles on 
exposure to live measles virus (ACIP, 1967). By the mid to late 1960s, new strains of 
measles vaccine had been developed in the USA, Japan, Yugoslavia, the USSR, and 
China, by further attenuation of Edmonston (AIK-C), Edmonston A (Schwarz), 
Edmonston B (Moraten, Edmonston Zagreb (EZ)) or separate isolates (Leningrad 16, 
CAM-70, Shanghai-191). Further attenuated vaccines were associated with lower rates of 
clinical reactions and were suitable for widespread use without the need for concurrent 
administration of gamma globulin. 
Different factors affect the response to immunization, such as, age and maternal antibody 
level (Cutts, 1993). Wesley et al., 1978 reported that the response to measles 
immunization was delayed among malnourished children. The optimal age at delivery of 
measles vaccine depends upon the relationship between the average age at infection and 
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the rate of loss (average duration) of maternal antibodies specific to measles (McLean 
and Anderson, 1988; McLean, Nokes and Anderson, 1991). Maternal antibodies typically 
provide protection during the first 6 months of life, but often longer (McLean, Nokes and 
Anderson, 1991; Williams, Cutts and Dye, 1995). Interference with the replication of 
vaccine virus is frequently still seen at the age of 12 months (Albrecht et al., 1977; Marks 
et al., 1978; Nader et al., 1968). As a consequence vaccination in the first year of life 
gives inadequate immunity to measles. The earlier the age the lower the seroconversion 
rate (McLean, Nokes and Anderson, 1991; Williams, Cutts and Dye, 1995). The 
requirement for delay until maternally derived antibody has been lost is an impediment 
for early vaccination. The duration of maternally derived immunity in a child depends on 
the mother's antibody titer, the efficiency of transfer across the placenta and the rate of 
catabolism in the child (Lee TL, 1983; Black et al., 1986). A child exposed to many 
infections makes a large variety of IgGs; in order to keep the total blood IgG level in the 
normal range, catabolism is accelerated and passively acquired antibodies are swept out 
at an accelerated pace. In this way, early susceptibility to measles is strongly correlated 
with low economic status (Black et al., 1986). To meet this challenge age cross-sectional 
sero-epidemiological surveys and seroconversion studies are important for 
recommending the proper age for vaccination. An evaluation of the routine immunization 
programme in Ethiopian children, reported here (Nigatu et al., in press), gives support for 
the WHO recommended age for measles vaccination at 9 months (WHO, 1979). The 
ability of a measles vaccine to induce an immune response, particularly in the presence of 
maternal antibody, varies according to the strain and the dose of vaccine (McLean et al., 
1991). Studies compared the effect of standard EZ and Schwarz vaccines found that EZ 
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vaccine gave superior sero-conversion rates to Schwarz (Whittle et al., 1988; Markowitz 
et al., 1990c; Job et al., 1991). Another study compared AIK-C vaccine with EZ vaccine 
found that this vaccine was as immunogenic as EZ vaccine (Tidjani et al., 1989). 
Serological studies in developing countries have shown sero-conversion rates following 
immunization at age 9 months of 80% to 90% (Black et al., 1984; Ndikuyeze et al., 1988; 
Li-Min Huang et al., 1990). Field studies of vaccine efficacy have given estimates of 
85% protection (Hull et al., 1983). 
IV. WHO/EPI PROGRESS TOWARDS GLOBAL MEASLES CONTROL AND 
ELIMINATION 
In 1989, the World Health Assembly resolved to reduce global measles morbidity by 
90% and measles mortality by 95% by 1995, compared with the disease burden during 
the pre-vaccine era (WHO, 1997; 1999). By 1996, the estimated incidence and death rates 
for measles worldwide were reduced by 78% and 88%, respectively. In 1990, the World 
Summit for Children adopted a goal of vaccinating 90% of the world's children against 
measles by 2000 (WHO, 1993; WHO, 1994a). However, routine measles vaccination 
coverage has remained relatively stable since 1990, and an estimated 1 million children 
continue to die from this preventable disease each year (WHO, 1999). During the 1990s, 
the widespread use of innovative measles-control strategies in the Region of the 
Americas and in countries such as Mongolia, South Africa, and the United Kingdom 
demonstrated that high-level measles control and even interruption of transmission is 
feasible over large geographical areas (Bellini and Rota, 1998; Ramsay et al., 2003). 
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IV. 1.1 Stages of measles control 
Based on implementation of a combination of vaccination and surveillance strategies, 
countries are considered to be in 1 of 3 stages: control, outbreak prevention, or 
elimination (WHO, 1997; 1999) (see Figure 1.3). 
Figure 1.3. Phases for measles control/eradication programmes (source: WHO, 1999) 
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Control is defined as the reduction of disease incidence and/or prevalence to an 
acceptable level as a result of deliberate efforts, requiring continued interruption 
measures. In the control stage, the objective is to achieve high routine coverage with 1 
dose of measles vaccine among infants to reduce measles morbidity and mortality. To 
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accelerate measles control in large urban and other high-risk areas with a substantial 
proportion of unvaccinated children and measles associated deaths, mass vaccination 
campaigns targeting children aged 9 months to 3-14 years have been recommended (de 
Quadros et al., 1996; Cutts et al., 1999). 
2. Measles Outbreak Prevention (MOP) 
MOP aims to maintain low incidence and prevent outbreaks by the administration of 
supplemental doses of measles vaccine through mass vaccination campaigns. As 
programmes plan for elimination of measles, a high coverage of single dose vaccine with 
supplementary immunization is assumed be sufficient to interrupt transmission (WHO, 
1994b). The Africa region is adopting to raise routine vaccine coverage to at least 80% 
and using supplemental campaigns in all non-polio-reservoir countries by 2003 (WHO- 
Afro, 2000). 
3. Measles Elimination 
Elimination is defined as the reduction of endemic incidence of a disease to zero as a 
result of deliberate efforts, requiring continued control measures. WHO region of the 
America and Europe and Western Pacific aims to meet elimination goals (WHO, 1999). 
Although there has been tremendous success in the reduction of measles endemic 
incidence in many countries with measles elimination, the total interruption of measles 
transmission remains a major challenge due to importation of measles cases to these 
regions (Bellini and Rota, 1998; Hanratty et al., 2000, Ramsay et al., 2003). 
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IV. 1.2 Measles control and surveillance in Ethiopia 
Ethiopia is implementing the measles outbreak prevention phase of the Accelerated 
Measles Control Strategy (AMCS). This phase envisages 5 inter-linked interventions i. e. 
(i) measles vaccination through the routine EPI, (ii) targeted campaigns through the high 
risk approach, (iii) prevention of measles complications through effective case 
management, (iv) monitoring of EPI and epidemiological data to predict outbreaks and 
identify reasons for the outbreaks, and (v) increasing public awareness on measles 
infection, treatment and confidence in immunization. Targeted campaigns through the 
high risks approach are necessary to supplement the routine immunization activities and 
to extend full coverage to the un-reached communities. In response to this the Ministry of 
Health EPI in collaboration with WHO/EPI and other NGO's launched four measles 
immunization campaigns (Source: Family Health Department, MOH, 1999; 2002). 
The first measles immunization campaign was conducted in 1998 and targeted 9 main 
cities in Ethiopia i. e. Addis Ababa, Mekele, Bahir Dar, Dire Dawa, Harrar, Jimma, 
Nazareth, Dessie, and Gonder. 256,689 children aged between 9-59 months were 
reached during this campaign. As a continuation of the measles control strategy, in 1999, 
a second round of a measles immunization campaign was undertaken in 9 `high risk' 
zones in the three Regions of Amhara, Oromia, Southern Nations (total population of 23 
million). During this campaign 2,964,675 children age between 9-59 months were 
reached with measles vaccination representing 95% coverage of the targeted population. 
In a further continuation of the measles immunization campaign program under-five 
children were vaccinated in 45 zones in 2000 and another 18 zones were covered in 2001. 
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V. ORAL FLUID AS A DIAGNOSTIC FLUID 
The concentration of antibody in saliva was found at much lower levels compared to 
plasma (Table 1.4). This has limited its use as diagnostic specimen for viral 
immunological assays. However, research demonstrated that salivary antibody has two 
sources, the parotid and crevicular crevice, with different concentration levels of 
immunoglobulins (Mortimer and Parry, 1988). The transudate that comes from the 
gingival crevice, whilst being lower in concentration, closely reflects the immunoglobulin 
class and specificities of antibody found in plasma (Mortimer and Parry, 1991; Nishanian 
et al., 1998). The major reason for this is that the majority of the antibody present in the 
transudate comes from the small capillary bed beneath the margin that separates the teeth 
and gum. These properties of crevicular fluid lead investigators for measurements of 
virological markers of immune activation as an alternative to serum. 
Table 1.4. The mean concentrations (mg/L) of immunoglobulin components of saliva and 
plasma (source: Mortimer and Parry, 1988) 
Specimen IgG (mg/L) IgM (mg/L) IgA (mg/L) 
Plasma 14730 1280 2860 
Parotid saliva 0.36 0.43 39.5 
Crevicular fluid 3500 250 1110 
Whole saliva 14.4 2.1 19.4 
The other problem associated to the use of saliva as a viral diagnostic fluid is the need of 
immunological assays that have higher sensitivity. The development of antibody capture 
assays, 125I labeled (RIA) or ELISA, that are able to generate higher signals by capturing 
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a higher proportion of the total immunoglobulin (present in the oral fluid) specific for the 
antigen under test, enabled saliva to be used for successful immunological assays 
(Duermeyer et al., 1979; Flehmig et al., 1979). Presently the production of purified 
nucleoprotein through Baculovirus expression (Hummel et al., 1992) increases the utility 
of saliva in diagnostic enzyme immunoassays 
The value of saliva in screening for HIV infection is now well established with the use of 
IgG captures radioimmunoassay (Parry, 1993). The methodology has been applied to 
salivary diagnosis of measles, mumps, rubella, Epstein-Barr virus and hepatitis A and B 
infection (Parry, 1993; Vyse et al., 1997; 1999; Nigatu et al., 1999). Veterinarians found 
it useful for detecting feline immunodeficiency virus (FIV), (Poli, 1992) and feline 
leukemia virus (Lewis, 1987). Using PCR investigators found Hepatitis C virus RNA in 
saliva of patients with post-transfusion hepatitis C infection (Wang, 1991). Its potential 
application in bacteria was demonstrated with the measurement of specific IgA antibody 
to Bordetella pertussis antigens in saliva for diagnosis of whooping cough (Granstrom, 
1988). Other possibilities were seen in the diagnosis of cysticercoids by measuring 
specific salivary antibody to Taenia solium larvae (Feldman, 1990). Measuring of 
specific IgA antibodies to gliadin is used as a screening marker for coeliac disease 
(Hakeem, 1992). 
Generally saliva as diagnostic fluid has the following advantages: - 
(1) humanitarian- the patients are spared the discomfort of repeated venipunctures; 
(2) clinical- with less stress, non risk of anemia, infection or thrombosis; 
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(3) for children- saliva sampling is the technique of choice; 
(4) economic- patients can collect themselves, there by saving technicians' time, samples 
may also be mailed, eliminating travel time; 
(5) eliminates the issue of protection of privacy and adulteration during sample 
collection; 
(6) the ease and low cost of collection are major benefits in large-scale studies. 
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CHAPTER 2 
DEVELOPMENT OF GACELISA FOR THE DETECTION OF MEASLES SPECIFIC 
IgG IN ORAL FLUID 
Summary 
An IgG antibody capture enzyme linked immunosorbent assay (GACELISA) for the 
detection of measles specific IgG in oral fluid was developed using an FITC/anti-FITC 
amplification system. The GACELISA was evaluated by testing paired oral fluid and 
serum samples from 787 subjects in an epidemiological study of measles in rural 
Ethiopia. Oral fluids were tested by GACELISA and corresponding serum samples by a 
sensitive indirect ELISA for measles IgG (Behring Enzygnost). By comparison with the 
serum measles IgG assay, the oral fluid GACELISA had a sensitivity of 97.4% (95% 
confidence intervals: 95.9,98.2) and a specificity of 91.1% (81.9,94.3), with no 
significant differences observed by age group. Total IgG concentrations were measured 
on a subset of 160 oral fluids by an in-house ELISA. This showed that false negative 
GACELISA results tended to occur in samples with low concentrations of total IgG, 
although the trend was not statistically significant. We conclude that the overall 
performance of the GACELISA was satisfactory, showing close agreement to the serum 
ELISA, and has potential to serve as an easily transferable tool for large scale 
epidemiological studies as required for the World Health Organisation's programme for 
the global control of measles. 
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2.1. Introduction 
Radio-immunoassays for the detection of virus specific IgG and IgM in oral fluid have 
been developed for hepatitis A and B (Parry et al., 1989), HIV (Hunt et al., 1993), 
measles mumps and rubella (Perry et al., 1993) and parvovirus B19 (Rice and Cohen, 
1996). These assays are sensitive and specific but are inconvenient because of the 
biological hazard posed by the use of the radioisotope, I125, the high costs of specialized 
equipment required and the short shelf life of reagents. These limitations are an 
impediment to the wider adoption of oral fluid viral-specific antibody assays in 
laboratories, most particularly, in the developing world. There is a need, therefore, for 
more simple and robust assays, to facilitate greater use of oral fluid assays in both field 
epidemiology and surveillance contexts. The enzyme linked immunosorbent assay 
(ELISA) is presently the most feasible and appropriate assay format for such 
development and has been employed for the detection of HIV-1 specific IgG in oral fluid 
(Connell et al., 1993). More recently, an IgG antibody capture ELISA (GACELISA) 
using the FITC/anti-FITC amplification system has been developed for rubella specific 
IgG (Vyse et al., 1999). 
We now describe the development of an FITC/anti-FITC GACELISA for measles 
specific IgG in oral fluid. Although capture ELISA has been used previously to detect 
measles specific IgM in oral fluid (Helfand et al., 1996), we believe this is the first time 
such a method has been developed for measles specific IgG. The usefulness of an IgG 
antibody type assay is as a measure of past exposure to infection or vaccination, by which 
to estimate immune status of the individual or population. Such an assay would, ideally, 
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perform to a high specification on samples collected under demanding conditions of the 
field and across a wide range of age groups, but in particular young children. In accord 
with this we evaluated the measles GACELISA by testing oral fluid and matching serum 
samples collected from 787 individuals in a rural district of southern Ethiopia in 1997. 
The present study forms an important stage in a programme of research in Ethiopia 
investigating the utility of oral fluid as a replacement for large-scale blood specimen 
collection for epidemiological studies (Nokes et al., 1998a, b; Vyse et al., 1999). It also 
demonstrates the potential of the methods used for accessing hard to reach groups and 
children, using non-medical or non-nursing personnel, in countries with only basic 
laboratory facilities. 
2.2. Materials and Methods 
2.2.1 Study area and population 
The study was undertaken in the densely populated rural district of Butajira, 130 km 
south of Addis Ababa, Ethiopia. The district is situated at altitudes ranging from 2300 m 
in the North West to 1500 m in the South West. The 250,000 inhabitants are 
predominantly subsistence farmers with a main town of Butajira of some 10,000 
occupants. Since 1986 this has been the study base for a longitudinal demographic and 
health research programme called the Butajira Rural Health Project (Shamebo et al., 
1992; Shamebo et al., 1993), providing an ideal framework for epidemiological studies of 
vaccine-preventable viral infections. Routine measles vaccination of infants is offered 
through the Expanded Programme on Immunization at the recommended age of 9 
months, but coverage is low and variable (Anon., 1995). Ethical approval was gained 
from the Faculty of Medicine Scientific and Ethics Committee, Addis Ababa University, 
54 
and Coventry Research Ethics Committee. Agreement to participate in the study was 
gained through verbal consent of the subject or their guardian. 
2.2.2 Specimen collection 
Oral fluid was collected using a sponge swab (diameter 1.5cm x height 2 cm) and 
processed as described previously (Nokes et al., 1998b). Specimens were kept in a cool 
box with ice packs prior to transportation to the field station each day. Transport buffer 
(see A2, Appendix attached to this Chapter) made weekly and stored in a refrigerator at 
4-10°C, was added to each collection tube prior to storage at 4-10°C for up to one week 
until transfer to the EHNRI laboratory in Addis Ababa. Venous blood was collected by 
Vacutainer system (5mL Vacutainers and 21G or 22G needles, Becton Dickinson, 
Oxford, UK) usually on a certain day of a week and transported that same day to the 
laboratory in Addis Ababa. Of the 9 peasant associations (PAs) and one urban dwelling 
association (UDA), 4 PAs and 1 UDA were selected based on condusive conditions for 
the study. Total sample sizes of 5000 or 1000 for each cluster were determined. 
Households were identified from the census and 167 households were selected at random 
from each cluster. Paired blood and oral fluid samples were available from 787 subjects, 
representing approximately 20% of individuals who provided oral fluid (n=5000) 
between May and November 1997. Individuals were aged between 0 and 84 years with 
the following age stratification and sex ratios: 0-4 years, n=89 (% male=47.2); 5-9,144 
(50.7%); 10-19,238 (50.8%); 20-29,58 (32.8%), 30-49,156 (34.6%); 50+, 100 (54.0%) 
(totaling 785 since 2 individuals had no age recorded). 
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2.2.3 Total IgG concentration determination 
Total IgG concentration in oral fluids was measured by ELISA (Connell et al., 1990; see 
A2, Appendix attached to this Chapter). 
2.2.4 Serum measles antibody assays 
Serum samples were screened for measles specific IgG by a commercially available 
enzyme immunoassay kit (Behring Enzygnost, Dade Behring, Milton Keynes, UK). 
Antibody status (negative, equivocal or positive) and antibody concentration in milli- 
international units (mIU/mL) were determined according to the manufacturer's 
instructions. The relationship between antibody status and units was identified from the 
results as the following: <150 mIU/mL negative; 150-335 mIU/mL equivocal; >335 
m1U/mL positive. Serum samples giving measles specific IgG results discordant to those 
of corresponding oral fluid specimens were screened for measles antibody by plaque 
reduction neutralization test (PRNT, Brugha et al., 1996) using the wild type 'Loss' strain 
of measles (Sinitsyna et al., 1990) as challenge virus. 
2.2.5 GACELISA for measles specific IgG 
Wells of microtitre plates ("U" well Maxisorb, Life Technologies, Paisley, UK) were 
coated with 1001il of a 5.7 g/L anti-human IgG solution (Dako, Ely, UK) diluted 1: 1000 
in 0.05M carbonate/bicarbonate buffer, pH 9.6. After overnight incubation at 4°C, the 
unoccupied binding sites were blocked by 2 hours incubation at 4°C with 200µl of 5% 
Sol-u-pro (Dynagel Inc, Calumet City, Ill, USA). The Sol-u-pro solution was aspirated 
and the plates air dried by inverting and leaving at 37°C overnight. The dried plates were 
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stored at 4°C in plastic bags containing a sachet of desiccant until required. Plates were 
incubated with 1001tl undiluted oral fluid samples at 37°C for 30 minutes on a plate 
shaker set at 650 rpm (Dako, Ely, UK). Plates were then washed four times in 
phosphate-buffered saline (PBS) pH 7.4 (Oxoid Ltd, Basingstoke, UK) containing 0.05% 
Tween 20 (PBS-T) and incubated at 37°C for 1 hr with shaking with 100 /41/well of 
measles antigen diluted 1: 2000 in GACELISA buffer (PBS with 10% Fetal Calf Serum 
(FCS) and 0.2 % Tween-20). After washing 4 times with PBST, the plates were 
incubated at 37°C for ihr with shaking with 100µ. l/well of anti-measles haemagglutinin- 
FITC conjugate (Chemicon Inc., Temecula, California, USA) diluted 1: 4000 in PBS 
containing 10% FCS, 5% Normal Rabbit Serum (NRS), 2% measles antibody Negative 
Human Serum (NHS) and 0.2% Tween-20. Plates were washed 4 times with PBST and 
incubated at 37°C for 30 minutes with shaking with 100µ1/ well of anti-FITC-Horse 
radish peroxidase (Chemicon, Inc. ) diluted 1: 4000 in PBS containing 10% FCS, 10% 
NRS, 2% NHS and 1% Tween-20. Wells were washed 4 times with PBST and incubated 
at room temperature, in the dark, for 15 minutes with l00µ1/well of TMB (3,3', 5,5'-tetra- 
methyl benzidine) substrate. The reaction was stopped by adding 50µ1 2M H2S04. 
Optical density (OD) was measured at 450/620 nm (iEMS plate reader 4F, Life Sciences 
International, Basingstoke, UK) and converted to mOD (mOD = OD X 1000). For each 
microtitre plate, the mean mOD value plus 3 standard deviations (sd) calculated from the 
test results for subjects who had negative serum IgG results (mODneg+3sd) was used as 
the cut-off value, i. e. samples were defined as GACELISA positive if the 
mOD>(mODneg+3sd). (For standard operating procedure see A2). The number of oral 
fluid samples with corresponding negative sera used to determine the cut-off mOD in 
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each GACELISA plate ranged from 11-34. Different cut off value were used for each 
plate. Data stored on EPINFO V. 6 were analysed using STATA V7.0 (Stata Corp, 
College Station, Texas, USA) and Excel (Microsoft for Windows 95 v7.0a). 
2.2.6 Measles antigen preparation 
One 50 ml flask of Vero cells was infected with the wild type Loss virus strain (Sinitsyna 
et al., 1990) and when cythopathic effect (CPE) was positive after 3 days the cells were 
scraped into the medium and inoculated into eight 600 ml flasks of Vero cells. When 
CPE was advanced (about 6 days) the cells were scraped into the medium and cell debris 
pelleted at 500g for 10 minutes. The pellet was resuspended in 8ml of the supernatant 
(Si), disrupted by sonication for about 2 minutes in a bath sonicator and centrifuged at 
500g for 20 minutes. The supernatant (S2) was collected and the pellet of cell debris 
discarded. S2 was then combined with Si and centrifuged at 20000g for 1 hour at 5°C. 
The supernatant was discarded and the pellet resuspended in 4 ml of PBS by sonication. 
Fetal calf serum added to a final concentration of 10% and the antigen was aliquoted and 
stored at -70°C. Control antigen from uninfected Vero cells was prepared in the same 
way. 
2.2.7 Stability of measles antigen 
Aliquots of measles antigen, both undiluted and diluted 1: 2000 in GACELISA buffer, 
were placed at +8, +22, and +37, and undiluted at -70°C, for up to 30 days. The OD 
values of measles positive and negative control serum samples diluted 1: 100 in 
GACELISA buffer were determined by GACELISA using aliquots of antigen stored for 
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0,3,7,14,21 and 30 days. (Control sera were those in use in the Enteric and Respiratory 
Virus Laboratory: a measles IgG negative plasma unit from an individual blood donor 
and a pool of measles IgG positive sera). The haemagglutination activity of the stored 
aliquots was measured at 37°C using 0.5% rhesus monkey erythrocytes suspended in PBS 
containing 2% (w/v) dextrose and 0.2% (w/v) bovine serum albumin. 
2.3. Results 
2.3.1 Titration and stability of measles antigen 
From the titration illustrated in Figure 2.1, the optimum dilution of measles antigen for 
GACELISA was chosen as 1: 2000 in GACELISA buffer since after this dilution factor 
the OD reading start to decline. The same preparation of antigen had a haemagglutination 
titer of 1: 640. 
Figure 2.1. Titration of measles antigen (filled circles) and control antigen (open circles) 
in GACELISA using the measles IgG positive control serum. 
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The effect of storage of antigen, diluted or undiluted, at different temperatures (+8, +23, 
+37 or -70°C) on its activity in GACELISA is shown in Table 2.1. After 30 days, no 
decline in antigen activity was detected at any of the storage temperatures. In addition, 
no decline of antigen activity was detectable by haemagglutination assay (results not 
shown) 
Table 2.1. Stability of measles antigen at various temperatures and storage periods. 
Measurements are of mean OD values with positive (+) and negative (-) control serum 
samples. 
Storage period (days) 
Storage T° 0 3 7 14 21 30 
8°C diluted + 2.658 2.654 2.494 3.299 2.813 2.828 
0.062 0.105 0.095 0.122 0.700 0.125 
8°C undiluted + 2.783 2.509 2.142 2.798 2.611 2.298 
- 0.073 0.109 0.054 0.069 0.059 0.056 
23°C diluted + 2.786 2.918 2.670 3.106 3.012 2.962 
- 0.070 0.147 0.132 0.109 0.073 0.108 
23°C undiluted + 2.531 2.567 2.016 2.612 2.394 2.472 
0.078 0.082 0.054 0.065 0.054 0.055 
37°C diluted + 2.695 2.875 2.567 3.239 2.685 2.817 
- 0.069 0.148 0.127 0.146 0.081 0.107 
37°C undiluted + 2.706 2.707 2.578 3.098 2.916 2.721 
- 0.066 0.116 0.088 0.083 0.075 0.071 
-70°C 
undiluted 
+ 2.857 2.743 2.438 2.858 2.398 2.662 
i 
-i 0.070 0.072 0.067 0.073 0.062 0.069 
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2.3.2 Comparison of measles specific IgG measurements in oral fluid and 
corresponding sera 
Paired oral fluid and serum measurements were obtained for 787 individuals. Results 
were plotted (log scale, Figure 2.2) to show the quantitative relationship between measles 
specific IgG in oral fluid measured by GACELISA and in corresponding serum samples 
measured by Behring ELISA. This showed a direct relationship between measles IgG 
levels in oral fluid and in serum (Figure 2.2). Fourteen sera giving results falling within 
the two vertical lines in Fig 2 were equivocal by ELISA (i. e. >150 but <335 mIU/mL). Of 
these, 10 had paired oral fluid samples, which were GACELISA positive. A correlation 
coefficient of r=0.581 for serum positives (n=683) was calculated for serum antibody 
concentration and oral fluid mOD (using log-transformed data). The horizontal line in 
Figure 2.2 represents the mean of the cut-off mOD values estimated for the GACELISA 
(mean mOD 114, range 96.4-143, n=9). 
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Figure 2 
. 
2. Relationship between measles-specific IgG concentration measured in serum 
(Behring ELISA; rnlU/mL) and in oral-fluid GACELISA; mOD for 787 sample pairs 
From southern Ethiopia. 1997. Vertical lines mark the equivocal range in serum ELISA 
(antibody levels 150-335 mlU/mL). The horizontal line identifies the average cut-off 
level for oral-fluid GACELISA (114 mOD). Filled markers indicate 27 samples with 
discordant results for further analysis (see Table 2.3). 
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In qualitative analysis, and excluding 14 pairs with equivocal serum results, the 
GACELISA results agreed with serum results in 746 of 773 (96.5%) of samples tested, 
with a kappa statistic of 84% (i. e., the percentage of the difference between random and 
1)LF1CLt a,, reeinrnt, (K=(1.837 z=-)3.3, P<O. OUOI ). Overall sensitivity and specificity of the 
oral fluid GACELISA in comparison to the serum Behring ELISA were 97.4% and 
91.1%, respectively (Table 2.2). The considerably larger sample size of serum positives 
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(n= 683) compared with negatives (n=90) yields greater confidence in the sensitivity 
estimates (Table 2.2). No change in sensitivity or specificity is discernible with age (note 
overlapping confidence intervals in Table 2.2). 
Table 2.2. Evaluation of oral fluid GACELISA against serum Behring ELISA 
Age class Sensitivity Specificity 
(years) a/(a + b)° proportion 95% conf. limits d/(c+d)" proportion 95% conf. limits 
0-4 43/43 1 0.918 / 1.000 41/43 0.953 0.842 / 0.990 
5-9 101/105 0.962 0.905 / 0.985 34/36 0.944 0.813 / 0.988 
10 - 19 220/226 0.973 0.943 / 0.987 6/8 0.750 0.349 / 0.947 
20 - 29 54/56 0.964 0.877 / 0.992 0/1 0 0.000 /0.975 
30 - 49 150/152 0.987 0.953/0.997 0/1 0 0.000 / 0.975 
50+ 95/99 0.960 0.900 / 0.984 1/1 1 0.025 / 1.000 
Total 663/681 0.974 0.959 / 0.982 82/90 0.911 0.819 / 0.943 
a= Where a= Behring ELISA+/GACELISA+, b= Behring ELISA+/GACELISA-, c= Behring ELISA-/GACELISA+, d= Behring 
ELISA-/GACELISA-. 
h= Exact limits based on the F distribution (Armitage and Berry, 1987). 
c= Total does not includes samples from 2 individuals for whom no age was available. 
Specimens from 23 of 27 oral fluid/serum pairs showing discordant results were retested 
(Table 2.3). In general, this showed the results of both GACELISA and Behring ELISA 
were reproducible. However, 5 serum samples giving reactions close to the "cut off" OD 
re-tested equivocal, 3 oral fluids initially negative retested GACELISA positive and 1 
serum initially Behring ELISA positive re-tested negative. All 23 of the sera from this 
panel were also examined by PRNT that had a detection limit of 150 to 320 mIU/ml. The 
17 sera from the set where Behring ELISA was initially positive were PRNT positive 
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whereas only one of six sera where Behring ELISA was initially negative was PRNT 
positive. 
Table 2.3. Further results for 23 paired oral fluid and serum samples showing discordant 
results: repeat GACELISA and Behring ELISA, and PRNT 
Repeat results 
Initial results No. Oral fluid GACELISA Serum Behring ELISA Serum PRNT 
+- + +/- - +- 
Oral fluid GACELISA - 17 3 14 12 41 17 0 
Serum Behring ELISA + 
Oral fluid GACELISA + 6 60 015 15 
Serum Behring ELISA - 
2.3.3 Total IgG content of oral fluid 
In order to investigate the quality of oral fluid samples, total IgG concentrations were 
measured in a subset of 160 samples selected based on corresponding sera with different 
concentration of total IgG. The concentration of total IgG ranged from 1 to more than 60 
ng/mL. The effect of total IgG concentration in oral fluid on performance of measles 
GACELISA was analysed (Table 2.4). A trend was apparent for sensitivity of the 
GACELISA to increase with increasing total IgG concentration. However, sample sizes 
were small and there was no statistical evidence for an association between GACELISA 
sensitivity and total IgG in oral fluid (Fisher's Exact P=0.42). Of 160 oral fluids tested, 
136 (85%) gave the same results as the Behring ELISA on corresponding sera. Matching 
results, either GACELISA+/Behring+ or GACELISA-Behring-, were obtained with oral 
fluids with total IgG concentrations as low as 1.1 to 5.3ng/mL and as high as >60ng/mL. 
64 
Discordant results, which were obtained with 23 paired oral fluid/serum samples, varied, 
however, according to total IgG concentration of oral fluid. Most of the discordant 
results were in the category GACELISA-/Behring+ and were more frequent with oral 
fluids with a low total IgG concentration (Table 2.4). Only 2 discordant results were in 
the category GACELISA+/Behring- and both were with oral fluids with high total IgG 
concentrations. 
Table 2.4. Performances of measles GACELISA in 160 oral fluid samples compared to 
Behring ELISA in corresponding sera with different concentration of total IgG 
Total IgG conc. Number of paired oral fluid / serum samples Sensitivity of 
In oral fluid GACELISA+ GACELISA- GACELISA- GACELISA+ GACELISA vs 
(ng/mL) Behring + Behring - Behring + Behring - 
Behring (%) 
1.1-5.3 15 9 6 0 71.4 
5.4-10 14 6 5 0 73.4 
10.1 - 20 20 10 4 1 83.3 
20.1 - 40 20 13 5 0 80.0 
40.1 - 60 10 3 2 1 83.3 
> 60 12 4 0 0 100 
Total 91 (56.9) 45 (28.1) 22 (13.8) 2 (12) 
2.4. Discussion 
Of importance to any measles vaccination control programme is the capability to assess 
the effectiveness of immunizations, to identify individual and population susceptibility, 
and verify disease diagnosis. In this context the need for simple robust assays for the 
determination of immune status is recognised, and is particularly acute in the developing 
world (Cutts & Brown, 1995). Ideally, assessment of immune status should be made on 
the basis of specimens collected by painless non-invasive means (especially relevant to 
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measles as an infection and disease predominantly of the young), using assays based on 
standard technology suited to most basic laboratories around the world. Previous work 
has clearly shown the relative ease and acceptability of collecting oral fluid samples 
compared to collecting blood samples, from individuals of all ages, either within 
communities (Nokes et al., 1998b; Azevedo Neto et al., 1995; Cutts et al., 1995) or in the 
medical environment (Brown et al., 1994; Ramsay et al., 1998). The adequacy of oral 
fluid for specific IgG determination for a range of viruses has been demonstrated (Vyse et 
al., 1997; 1999; Nokes, 1998a, b; Parry et al., 1993; Perry et al., 1993; Rice and Cohen, 
1996; Ramsay et al., 1998). The present work now describes an assay for measles 
specific IgG using oral fluid which, since it has an ELISA format, is more simple and 
robust than the radio-immunoassay previously used to measure measles IgG in oral fluid 
(Perry et al., 1993). Moreover, as the method does not require a high degree of 
laboratory sophistication, it could be performed in most laboratories in both developed 
and developing countries. The assay has the limitation of reproducibility since the 
components of the assay are not provided as ready to use reagents. 
The measles GACELISA method described here is similar to that recently developed to 
measure rubella specific IgG in oral fluid (Vyse et al., 1998). It used the same FITC/anti- 
FITC amplification system (Samuel et al., 1998) to enhance the sensitivity of the 
GACELISA to a level comparable to that of corresponding radio-immunoassays. The 
GACELISA also uses a monoclonal antibody to measles haemagglutinin and Vero cell 
culture-grown measles antigen. Other than the measles antigen, all reagents are 
commercially available; thus minimising problems of availability of reagents to any 
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laboratory wishing to establish the assay. One practical issue investigated was the 
stability of the measles antigen at a range of storage temperatures. In the presence of 
10% fetal calf serum, in either a concentrated or diluted suspension, no loss of 
antigenicity in GACELISA or haemagglutination assay was observed after 30 days 
storage at temperatures ranging from -70 to +37°C. (We did not measure the infectivity 
of measles virus stored under these conditions). The results indicate that low temperature 
storage of measles antigen for GACELISA is therefore not essential. 
The performance of the GACELISA was assessed by testing a large panel of paired oral 
fluid and serum samples collected during a community-based health project in rural 
Ethiopia. It is clear that oral fluid collected in this way using a simple sponge swab 
device provides an adequate sample for measles IgG determination. Corresponding serum 
samples were tested by a commercial indirect ELISA (Behring) which can detect as little 
as 80 mIU/ml of measles specific IgG (Hesketh et al., 1997) although, following the 
manufacturers guidelines, a cut-off level of 150mIU/ml was used in this study. 
Compared to this sensitive serum ELISA, the oral fluid GACELISA had a sensitivity of 
97%. This was higher than the 82% sensitivity of the similar oral fluid rubella FITC/anti- 
FITC GACELISA (Vyse et al., 1998). The sensitivity of the rubella GACELISA was 
shown to decrease markedly with increased age of the subject (Vyse et al., 1998). By 
comparison, no age-specific sensitivity of the measles GACELISA described in this study 
was observed. Greater precision of the estimate of specificity of 91% (95%CI: 82%- 
94%) for the oral fluid GACELISA, compared to Behring ELISA on serum, would be 
desirable. In particular, where the identification of true negatives for selective 
67 
vaccination, or the proportion seronegative for triggering campaign intervention, are the 
objectives, then a high specificity assay would be critical (Cutts & Brown, 1995). 
Discordant results from 23 of 27 oral fluid/serum sample pairs were investigated by 
testing serum samples by PRNT. This confirmed a positive Behring result in 17 sera and 
a negative Behring result was confirmed in five of six sera (Table 2.3). These PRNT 
results support the conclusion that the oral fluid GACELISA was less sensitive than the 
serum Behring ELISA and that a small number of oral fluid samples gave falsely positive 
GACELISA results. The reason for false positive reactions is not known but two oral 
fluids giving false positive reactions contained high concentrations of total IgG (Table 
2.4). 
The concentration of total IgG in oral fluid is variable and is considered to be an 
important factor in determining the quality of an oral fluid for virus specific antibody 
assay (Parry, 1993). For the measurement of antibody to hepatitis A and B and HIV, a 
minimum total IgG of 0.5 ng/mL in oral fluid was deemed to be required (Parry, 1993). 
For oral fluid EBV antibody, a minimum of 2 ng/mL was required (Vyse et al., 1997). In 
our study of measles IgG, a minimum level of total IgG was not determined but many 
oral fluids with as little as 1.1 to 5.3 ng/mL gave results matching those of corresponding 
sera (Table 2.4). However, the sensitivity of the oral fluid GACELISA tended to increase 
with increased total IgG concentration (Table 2.4), though the association was not 
significant and requires further investigation. By contrast, it was previously observed in 
a study of measles IgG in oral fluid samples collected in Bolivia that the sensitivity of the 
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virus specific antibody assay used (radio-immunoassay) decreased with increased total 
IgG concentration, a phenomenon ascribed to competition from local production in the 
oral cavity of IgG of other specificities (Cutts et al., 1995). In a more recent study 
(Nokes et al., 1998b) it was shown that the relationship between rubella-specific and total 
IgG in oral fluid was variable, differing between type of collection device used; for the 
sponge swab device used in this study, the association was positive. We did not find false 
negative measles specific IgG results in oral fluids with high levels of total IgG in the 
study reported here but we did find a few false positive results. Our understanding of the 
composition and properties of oral fluid remains at an early stage and future investigation 
in this direction would be useful. The relationship between the data presented in Table 
2.2 and Table 2.4 were not comparable as samples tested in Table 2.4 are not 
representative samples selected randomly. All the discordant samples were also included 
in this test panel. 
We conclude that, in spite of minor deficiencies, the specificity (91.1%) and certainly the 
sensitivity (97.4%) of the oral fluid measles GACELISA can be considered adequate for 
sero-epidemiological studies. Coupled to the numerous practical advantages of both oral 
fluid sampling and ELISA methodology, this new measles assay should be useful for 
population screening, surveillance and assessing the efficacy of vaccination programmes 
as required for the World Health Organisation's objective of the global control of measles 
(World Health Organisation, 1997). 
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A2 (APPENDIX TO CHAPTER 2) 
I. MEASUREMENT OF TOTAL IgG CONCENTRATION IN ORAL FLUID 
1. IgG standard Curve 
I. I. A calibration curve ranging from 2.5 mg/L to 0.039mg/L is prepared in PBST as 
described below. Each standard is tested in duplicate in each assay or each plate. 
1.2. Check the concentration of the standard in use. In a separate microtitre plate prepare a 
2.5 mg/L. For example dilute a 45mg/L calibrant 1 in 18 (1Oul to 170u1 PBST). 
1.3. Prepare the remaining standards by doubling dilutions, from the 2.5 mg/L-diluted 
standard, in' PBST (50ul standard + 50ul PBST). A new pipette tip must be used for 
the preparation of each dilution. 
2. Test Procedure 
2.1. This assay is only accurate in the approximate range of 0.1mg/L to 10mgIL. 
Therefore, if a sample is likely to contain a concentration of IgG outside this range it 
must be tested at a different dilution. 
2.2. Add 40ul of PBST to the wells. Add 10ul of oral-fluid to its allocated microtitre well. 
2.3. After the addition all the samples add a further 10ul of PBST to wells Al and A2 to 
act as blanks for the assay. Add 10ul of each of the standards, in duplicate, to their 
allocated wells in columns 1 and 2. 
2.4. Cover the plate with a plate sealer and incubate at 37 °C for 2 hours. 
2.5. Wash the microtitre plate 4 times with a plate Washer. 
2.6. Prepare a1 in 10,000 dilution of rabbit HRPO conjugated anti-human IgG (Dako) 
[lul + 10m], 10mis per plate], and add 100ul to each well. 
2.7. Cover the plate with a plate sealer and incubate at 37 °C for 30 minutes. 
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2.8. Wash as described previously but include an additional wash, giving a total of 5 
washes. 
2.9. Add 100u1 TMB substrate to each well, cover the plate with a plate sealer and 
incubate in the dark at room temperature for 25 minutes. 
2.10. Stop the reaction with 0.25M H2SO4 and read in a plate reader at 450nm (reference 
620nm) using wells Al and B1 as blanks. It is recommended that a reader capable of 
reading OD values > 3.0 is employed in order to extend the dynamic range. 
2.11. Appropriate software (e. g. Mikrotek-Laborsysteme) should be used to analyse the 
data and to produce the standard curve against which oral fluid sample concentrations 
are determined. 
Useful notes: 
" The critical part of this assay is the preparation of the calibration curves. Great care is 
needed when preparing the dilution series. 
" When calculating the actual IgG concentration do not forget to compensate for the 
sample dilution. 
II. MEASLES IgG & IgM DIAGNOSIS IN ORAL-FLUID USING SIMPLE 
CAPTURE ELISA 
1. Processing of Oral-fluid Samples 
1.1. Pink Sponge Swabs (Malvern Medical) 
Add lml. Transport medium (recipe below) to swab in tube. Mix the swab thoroughly in 
the medium, creating a froth. Invert the sponge stick in the tube and replace the cap. 
Centrifuge the tube at 2000 rpm for 5 minutes. Discard the sponge stick immediately and 
pipette the oral fluid into a storage vial. 
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1.2. Omni-sal (SDS) 
Detach the flat sponge swab from the stick using a disposable pipette or pipette tip, into 
the tube. Take an omni-sal filter plunger from the laboratory stock and push it into the 
tube. Push it down onto the sponge using sufficient pressure to filter the fluid. Pipette the 
fluid, which is blue colored, into a storage vial. 
1.3. Orasure 
Break off the small plastic tip at the bottom of the orasure tube. Place the tube within a 
centrifuge tube (blue-capped, graduated plastic tubes). Centrifuge at 2000rpm for 5 
minutes. Pipette the fluid from the centrifuge tube into a storage vial. 
Transport medium for use with pink sponge swabs 
PBS with 
10% Fecal Calf Serum (FCS) 
0.2% Tween 20 
0.5% Gentamicin (50mg/ml stock) 
0.2% Fungizone 
2. Blocking of Plates with SOL-U-PRO: Preparation of Plates for Long Term Dry 
Storage 
2.1. Coat plates with 100ul DAKO anti human IgG or IgM at the appropriate dilution in 
carbonate / bicarbonate buffer (recipe below) and incubate over night at 37 °C. 
2.2. Aspirate (i. e. remove but do not wash) the anti-human IgG / IgM solution and add 
200 ul of 5% Sol-u-pro (Sol-u-pro is provided as a 25% stock solution; to make a5% 
solution dilute the stock 1: 5 in distilled water). 
2.3. Leave at room temperature for a minimum of 1 hour and a maximum of 4 hours. 
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2.4. Aspirate the solution, invert the plates and leave at 37 °C over night. 
2.5. Package the dried wells into plastic bags containing a sachet of desiccant previously 
heated sufficiently to remove any moisture. Ensure the bags are properly sealed. 
2.6. Store the plates at 4 °C (plates will last -3 months). 
Coating Buffer 
0.05M Carbonate-bicarbonate pH 9.6 preparation 
Solution A: 0.2M anhydrous sodium carbonate 
21.2g Na2Co3 / 1000ml H2O 
Solution B: 0.2M sodium bicarbonate 
16.8g NaHCO3 / 1000ml H2O 
Add 16m1 Solution A 
34ml solution B 
150m1 H2O 
2m1 8%sodium azide 
3. Preparation of Measles Antigen for Solid Phase Assays 
3.1. Infect one 50 ml flask of Vero cells with Loss virus. When cythopathetic effect 
(CPE) is just +++ (about 3 days) scrape the cells into the medium and inoculate in to 
eight 600 ml flasks of Vero cells. 
3.2. When CPE is advanced (about 6 days) scrape the cells into the medium, and pellet 
cell debris at 2000 rpm for 10 minutes. 
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3.3. Remove supernatant (S 1). Resuspend pellet in 8 mis of supernatant and disrupt cells 
by sonication for about 2 minutes. Spin at 2000 rpm for 20 minutes, remove supernatant 
(S2) and discard pellet. 
3.4. Add S2 to S 1, and spin at 40,000 rpm for 1 hour at 5 °C. 
3.5. Discard supernatant and resuspend pellet in 4 mis of PBSA. Sonicate to break up 
clumps, add FCS to a final concentration of 10%, aliquot and store at -70 °C. 
[Initial harvest is spun in 16 universals; pooled supernatant is spun in 10 1" x3 1/2" 
Beckman tubes]. 
Final antigen concentration is about 1 in 80. 
4. Fluorescin Isothio Cyanate (FITC) Labeling of Antibody 
4.1. Labeling_reaction 
4.1.1. To 1 mg of antibody in 0.5 ml of 0.1M carbonate / bicarbonate buffer, pH 9.2-9.3 
containing 0.15M NaCI. 
4.1.2. Add 9.2u1 FITC (5mg /ml in absolute alcohol kept dry with anhydrous NaSO4 or 
MgSO4) in 3 equal parts with stirring over a5 minute period. 
4.1.3. Leave to react for a further 45 minutes at room temperature in the dark. 
4.2. Separate unbound FITC 
4.2.1. Pre-block PD 10 column (Pharmacia) with lml 1% bovine serum albumin (BSA). 
4.2.2. Wash column with 3x column volume of PBS with NaN3 
4.2.3. Add conjugate to column and elute with PBS with NaN3, collecting 0.5m1 
fractions. 
4.2.4. Measure OD280 and OD495 of fractions. 
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4.2.5. Pool fractions with peak OD (usually fractions 6-8). 
4.2.6. Add glycerol to final concentration of 20-25 % and store in dark at 4 °C. 
5. Preparation of TMB Substrate 
5.1. TMB: 100mg in 10 ml DMSO 
final concentration 42 mM 
5.2. Citrate /Acetate 
Buffer pH 6.0 : 0.1M citric acid 21.014 g/L 
0.2M sodium acetate 16.40 g/L 
2m1 O. 1M citric acid 
48m1 0.2M sodium acetate 
50 ml distilled water 
5.3. For 10 ml of substrate : 10m] of citrate / acetate buffer 
7.5u1 H202 6% 20 volumes 
100ul TMB solution -add slowly 
5.4. Stop solution: 2M H2SO4 
5.5. Read OD at 450 / 620nm 
6. Procedure for Measles FITC/Anti-FITC GACELISA 
6.1. Materials: 
- Anti-human IgG (Fc) specific antibody coated microtitre wells (In-house preparation) 
- Positive and negative control serum (tested in other serum assays) diluted 1/100 before 
use in GACELISA buffer (10%FCS, 0.2% Tween-20 in PBS) 
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- Measles Loss virus antigen (cell lysate) diluted 1/2000 in GACELISA buffer 
- Anti-measles haemagglutinin-FITC conjugate (1/4000) in PBS containing 10% FCS, 
5% Normal rabbit serum (NRS), 2% Measles-negative human serum (NHS) and 0.2% 
Tw-20 
- Anti-FITC-HRP conjugate diluted 1/4000 in PBS containing 10% FCS, 10% NRS, 2% 
NHS and 1% Tw-20 
- Wash buffer (PBS containing 0.05% Tw-20) 
- TMB substrate-freshly prepared from stock TMB in DMSO added to citrate/acetate 
buffer, 0.1M, (pH 6.0) containing hydrogen peroxide 
- 2M H2SO4 
6.2. Procedure: 
6.2.1. Add 100ul of diluted POS and NEG control serum samples in duplicate to assigned 
wells. 
6.2.2. Add 100ul of each of the saliva samples to assigned wells. 
6.2.3. Incubate at 37°C for 30 minutes in plate shaker (-500 rpm). 
6.2.4. Wash wells 4X in wash buffer. 
6.2.5. Add 100 u/ well of the diluted measles antigen at 37 °C for 60 minutes with 
shaking as in step 6.2.3. 
6.2.6. Wash wells 4X in wash buffer. 
6.2.7. Add 100 ul / well of the diluted anti-measles haemagglutinin-FITC conjugate and 
incubate at 37 °C for 60 minutes with shaking as in step 3. 
6.2.8. Wash 4X in wash buffer. 
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6.2.9. Add 100 ul / well of the diluted ant-FITC-HRP conjugate and incubate at 37 °C for 
30 minutes with shaking. 
6.2.10. Wash wells 4X with wash buffer. 
6.2.11. Add 100 ul/well of freshly prepared TMB substrate and incubate at room 
temperature, in the dark, for 15 minutes. 
6.2.12. Stop reaction by adding 50u1 of 2M H2SO4. 
6.2.13. Read optical density at 450/620. 
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WORKSHEET FOR MEASLES IN GACELISA 
DATE OPERATOR 
Preparation of Ant- 
MH-FITC conj. 
Total volume = 
6000u1(6strips) 
Total volume = 
8000u1(9strips) 
Total volume = 
12000u1(12strips) 
Incubation 
°C 
Remark 
PBS 4968 tl 6624 µl 9936 µl 37oC Ihr 
10% FCS 600 µl 800 µl 1200 µl 
5% NRH 300 µl 400 µl 600 µl 
2% NHS 120 Al 160 µl 240µl 
0.2% Tw-20 12 µl 161A 24 Al 
Anti- MH-FITC 1/10 
stock 
15 µl 20 µl 30µl 
Preparation of Anti- 
FITC-HRP conj. 
PBS 4620 µ1 6160 µ1 9240 µ1 37°C 30 
min. 
10% FCS 600 µl 800 µl 1200 µl 
10% NRH 600 Al 800 lal 1200 µt 
2% NHS 120 µl 160 µl 240 µl 
Anti-FITC-HRP 
1/100 stock 
150 µl 200 µl 300 µl 
TMB substrate 
preparation 
Citrate/acetate buffer 6 ml 8 ml 12 ml Dark (RT) 15 
min. 
H202 4.5 µl 6 µl 9 Al 
TMB 60 µl 80 µl 120 µl 
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CHAPTER 3 
PRE- AND POST-VACCINE MEASLES ANTIBODY STATUS IN INFANTS USING 
SERUM AND ORAL-FLUID TESTING: AN EVALUATION OF ROUTINE 
IMMUNIZATION IN ADDIS ABABA, ETHIOPIA 
Summary 
This study evaluated pre- and post-vaccine antibodies in children attending for routine 
measles immunization in Addis Ababa. Infants who presented to 3 health centers 
between September-November, 1998 for routine measles vaccination were enrolled in the 
study. In total 296 infants (median age 9 months) provided blood and oral-fluid samples, 
of which 230 (77%) returned to provide post vaccine samples (median interval of 15 
days). Screening of sera was undertaken using commercial indirect ELISA kits, and of 
oral fluids using an in-house IgM-capture ELISA. Pre-vaccination serology showed 
1.4% IgM positive, 2.0% IgG positive, and 97.0% seronegative. Post-vaccination 
seroprevalence of IgM and IgG was 91.3% and 85.0%, respectively, and 92.9% overall. 
The seroconversion rate was 92.6% (95%CI 88.2-95.7). Based on oral fluid results, 
87.3% (95% CI 82.0-91.4) of children showed specific IgM antibody conversion. These 
results are in support of the recommended age for measles vaccination in Addis Ababa, 
and show the merit of oral-fluid IgM screening as a non-invasive alternative to blood for 
assessing vaccine immunogenicity. 
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3.1. Introduction 
Worldwide it is estimated that measles kills some 880,000 children annually, a toll more 
than any other vaccine-preventable disease. The global plan, established by the World 
Health Organization (WHO) and UNICEF, is to cut this burden by two-thirds between 
2000 and 2005, and thereafter to prevent 600,000 measles fatalities annually (Brown, 
2000). Half of the total deaths are concentrated in three African countries (Congo, 
Ethiopia and Nigeria) and one Asian country (India). Progress towards the control of 
measles requires that countries develop national capacity to measure programme 
effectiveness by which to assess and refine immunization policy. This includes evaluation 
of vaccine effectiveness in infants attending routine immunization clinics. 
The Expanded Programme on Immunization (EPI) in Ethiopia was launched in 1980 
(MOH, 1981a; 1981b), and offers a single dose of measles vaccine at 9 months of age. In 
1999 the national measles coverage was 53% with uptake ranging from 7-88% (the 
highest 88% recorded for Tigray region the lowest 7% recorded for Somali region) in the 
different administrative regions (Source: Department of Family Health, MOH, 2000). 
Research has demonstrated oral fluid to yield detectable levels of immunoglobulins (IgG 
and IgM antibodies) against a wide variety of infections (Parry et al., 1989; 1993; Hunt et 
al., 1993; Perry et al., 1993; Rice and Cohen, 1996; George and Fitchen, 1997; Nokes et 
al., 1998a; 1998b; Vyse et al., 1999; Helfand et al., 1996; Nigatu et al., 1999) using 
sensitive and specific antibody capture assays. The detection of measles specific IgM 
antibodies in oral fluid by antibody capture ELISA (MACELISA) has previously been 
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reported in a study of children who received measles vaccine (Helfand et al., 1996). The 
position of non-invasive antibody testing for measles grows stronger as emphasis on 
vaccine programme surveillance increases, accompanied by technical developments in 
oral-fluid assays (Helfand et al., 1996; Nigatu et al., 1999) and favorable evaluations 
under a variety of settings (Helfand et al., 1996; Nokes et al., 2001; Vyse et al., 2001; 
Ramsay et al., 2003). 
The aim of this study is to evaluate pre- and post-vaccine antibody in children attending 
for routine measles immunization in Addis Ababa. Furthermore, we aim to evaluate the 
use of oral-fluid testing for measles specific IgM as an alternative to serum assays in 
estimating vaccine response and effectiveness. For this an enhanced measles MACELISA 
that incorporates an amplification stage is developed. 
3.2. Materials and methods 
3.2.1. Study population 
Addis Ababa, the capital of Ethiopia, has a population of 2,570,004 (density of 
4,847.8/km2 (CSA, 2000) settled at 2000-2800m altitude above sea level. 
Administratively there are 6 `Zones' (each divided 4-7 Weredas), and 28 `Weredas' 
(=district) each with a population of 45,277-153,688. In 1998/99 measles vaccination was 
given in 7 hospitals, 17 health centres, 9 health clinics, 20 health posts, 104 out reach 
sites under the Region 14 Health Bureau. The estimated measles vaccination coverage in 
1998/99 (1991 E. C. -Ethiopian Julian Calendar) was 86% with variation in the different 
`Zones' and `Weredas'(63-100%). Measles vaccine consumption for the year was 10,250 
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vials given to 32,548 children aged under one year (Source: Addis Ababa City 
Government Health Bureau). 
Three of 19 Government health centers were selected for the study: one from the center 
of the city (Arada, Wereda 1), one in the outer city (Akaki, Woreda 26 and 27), and the 
third from western part of the city (Wereda 25). All infants who presented to these health 
centers between September-November, 1998 for routine measles vaccination were 
eligible for enrolment in the study. All the children had received vaccinations of BCG 
and OPV at birth, and 3 doses of DPT and OPV according to the recommended schedule 
of the EPI Global Advisory Group (6,10 and 14 weeks)(WHO, 1985). Oral informed 
consent was obtained from guardians. Permission for this work was obtained from Addis 
Ababa City Government Health Bureau (No. 1370/172) in 29`h August 1998. 
3.2.2. Sample collection 
Blood samples were collected by finger prick using Safety Flow Lancet into Microtainers 
(Becton Dickinson, Oxford, England). Oral-fluid specimens were collected and processed 
as described previously (Nokes et al., 1998b) by sponge swab collection devices (Oracol: 
Malvern Medical Developments, Worcester, England) from infants before they received 
live attenuated measles vaccine (Schwartz strain, SmithKline Beecham Biologicals, 
Rixensart, Belgium). Mothers were requested to return with their infants two weeks after 
vaccination for a second oral-fluid and blood sample. Samples collected were processed 
at the virology laboratory of the Ethiopian Health and Nutrition Research Institute 
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(EHNRI). OF specimens were transported on dry ice to the UK for advanced laboratory 
analysis. 
3.2.3. Serum measles IgM/IgG determination 
Serum samples were screened for measles virus (MV) specific IgM and IgG by using a 
commercial ELISA kit (Enzygnost for IgM, and IgG; Behring Diagnostics, Marburg, 
Germany). In the IgG ELISA optical density (OD) readings of <0.100, >0.200 and 
between 0.100- 0.200 obtained from 1: 231 IgG serum dilution were considered as 
negative, positive and equivocal respectively. The limit of the IgG detection of the test is 
150 mIU/ml, equivalent to an OD of 0.100. Similarly, in the IgM ELISA OD readings of 
<0.100, >0.200 and between 0.100- 0.200 obtained from 1: 42 IgM dilution were 
considered as negative, positive and equivocal respectively. 
3.2.4. Oral-fluid MV IgM detection 
MV specific IgM in oral fluid was determined by MACELISA, which was a modification 
of the FITC/anti-FITC IgG capture ELISA (GACELISA) described previously (Nigatu et 
al., 1999). For detailed laboratory operating procedure see A2 (Appendix for Chapter 2). 
A description of these modifications follows. Wells of microtitre plates (Maxisorb "U" 
wells, Life Technologies, Paisley, UK) were coated with 100µ1 of a 11.2 g/L solution of 
rabbit anti-human IgM serum (Dako, Ely, UK) diluted 1: 3000 in 0.05M 
carbonate/bicarbonate buffer, pH 9.6. After addition of measles antigen, anti-measles 
haemagglutinin monoclonal antibody-FITC conjugate (Chemicon Inc., Temicula, CA., 
USA) diluted 1: 3000 (instead of 1: 4000 for GACELISA). Anti-FITC horseradish 
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peroxidase conjugate and TMB were then added and the reaction stopped by adding 100 
ul of 0.5M HCI. 
OD results from the MACELISA were expressed as T/N ratios (test sample OD /negative 
control OD). The receiver operating characteristics (ROC) curve was generated (Choi, 
1998) to determine the appropriate cut off T/N value (set to the maximum sensitivity and 
specificity relative to serum results). Relative to serum IgM results (excluding equivocal 
results), the MACELISA was 93.6% (190/203) sensitive and 93.4% (284/304) specific, 
using a T/N ratio of 1.14. T/N ratios less than the cutoff value (1.14) were considered as 
negative in the analyses. 
3.2.5. Statistical analysis 
Analysis was conducted using STATA V7.0 (Stata Corp, College Station, Texas, USA). 
Comparison between median ages uses the non-parametric Kruskall-Wallace test (with 
ties). Estimates of the proportions seropositive for either IgM or IgG exclude samples 
with equivocal results. Overall proportions based on serum specific IgM or IgG results 
exclude only samples equivocal by both tests. Estimates of seroconversion are derived 
from the proportion of individuals specific-antibody negative pre-vaccine whose status 
changes to specific-antibody positive post-vaccination. Proportions seropositive are 
compared using Fisher's Exact test. Exact binomial confidence intervals are calculated 
for prevalence estimates. 
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3.3. Results 
A total of 296 infants were recruited with median age 9 months (range 5-40 m) all 
providing a blood and an oral-fluid sample. The number and median age of individuals 
attending Akaki, Arada and Woreda 25 clinics were, respectively, 86,8m, 41,9m and 
169,10m (median ages did not differ between clinics: %2(2) 5.235, P=0.073). Of the 296 
recruits, 230 (77%) returned to provide post-vaccine samples (median interval of 15 days, 
range 14-46 days) of oral-fluid and blood. Results of the measles-specific IgG and IgM 
tests on serum samples from pre- and post-vaccinated children are shown in Table 3.1. 
Seroprevalence estimates were made excluding equivocal results. Pre-vaccination, 1.4% 
of children were IgM seropositive and 2.0% IgG positive. Post-vaccination 
seroprevalence of IgM and IgG was 91.3% and 85.0%. 
Table 3.1. Seroprevalence of measles antibody status (IgM and IgG) in the pre- and post- 
vaccinated children in Addis Ababa, Ethiopia 1998. 
IgM IgG 
Results Pre-vacc. Post-vacc. Pre-vacc. Post-vacc. 
Positive 4 199 6 170 
Negative 285 19 290 30 
Equivocal 6 9 0 28 
NTa 1 3 0 2 
Total 296 230 296 230 
Proportionb 1.38 % 91.3 % 2.03 % 85.0% 
a NT = Sample collected but not tested because of insufficient serum 
b Proportion = Number Positive / Number (Positive + Negative) 
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Of the 4 pre-vaccination IgM positive samples, 3 were IgG negative (2 aged 9m and 1 
age 10m) and one was high titer IgG positive (age 9m). All the 4 samples were repeated 
by Behring serum IgM ELISA and found to remain positive. Of 6 pre-vaccination IgM 
equivocal results all were IgG negative. Of 6 pre-vaccine sera that were measles-specific 
IgG positive, 5 had high titres (>900mIU/ml), three of which were aged 9m, one 10m and 
one 11 m. One of the 5 was IgM positive, and one (age 10m) had low level antibody 
(296mIU/ml) for which the paired post-vaccine sample showed a greater than fourfold 
rise in titer (i. e. suggesting this individual had residual maternal antibody). 
Of 19 children specific-IgM negative post-vaccination, in pre-vaccination samples 5 were 
IgG positive and one other was IgM positive. Of 9 post-vaccination IgM equivocal 
samples, all were IgM and IgG negative pre-vaccine and, post-vaccine, 2 were IgG 
equivocal and 2 were IgG positive. The time between the pre- and post-sample collection 
for the 2 IgG positive specimens was 15 and 39 days. Post-vaccine, there were 30 
samples negative and 28 equivocal for measles specific-IgG; results which should be 
interpreted in relation to the short interval (median of 15 days) between vaccination and 
second sample collection. Of the 30 samples IgG negative post-vaccination, pre- 
vaccination, none were IgG positive, 1 was IgM positive and 2 had equivocal IgM status. 
Overall prevalence and antibody conversion rate for the sera (based on IgG and IgM 
results) and oral fluid are presented in Table 3.2. 
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Table 3.2. Overall antibody prevalence and conversion rate in vaccine recipients in Addis 
Ababa, Ethiopia 1998. 
Sample type Pre-vaccine % Post-vaccine % Antibody conversion % 
(positive/total) (positive/total) (converters/total) 
95% CI 95% CI 95% CI 
Serum 3.04% (9/296) 92.9% (208/224) 92.6% (200/216) 
1.40%-5.69% 88.7%-95.9% 88.2%-95.7% 
Oral fluid 6.76% (20/296) 86.9% (199/229) 87.3% (185/212) 
4.18%-10.2% 81.8%-91.0% 82.0%-91.4% 
Exact binomial 95% confidence intervals (CI) are shown. There was no significant 
difference between the three clinics in seroprevalence pre-vaccination (Fisher's Exact 
P=0.066) or post-vaccination (P=0.752). Compared with serum estimates, oral-fluid 
prevalence was nearly 4% higher pre-vaccine, and 6% lower post-vaccine, although these 
differences were not significant (95% confidence intervals on prevalence estimates 
overlap). The overall antibody conversion rate for serum was 92.6% (200/216), which 
was higher (but not significantly higher) than for oral-fluid, 87.3% (185/212). 
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3.4. Discussion 
3.4.1. Pre- and post-vaccination status of children 
Assessment of vaccine recipient children (median age 9 months) at three representative 
vaccine clinics in the city of Addis Ababa, showed an absence of measles-specific IgM 
and IgG antibody in 99% and 98% of serum samples, respectively. Considering either 
antibody class, the data suggest that 97% (95%CI 94-98%) of the children attending for 
routine (9 months of age) measles vaccination would respond to vaccine. Following 
measles vaccination the seroconversion rate (based on either antibody class) was 93% 
(95% CI 88-96). Children attending for routine measles vaccination had a median age of 
9m; only 5% were less than 9m and 10% were 1 year or over. Together these results 
indicate a highly successful routine immunization programme. The present 
seroconversion rate study confirms vaccinating children at age 9 months in the Ethiopia 
setting is in accordance to the WHO recommendation (WHO/MOH-Kenya, 1977; WHO, 
1979) and previous mathematical model studies made for developing countries (MacLean 
and Anderson, 1988; Nokes et al., 1990). 
A full assessment of whether or not the present age at immunization is optimal should 
consider the prevalence of residual maternal antibodies and proportion with evidence of 
recent infection in samples from infants attending for routine vaccination. In this study, 
of 15 samples that were positive or equivocal for serum measles-specific antibody prior 
to vaccination, only 1 appeared to indicate the presence of residual maternal antibody 
(low specific-IgG titer with subsequent four fold rise post-vaccination). In contrast there 
were 8 pre-vaccine serum samples specific-IgM positive and/or high specific-IgG titer 
88 
positive, indicative of recent infection (6 aged 9m, and 1 each aged 10 and l lm). These 
results suggest that at the routine target vaccination age a negligible proportion of infants 
have residual maternal antibody, but a small but significant proportion (8/296=2.7%) 
have been exposed to measles virus. This is, at least, an indication of the need to 
discourage any delay in bringing children for measles vaccination beyond the appointed 
age. 
With an average interval of 15 days between receiving vaccination and the collection of 
second samples, the study was primarily designed to investigate the development of 
measles virus specific IgM antibodies. Consequently the results yield a high proportion of 
serologically negative and equivocal IgG results post-vaccination, compared to IgM data. 
Taking IgM serological data alone yields a serconversion estimate of 90%, only 
marginally lower than that based on IgG and IgM results. 
3.4.2. Serum/oral fluid comparison 
The detection of oral fluid specific IgM for measles virus by antibody capture ELISA in 
pre- and post-vaccinated infants has been previously described (Helfand et al, 1996). In 
the present work a new MACELISA test is described that employs an FITC/anti-FITC 
amplification system (Samuel, Patt and Abuknesha, 1998) to enhance the sensitivity of 
the oral fluid assay to a level comparable to that of the corresponding `gold standard' 
serum testing using a commercial kit. Using this amplification system, adequately 
sensitive and specific measles and rubella virus specific IgG oral fluid assay methods 
have been developed (Vyse et al., 1999; Nigatu et al., 1999). The IgM assay developed 
89 
in this study demonstrated 93.6% sensitivity and 93.4% specificity, which is comparable 
to the results of 91% sensitivity and 95% specificity found in a previous oral-fluid testing 
study (Helfand et al., 1996). Based on oral-fluid samples screened using the MACELISA, 
an estimate of specific antibody conversion of 87% (82-91) was obtained. Although 
lower than the overall serconversion rate obtained by Behring ELISA, the result is not 
significantly lower. With such performance the oral-fluid testing method (MACELISA) 
would be of use for measuring measles antibody prevalence in pre- and post-vaccine 
infants. 
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CHAPTER 4 
MEASLES VIRUS CIRCULATING IN ETHIOPIA DURING 1998-9: IDENTIFICATION 
OF A NEW GENOTYPE 
Summary 
Molecular characterization of measles virus (MV) strains contributes to measles control 
programmes by enabling the source and transmission pathways of the virus to be 
investigated. An outbreak of measles in 1998/99 in the Bedelle district in western 
Ethiopia, where routine measles vaccine coverage was <50%, provided an opportunity 
for a molecular epidemiological study. Sporadic cases of measles in the city of Addis 
Ababa, at the same time, where vaccine coverage was 88%, were also examined. To 
identify the genotype and source of MV strains causing the outbreak in Bedelle paired 
serum and oral-fluid samples were collected from 55 cases from the outbreak and from 2 
sporadic cases in the city. Serum and oral-fluid samples were tested for MV-specific 
IgM. Oral-fluid samples were tested for MV RNA by reverse transcriptase-polymerase 
chain reaction (RT-PCR). Nucleotide and deduced amino acid sequences were analyzed 
and compared to those of reference MV genotypes. 53 of 55 cases from the Bedelle 
outbreak and both sporadic cases from Addis Ababa were positive for serum MV-specific 
IgM. Oral-fluid MV-specific IgM was positive in 40 (75%) of the outbreak cases and in 
both of the sporadic cases. RT-PCR using oral fluid was positive in all 55 serologically 
confirmed cases. Sequence analysis was performed on 28 strains from the outbreak; all 
were identical and closely related to the reference genotype D4 strain. One of the strains 
from Addis Ababa was also similar to genotype D4 but the strain from the other sporadic 
case was distinct. It was assigned to Glade D but was not closely related to any other 
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genotype. The MV strain in the Bedelle outbreak was identified as genotype D4. A 
similar D4 strain was identified in sporadic cases in Addis Ababa. The Bedelle outbreak 
may therefore have been caused by the introduction of a case from an urban area where 
measles is endemic into a population with low vaccine coverage. One other sporadic case 
in Addis Ababa was due to a distinct genotype and might be representative of a 
previously undescribed genotype within Glade D. The study clearly demonstrates the use 
of oral fluid for viral genetic analysis, but is less convincing for a role in IgM-based 
diagnosis. 
4.1. Introduction 
Analysis of sequence data of different measles genotypes has been used as an 
epidemiological tool to investigate transmissions of measles in endemic infections and in 
outbreaks. Genetic analysis of strains associated with the 1994 and 1995 measles 
outbreaks in the United States confirmed that infections were the result of international 
importation of the virus (Rota et al., 1995). Recent studies demonstrated the endemic co- 
circulation of two distinct measles genotypes of Glade B in western and central Africa 
(Hanses et al., 1999) while in countries from southern Africa genotypes of Clade A and 
Glade D predominate (Truong et at., 1999). Apart from one report of genotype D4 from 
Kenya (Truong et at., 1999) there is no information available on measles strains 
circulating in countries of eastern Africa such as Ethiopia. Molecular identification of the 
geographical origin of measles virus strains is a key strategy in achieving the aims of the 
World Health Oganization measles elimination/eradication programme (WHO, 2001). 
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In November 1998 a measles outbreak was reported in the regional state of Oromia in 
western Ethiopia, affecting 3 districts. An outbreak investigation was mounted in one 
district, Bedelle, during which paired oral fluid and serum samples were collected for 
MV-specific IgM serology to confirm recent measles infection. Oral fluids have also 
been used as a source of viral RNA for genetic analysis of measles virus strains (Jin et al., 
1996; 1997) and it was decided to use these samples to characterise the virus strain 
causing the outbreak. Measles virus strains detected in oral fluids from sporadic cases 
from Addis Ababa in 1998 were also analysed. The phylogenetic relationships of these 
Ethiopian strains and of others from different geographical origins were studied in order 
to investigate the source of the outbreak and to identify epidemiologically related strains. 
4.2. Materials and Methods 
4.2.1. Study areas and populations 
i). The measles outbreak occurred from 25/12/98 to 30/1/99 in Illubabor, one of 12 
administrative zones of the Oromia regional state in western Ethiopia. The population of 
Illubabor zone is 954,352 (Population and Housing Census Commission, 1995) and 
consists of 12 districts with one hospital, five health centers and 78 health stations. All 
health facilities undertake integrated maternal and child health activities including 
immunization services for children less than one year of age and women of childbearing 
age. There are 57 static sites and 105 outreach teams conducting immunizations. Measles 
immunization coverage in the zone was 36% in 1998. 
Of the 12 districts in the Illubabor zone, three were affected by the 1998/9 measles 
outbreak. These were Chora, Bedelle and Gachi districts, which lie adjacent to each other 
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between longitude 36°20' and latitude 8°20' and an altitude of 1500-2000 meters above 
sea level (Figure 4.1). Chora district was the first to report the outbreak (25/12/98) 
followed by Bedelle and Gachi. A total of 30 villages and two towns were affected by the 
epidemic 
ii). Addis Ababa (population 2.4 million in 1998) has six administrative zones with 
different vaccination coverage. For the target population (children of 9 months) of 32,548 
measles vaccination coverage was 88.5% in 1998 (Source: statistical record of region 14 
Health Bureau). 
4.2.2. Study subjects and specimens examined 
The study subjects were 55 patients visiting the Bedelle Health Center and the Health 
Clinic in Abdella; a town located 15km south west of Bedelle town (Figure 4.1). Acute 
measles patients reported by Health Post attendants (non-medical personnel trained for 
notifying infectious epidemic diseases) were also traced from house to house in the 
different villages of Bedelle district. The clinical characteristics of the measles infection 
observed by the Health Center doctor or nurse were recorded. Paired oral fluid and serum 
samples were collected from patients 2 to 8 (mean 4.4) days after onset of symptoms. 
Oral fluid specimens collected using the sponge swab collection devices were processed 
as previously described (Nokes et al., 1998b; Nigatu et al., 1999) in the Health Center 
and transported in liquid nitrogen to EHNRI, Addis Ababa for storage at -20°C. 
Specimens packed in polystyrene boxes with dry ice were then transported to CPHL, UK 
for measles IgM testing and genotyping. In addition to the outbreak samples, 2 paired 
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oral fluid/serum specimens were collected from Addis Ababa. One was collected from a 
patient diagnosed at a private clinic in 'Zone 5' and the other from a patient at Akaki 
Health Center in 'Zone 6'. 
4.2.3. Serum MV IgM 
MV-specific serum IgM was detected by antibody capture ELISA according to the 
manufacturer's instructions (Light Diagnostics, Chemicon International, Inc., Temecula, 
CA, USA). The Light Diagnostics measles capture ELISA utilises a recombinant MV 
nucleoprotein antigen. 
4.2.4. Reverse transcription-polymerase chain reaction (RT-PCR) 
Nucleic acid was extracted from oral fluid specimens using the silica-guanidinum 
thiocyanate method and MV cDNA produced by RT-PCR as described previously (Jin et 
al., 1996). The primers for amplifying and sequencing a 550 and a 450-nucleotide (nt) 
fragment of the haemagglutinin (H) gene, the entire H gene and the entire nucleoprotein 
(N) gene have been described (Jin et al., 1997; 1996; 1998). In parallel with negative 
controls (deionised H20), the laboratory MV strain, Loss (Sinitsyna et al., 1990), was 
used as positive control. The full laboratory protocol is attached as A4 (Appendix for this 
Chapter). 
4.2.5. Nucleotide and amino acid sequence determination 
PCR amplicons were excised and purified from agarose gels prior to sequencing (Jin et 
al., 1996). Sequencing was performed using the Taq DyeDeoxy-terminator cycle 
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sequencing kit (PE Applied Biosystems, Warrington, UK) with specific primers (Jin. et 
al., 1997; 1996; 1998) in an AB1373A automatic DNA sequencer. Nucleotide and 
deduced amino acid (aa) sequences were analysed with SeqEd (version 1.0.3. 
programme, PE Applied Biosystems). Phylogenetic trees were constructed either by the 
Clustal of Megalign program (DNASTAR, Madison, W1, USA) or bootstrap analysis 
(1,000 times) using neighbour joining of the PAUP 4.0 Beta 2 packages (Sinauer 
Associate, Inc., Sunderland, MA, USA). 
4.3. Results 
4.3.1. Epidemiological findings 
A total of 1,603 cases fulfilling the WHO case definition of measles infection (Strebel, 
1998) were reported in the three districts. The outbreak was first reported in Chora 
district on 25/12/98 and within 20 days spread to all 20 villages in this district. After this 
time the number of reported cases declined. The incidence of measles was higher in the 
Chora district (1,087 per 100,000) than in Bedelle (373 cases) and Gachi (221cases) 
districts to which it subsequently spread (Figure4.1) 
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Figure 4.1. Districts affected by the 1998-99 measles outbreak in Ethiopia. The area in 
which measles infection occurred is highlighted. 
The age group most affected was children between 1 and 4 years who comprised 47.7% 
of clinically reported cases. Most of the remaining cases were in children between 5 and 
14 (39.5(4) or in infants less than one year (9.8(%). Only 3.1% of the clinically reported 
cases were in those aged 15 years or more. The age distribution of the subset ofthe 
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laboratory confirmed cases from Bedelle district was similar (Table 4.1), though fewer of 
the laboratory confirmed cases were in children less than 5 years. 
Table 4.1. Age distribution of reported and laboratory confirmed measles cases 
Age group 
(years) 
Reported cases ( %) Confirmed cases (%) 
<1 156 (9.8) 2 (3.8) 
1-4 762 (47.7) 14 (26.4) 
5-9 393 (24.6) 19 (35.8) 
10-14 238 (14.9) 15 (28.3) 
15+ 50(3.1) 3(5.7) 
Total 1599 53 
Reported coverage for measles vaccine was less than 50% in the 3 districts. Of the 1603 
reported cases, 1440 were in non-vaccinated people and only 163 in those who were 
vaccinated. Management of the epidemic consisted of supportive therapy (antibiotics, 
oral re-hydration salt (ORS) administration and vitamin A supplement) and health 
education. Schools in affected area were closed for approximately one month and 7823 
children under 5 years in adjacent villages were given measles vaccine. 
4.3.2. Laboratory confirmation 
Of 55 cases from Bedelle district, 53 were confirmed as recent measles by both IgM 
serology and RT-PCR with the primer set for amplifying a 450 nt region of the H gene. 
The two cases that were not confirmed were an infant of 7 months and an 18-year-old 
female with a clinical diagnosis of varicella. Of the 53 confirmed, 40 (75%) were measles 
IgM positive in oral-fluid samples. The oral fluid measles IgM detection rate increased 
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from 63-67% at days 2 and 3 to 100% at days 6 and 7 (Table 4.2). The two sporadic cases 
from Addis Ababa were both IgM and RT-PCR positive on oral fluids. 
Table 4.2. Oral fluid measles-IgM detection and date of sample collection in days after 
onset of symptoms in laboratory confirmed cases from Bedelle outbreak 
Oral fluid Days after onset of symptoms No. of 
measles IgM 2 3 4 5 6 7 8 cases 
Pos 2 10 10 8 3 7 0 40 
Neg 1 6 3 2 0 0 1 13 
% 67 63 77 80 100 100 - 75 
4.3.3. Genetic characterization of MV strains 
Of the 53 PCR positive specimens, 28 chosen at random from the Bedelle outbreak and 
two from the sporadic cases in Addis Ababa were sequenced, initially over the 450-nt 
region of the H gene. Identical sequences were obtained in all 28 specimens from the 
Bedelle outbreak, and two distinct strains were identified from the sporadic cases. 
Subsequently, the entire H and N genes of these three representative strains were 
amplified by RT-PCR and the amplicons were directly sequenced. The three strains were 
named as MVsBedelle. ETH/5.99 (ETH10/99) from a 5-year-old child from the Bedelle 
outbreak and MVs/Addis Ababa. ETH/50.98 (ETH54/98) and MVs/Addis Ababa 
ETH/2.99 (ETH55/99) from 10 and 2-year-old sporadic cases from Addis Ababa 
respectively. 
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Figure 4.2 shows the phylogenetic relationships between the three Ethiopian and 33 other 
MV strains including 18 WHO reference strains (WHO, 1998), 10 previously reported 
African strains (Truong et al., 1999), one suspected Indonesian strain, assigned recently 
to genotype G2 (Swart et al., 1999) and three strains (UK140/94 (D8), UK160/94 and 
UK226/94) identified in the UK in 1994 (Jin et al., 1998) which are closely related to 
ETH54/98. The phylogenetic tree in Figure 4.2 was constructed by analysing the entire H 
gene sequence (1854-nt). The three Ethiopian (ETH) strains were clustered in the D but 
located on two different branches. Strains ETH10/99 and ETH55/99 were closest to 
genotype D4 and there were respectively, 32(1.7%) and 29 (1.6%) nucleotide differences 
and 7 (1.1%) and 3 (0.5%) amino acid differences between these two ETH strains and the 
D4 reference strain (Monteral. CAN/89). There was at least 2.5% divergence between 
these two ETH strains and other genotypes of Glade D. Strain ETH54/98 showed at least 
2.4 % divergence to all reference genotypes but over 98% similarity to the three strains 
(UK140/94 (D8), UK160/94 and UK226/94) identified in the UK in 1994 (Jin et al., 
1998) and formed a new branch together with these three strains. The degree of 
divergence would suggest that this group should be considered an additional genotype of 
Glade D. 
A similar phylogenetic tree based on the C-terminus of the N gene was constructed by the 
Neighbour joining method (PAUP version 4.0) and subjected to bootstrap analysis (1,000 
times, Figure 4.3). Strains ETH10/99 and ETH55/99 were close to genotype D4 but strain 
ETH54/98 appeared on a new branch with the strains detected previously in the UK. This 
confirmed phylogenetic relationships based on analysis of the H gene. On the basis the 
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entire N gene sequence, there were 34 (2.2%) and 32 (2.0%) nt differences and 8 (1.5%) 
and 5 (0.9%) as differences between the ETH strains 10/99 and 55/99 and D4 reference 
stain (Montreal. CAN/89), while there was at least 3% divergence from other reference 
genotypes. There were 17 (1.1%) nt differences between strain ETH54/98 and the UK 
strains and at least 2.7% divergence from other genotypes. 
Amino acid differences between the three ETH strains and closely related MV strains are 
summarised in Table 4.3. Amino acids coded by consensus nt sequences (con. ) were 
based on the sequences of strains selected for phylogenetic analysis that covered all M 
genotypes defined by the WHO (1998). Compared with the as sequence of the 
Mont89/D4 strain, there were 7 (ETH10) and 3 (ETH55) as differences in the H gene and 
8 and 5 as differences in the N gene. Compared with the as sequence of the UK140 (D8) 
strain, there were 13 as differences in the H gene of strain ETH54 but no as differences in 
the N gene because, although there were 17 nt substitutions, all were synonymous. 
101 
Table 4.3. Amino acid differences between ETH and closely related MV strains 
Gene as Con. * Measles strain 
D4 D? 
Mont89 ETHIO ETH55 UK140 ETH54 
11 34 R K K 
79 D N 
120 D N 
160 E D 
174 T A A A A A 
176 T A A A A A 
192 T p 
194 T L 
196 G S 
212 R Q 
247 S p 
252 Y H H H H H 
283 L F F F F F 
296 L F F F F F 
302 G R R R R R 
305 S A A 
307 T A A 
366 A V 
400 A T 
416 D N N N N 
451 V M M 
473 I V V V 
517 L I 
546 S G 
560 K R 
577 L p 
594 1 L 
608 V A 
612 D E 
N 61 N D 
137 S G 
138 I 
139 G G 
144 F S S S S S 
406 1 T T 
420 L I I I 
441 K R R 
450 S N 
451 Y N N 
456 P S S S S S 
459 A T T L L 
470 G S S S S S 
482 S G G G G G 
514 T I I I 
521 R K 
522 D N N N N 
* amino acids coded by consensus nucleotide sequence 
Notes: only differences are indicated and important functional sites are highlighted. 
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Figure 4.2. Genetic relationships between measles strains detected in Ethiopia and 
previously reported genotypes. An unrooted tree diagram was constructed on the basis of 
the entire H Lene (1854 nt) sequence using the Clustal method (Megaliga programme, 
DNASTAR). Strains reported in this study are highlighted. WHO reference strains are in 
boxes and genotypes assigned previously are indicated at the end of the strain 
designation. 
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Figure 4.3. Genetic relationships between measles strains detected in Ethiopia and 
previously reported genotypes on the basis of the C-terminus of the N gene (456 nt). The 
phylogenetic tree was drawn by bootstrap analysis (1,000 tines) using the Neighbor- 
joining method (PAUP 4.0 package). MV strains reported in this study are highlighted 
and the reference strains (in boxes) with the designated WHO MV genotype are indicated 
at the end of each strain designation. 
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4.4. Discussion 
Factors contributing to the spread of measles infection included the low vaccination 
coverage of less than 50% and the gathering of people in schools and market places. The 
age groups affected were principally children between 1 and 14, as observed in England 
and Wales prior to the introduction of measles vaccine (Benjamin, 1968). 
Although infections with other agents such as rubella, parvovirus B 19, human herpes 
virus-6 (HHV-6) and Group A streptococcus may resemble measles clinically (Nur et al., 
1999), the diagnosis of measles cases in this study by staff at Health Centers was mostly 
confirmed where laboratory investigations were done. Of the 55 clinically diagnosed 
cases investigated in the Bedelle outbreak, 53 were confirmed as recent measles by serum 
IgM testing and PCR. Two cases were not confirmed. One was an adult in whom 
varicella was suspected. The other was a 7-month infant. A frequent cause of measles 
misdiagnosis in this age group is roseola infantum, primary infection with HHV-6 (Tait et 
al., 1996). 
The performance of oral fluid IgM assay was poor in detecting early onset natural 
measles infections. This shows that with greater time from rash onset, there was high 
predictive value of positive for oral fluid. This suggests a sensitivity problem of the 
assay, requiring longer developing antibody to be detected. This indicated that taking oral 
fluid for IgM diagnosis should be excluded, as delays patient diagnosis should not occurs. 
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Sequence analysis of measles RNA amplified by RT-PCR identified three virus strains. 
All 28 strains from the Bedelle outbreak were identical and closely related to genotype 
D4. One of the strains from sporadic cases in Addis Ababa was also similar to genotype 
D4 but the ETH54 strain from Addis Ababa was distinct. It was closely related to strains 
identified in the UK in 1994 (Figure 4.2,4.3). While ETH 54 could be assigned to Glade 
D it was not identical to any previously described genotype within this Glade and might 
be representative of a previously undescribed genotype. The occurrence of this genotype, 
in addition to the genotypes A, B1, B2, B3, D2 and D4 previously identified in Africa, 
suggests that antigenically and genetically distinct MV lineages are co-circulating in 
Africa. The results in this study indicate the need for continued molecular and antigenic 
surveillance of wild-type MV strains. 
Analysis of as sequence variation in the entire H and N genes of the three ETH strains 
revealed that there were significant changes (Table 4.3) affecting sites currently 
recognised as having important biological and immunological functions. These sites 
include the predicted B-cell epitope at aa309-318 of the H gene (Partidos et al., 1991; 
Makela et al., 1989) and three antigenic sites at aa122-150, aa457-476 and aa519-525 of 
the N gene (Buckland et al., 1989; Komase et al., 1990). Amino acid 416 of the H gene, 
which is postulated to affect hemagglutination (Saito et al., 1995), was found changed in 
all three Ethiopia strains compared to the as coded by the consensus nt sequence (Table 
4.3). The nt substitution G to A, which results in the change at aa416, produces an 
additional potential N-linked glycosylation site which has been found in isolates from 
Japan (Saito et al., 1995) and the USA (Chil/89, D3; WHO reference strain). Analysis of 
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the nt sequences of strains ETH10 and ETH55 (detected in 1998/9), the reference 
genotype D4 strain (isolated in 1989), strain ETH54 (detected in 1998/9) and the closely 
related UK strains (identified in 1994) showed significant genetic relationship. 
Furthermore, in previous studies, antigenic reactivity demonstrated by different 
monoclonal antibodies indicated that current wild-type MV genotypes contain strain 
specific epitopes (Komase et al., 1998). Further studies to attempt isolation of the ETH 
MV strains in cell culture and to map their antigenic epitopes and genetic evolution are 
currently in progress. 
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A4 (APPENDIX TO CHAPTER 4) 
MEASLES VIRUS POLYMERASE CHAIN REACTION 
(No cross reference in this version, however, Jin et al. 1996 can be refer) 
1. Equipment 
9 Micropipettes capable of dispensing volume range of 1 -4 1000 ul range and 
compatible sterile plugged tips. 
" Thermocycler and compatible thin walled micro-reaction tube. 
9 Sterile 1.5 ml micro-tubes 
Latex gloves and laboratory coat dedicated for use in each lab. 
9 Glax pyrex conical 500 ml flask. 
" Electrophoresis equipment; gel pouring tray, combs, tank unit and power pack. 
" Assorted sterile racks 
" Dispojars 
" Autoclave bins 
2. Reagents 
" Polymerase Taq 
" 10 X Taq buffer 
9 Pri mer 'h 1' 5'ACTACAATCAGAGGTCAATTC 3' 
9 Primer `h2R' 5'AGCATGTCTCCATTCGCAACT 3' 
" Primer `h3' 5'CAGAGGTCAATTCTCAAACA 3' 
" Primer `h4R' 5'CATTCGCAACTTGTCATCTG 3' 
9 Primer `nl' 5'TGCATACTACTGAGAACAA 3' 
" Primer `n2R' 5'TCTCGCACCTAGTCTAGAA 3' 
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" Primer `n3' 5'ATCAGTAGAGGCGGTTGGA 3' 
" Primer `n4R' 5'GTCTGAGCCTTGTTCTTC 3' 
" MgCI2 (50mM) 
" dNTPs (10mM) 
" Sterile distilled high quality water (Sigma) 
" Sterile mineral oil 
9 Seakem Agarose 
9 TBE buffer 
" 0.25% orange G, 10% Ficol in TBE buffer, filtered (+4°C) 
" Ethidium Bromide (10mg/mi) 
3. Operating Procedure 
3.1. Extraction of Measles 
For one reaction mix combine 
L6 860u1 
Silica 40u1 
Specimen 100u1 
Total 1000u1 
" Vortex 10 seconds, keep at room temperature for 10 minutes (mix or vortex every 2-3 
minutes). 
" Centrifuge 15 seconds, discard supernatant by suction 
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" Wash the silica-NA pellet twice with L2, twice with 70% ethanol, once with acetone 
(lml wash solution, vortex briefly, centrifuge for 15 seconds and discard the 
supernatant). 
" Dry the silica-NA pellet at 56°C with an open lid for 10 minutes. 
" Add 59u1 RNASE free dH2O and lul RNAsin, Vortex and incubate for 10 minutes at 
56°C, overnight at 4°C. 
" Centrifuge for 2 minutes and use 40u1 of the supernatant for the cDNA synthesis. 
3.2. cDNA Synthesis of Measles Virus RNA 
For one reaction mix combine 
Extracted RNA 40u1 
10 x PCR buffer lOul 
50 mM MgC12 3u1 
10 mM dNTPs 2u1 
400u R. T. 2u1 (M-MLVRase) 
RNAsin (40u) lul 
pd(N6) lul (0.02u) 
H2O 41 u1 
Total 100ul 
The reaction mixture was incubated at room temperature for 10 minutes, at 37°C for 60 
minutes, at 95°C for 5 minutes and cooled on ice for 3 minutes. The synthesized cDNA 
was stored -20°C or used for PCR. 
110 
3.3. First round amplification 
3.3.1. For 1 reaction mix combine 
5u1 of 10 x Taq buffer 
1.5u1 of 50mM MgC12 
lul of primer `hl' at lOpmol/ul 
lul of primer'h2R' at 10 pmol/ul 
I ul of pri mer `n 1' at 10 pmol/ul 
lul of primer 'n2R' at 10 pmol/ul 
1 ul of 10mM dNTP mixture 
0.4u1 of Taq 
20.175u1 H2O 
Final volume of 30u1 
3.3.2. Multiply by the above volumes the number of tests you have (plus two to allow for 
pipetting errors) to make up the bulk reaction. 
3.3.3. Pipette 30u1 of reaction mix to labeled thin-walled tubes. Add 1 drop of oil to each 
tube and close the caps. 
3.3.4. Take tubes to the thermal cycler room, open caps and short spin the sample to add 
20u1 of the sample (cDNA) to each tube. 
3.3.5. Start the thermal cycling with the following conditions. 
95°C 2 minutes 
95°C lminute (denaturation) 
50°C 2 minutes (annealing) X 25 
65°C 3 minutes (extension) 
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Note: - Single gene target PCR can be carried out with either pair of primers and the 
following thermal cycling conditions: - 
95°C 2 minutes 
95°C 1 minute (denaturation) 
50°C 1 minute (annealing) X 25 
72°C lminute (extension) 
For PTC-200 Thermal cycler 
" Switch on 
9 Press proceed 
9 Proceed again 
" Press arrow to MPLEX-1 
" Press proceed 
" "Enabled" - proceed 
9 Run has started 
3.4. Second round amplification 
3.4.1. For 1 reaction mix combine 
5u1 of 10 X buffer 
1.5u1 of 50 mM MgC12 
1ul of primer `n3' at 25pmol/ul 
lul of primer `n4R' at 25pmoUul 
lul of primer `h3' at 25pmo1/ul 
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lul of primer `h4R' at 25 pmol/ul 
lul of 10 mM dNTP mixture 
30.4 ul H2O 
0.4 ul Taq 
Final volume of 40u1 
3.4.2. Multiply by the above volumes the number of tests you have (plus two to allow for 
pipetting errors) to make up the bulk reaction. 
3.4.3. Pipette 40ul to labeled thin-walled tubes add 1 drop of oil to each tube and close 
the caps. 
3.4.4. Take tubes to the thermal cycler room, open caps and add 10ul of 151 round product 
to each tube. 
3.4.5. Start the cycling with the following conditions 
95°C 2 minutes 
95°C 1 minute (denaturation) 
50°C 2 minutes (annealing) X 35 
65°C 3 minutes (extension) 
Note: - Single gene target PCR can be carried out with either pair of primers and the 
following thermal cycling conditions: 
95°C 2 minutes 
95°C 1 minute (denaturation) 
55°C 1 minute (annealing) X 25 
72°C 1 minute (extension) 
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For PTC-200 Thermal cycler proceed as in 3.3.5. above except at stage 4 press arrow to 
MPLEX-2. 
3.5. Agarose gel analysis of PCR products 
3.5.1. Make up a 2% agarose gel in TBE buffer by dissolving 1.6g Seaken agarose in 
80mis TBE buffer in 500 ml flask in microwave. Pour molten gel on to gel plate with 
gel comb. When gel has set remove comb. 
3.5.2. Combine lOul of the sample with 5ul of orange G/Ficol with 15u1 of TBE buffer. 
Use a 96 well microtiter plate to prepare the samples for electrophoresis. 
3.5.3. Add TBE to the electrophoresis tank so that the buffer just reaches the top surface of 
the gel, but does not submerge it. Load samples into the dry wells. Electrophoresis 
samples for 5 minutes until the gel enter. Add TBE to submerge the gel and continue 
electrophoresis at approximately 120V for 1 hour. Stain with Ethidium Bromide and 
photograph the gel. 
3.6. Gene clean 
3.6. x. Fragments were cut from agarose gels, using modified geneclean method. 
3.6.2. Put it in tube, add 900u1 (9m1 6M NAI + Iml of 1OxTBE) mixture, add 10 ul of 
silica, keep at 56°C for 10 minutes (vortexing every 2-3 minutes), and then centrifuge 
for 6 seconds. 
3.6.3. Wash the pellet with 1-ml new wash (70% cold ethanol) for 3 times. 
3.6.4. Dry the pellet at 56°C for 5 minutes; add 22u1 of water, vortex, and keep at 56°C for 
3 minutes. 
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3.6.5. Centrifuge for 30 seconds, and then at 56°C for 3 minutes, centrifuge for 30 
seconds. 
3.6.6. Store the supernatant at -20°C for sequencing. 
3.7. Sequencing 
3.7.1. For one reaction i 
Sequencing mix 
3.2 Pmol primer 
DNA 
H2O 
nix combine 
8u1 
1 ul (M3, or M4, H3, H4, N3, N4) 
2-9u1 
9-2u1 
Total 20u1 
3.7.2. Spin and 25X cycles (96°C for 30 minutes, 50°C for 15 minutes, 60°C for 4 
minutes). 
3.7.3. For one reaction mix combine 
The reaction 20u1 
3M NA AC 2u1 
100% Ethanol 50ul (cold) 
3.7.4. Vortex on ice for 10 minutes, centrifuge for minutes. 
3.7.5. Wash the pellet with 50u170% cold ethanol (no vortex), centrifuge for 5 minutes. 
3.7.6. Discard supernatant by suction and dry the pellet at room temperature for 
sequencing. 
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CHAPTER 5 
SEROLOGICAL AND MOLECULAR EPIDEMIOLOGY OF MEASLES VIRUS 
OUTBREAKS REPORTED IN ETHIOPIA DURING 2000-2002 
Summary 
For the past five years, from 1998 to 2002, Ethiopia implemented a measles supplemental 
immunization (MSI) programme targeted at 9m-59m old children in addition to the 
routine vaccination given at 9 months. Despite this initiative measles outbreaks occurred 
throughout the country. In this study serological and molecular diagnosis of measles 
outbreak samples demonstrated the need for refining of the measles immunization 
programme. During 2000 - 2002 through the MOH/EPI network suspected measles 
cases were identified across the country. As a result 150 serum and/or oral-fluid samples 
were collected from 17 suspected measles outbreaks, which occurred throughout the 
country. Of the total, 119 and 140 of them were characterized serologically and 
molecularly, respectively. Based on the serological investigation about 93% of the 
confirmed cases were children under 15 years of age and 6.5% were 15+ years old. Of the 
total unvaccinated suspected measles cases (n = 108), 83.3% (90) had confirmed measles 
infection. Of the total vaccinated measles cases (n =11), 27% (3) had confirmed measles 
infection. Of 140 samples analysed by RT-PCR measles virus specific cDNA was 
detected in 39% (54). A total of 31 wild-type measles viruses were characterized by 
nucleic acid sequence analysis of the nucleoprotein (N) and haemagglutinin (H) genes. 
Two recognized genotypes (D4 and B3) were identified. Each outbreak comprised of 
only a single genotype and outbreaks of each genotype tended to occur in distinct 
geographical locations. The study appeared to clarify the epidemiological links of the 
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outbreaks of B3 genotype, which occurred in Khartoum, Sudan, near to the Ethiopian 
border. D4 genotype was previously observed in an outbreak in 1999 and occurs in more 
diverse locations throughout the country than B3. B3 was first observed in 2002, has now 
been the cause of 3 outbreaks. It is concluded that both genotypes have contributed to the 
maintenance of measles in the country. Furthermore, it is concluded that control measures 
have failed to interrupt transmission. These serological and molecular results provide 
important information for refining the measles immunization activities. If measles is to be 
controlled, routine immunization should be strengthened and the MSI should involve 
older children (5-14 age groups). 
5.1. Introduction 
In Ethiopia, measles is the commonest single (aetiologically) cause of mortality and 
morbidity in children. Measles together with malaria, acute respiratory infection, 
diarrhoea and malnutrition are responsible for 70% of under-five morbidity and mortality 
(MOH, 1998). 
In 1990 (when the EPI began monitoring the routine measles uptake), the national 
measles immunization coverage was 9%. In subsequent years the coverage increased 
every year to a maximum of 54% in 1996. This level was maintained for the following 
three years after which it dramatically falls to 37% in 2000. As shown in Figure 5.1 
measles reported cases declined as the EPI coverage increased after 1990 at least for five 
years. Although the routine measles EPI coverage reached 54% in 1996 and remained 
relatively stable for the following three years the number of measles cases reported 
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actually increased (Source: Disease Prevention and Control Department, Family Health 
Department; MOH 2002). 
Figure 5.1. Measles immunization coverage and number of reported measles cases in 
Ethiopia, 1990-2000*. 
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From these data it is clear that the measles coverage has remained low over the past 
decade, and that this level is inadequate for the control of transmission, for which >93% 
coverage is required (Anderson and May, 1991) During severe outbreaks the case fatality 
rate is in the range of 15 to 20%I% (Lindtjorn, 1986), where as in tines of low incidence it 
is 3 to 5% (MOH, 1998). 
Since 1998, Ethiopia has implemented the Measles Outbreak Prevention Phase of the 
Accelerated Measles Control Strategy (MOH, 2001). The term outbreak is used when the 
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observed number of cases is greater than that normally expected from the same 
geographical area over the same time period. During this phase, an outbreak is to be 
defined as more than 10 measles cases per Zone (= District) per week. 
As measles control accelerates and cases diminished, the clinical diagnosis becomes less 
efficient (WHO, 1999). Therefore diagnosis of measles should rely on laboratory 
confirmation. In this way it is possible to confirm the extent of each outbreak and assist 
in measuring the effectiveness of the vaccination programme. Molecular characterization 
of samples from outbreaks can assist in the detection of the different genotypes of the 
measles virus; identify the transmission pattern and the geographical (transmission) links 
of the measles outbreaks (Rota et al., 1996). Sequence variability among the strains and 
comparison with the consensus sequence of Glade D genotype was presented in Chapter 
4. This present chapter focuses on the differentiation of outbreaks resulting from either 
case importation or transmission of indigenous MV lineages. The distinction was made 
through the interpretation of temporal and spatial genotypic pattern. The occurrence of 
indigenous MV suggests failure of measles control measures to interrupt transmission. 
There are global implications of studies of this nature in relation to measles elimination 
nationally and internationally (Bellini and Rota, 1998; Chibo et al., 2000). The purpose of 
this paper is therefore to present the studies of 17 measles outbreaks reported in the 
country to identify through serological and molecular epidemiologic analysis, reasons for 
the outbreaks, which will assist in monitoring and control of the disease in the future. 
This study was partly linked to The National Measles Reference Laboratory (NMRL) 
activities at EHNRI. NMRL was established by the support of MOH and WHO country 
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office. It has a role in monitoring the measles control and surveillance programme by 
providing results of measles laboratory diagnosis to RHB, MOH/EPI and WHO/EPI. 
5.2. Materials and methods 
5.2.1 Study area and population 
The population for 2002 derived from projecting the 1994 census shows that 86.4% 
(58,103,000) of the Ethiopian population settled in Tigray (3,901,000), Amhara 
(17,205,000), Oromia (23,704,000) and SNNP (13,293,000) in high measles risk regions 
(CSA, 2001). The national routine EPI coverage for measles has declined from 53% in 
1999 to 37% in 2000 (see Figure 5.1). The routine measles coverage for Tigray, Amhara, 
Oromia and SNNPR during 2000 was 72%, 61%, 28% and 24% respectively (MOH, 
2001). Because of this low coverage repeated measles outbreaks were reported from 
various parts of the aforementioned regions for the last three years. In these studies 
laboratory investigations were performed for 17 suspected measles outbreaks, which 
occurred in Tigray (5 outbreaks), Oromia (2 outbreaks), Amhara (6 outbreaks) and 
SNNPR (3 outbreaks) regions (see Table 5.3). One other suspected measles outbreak 
occurred in Diredawa town and was also investigated. The study areas (districts or towns) 
where the investigations were carried out showed in Figure 5.2. 
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Figure 5.2. Districts affected by the 1998-02 measles outbreaks in Ethiopia. The area in 
which measles infection occurred is highlighted. 
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5.2.2 Clinical diagnosis 
Any person with fever and/or maculo-papular rash and/or cough and/or conjunctivitis 
was considered as clinically diagnosed for measles (WHO, 1999). The data reported in 
this study fulfill the above definition confirmed at hospital or health center level by health 
practitioners. 
5.2.3 Outbreak investigation 
When an outbreak occurred in a district the case was notified to the Regional Health 
Bureau (RHB) and Ministry of Health (MOH). Through the networks of the RHB, 
MOH/EPI and WHO/EPI, District laboratory personnel collected laboratory specimens 
with the assistance of district polio focal persons from measles outbreaks accompanied by 
case investigation forms for measles notification. In the case of early notification a team 
from EHNRI made a further investigations in districts of Gindeberete and Nono, and 
Tigray region. Usually serum samples reached processed otherwise samples (under cool 
condition in ice boxes) and forms were sent to EHNRI measles reference laboratory, 
Addis Ababa, Ethiopia. Specimens were then processed and stored at -20°C until tested. 
Serological results were reported to respective RHB, MOH/EPI and WHO/EPI country 
office. 
5.2.4 Laboratory confirmation of measles cases and genotyping 
Serum or whole blood /oral fluid specimens were collected from 5 or more of the first 10 
cases in each Zone (= District) for laboratory investigation. Serum samples were tested 
for IgM at the National Measles Reference Laboratory, EHNRI using the Behring Kits 
(Enzygnost for IgM, Behring Diagnostics, Marburg, Germany) and following the 
122 
manufacturer instructions. Detection of measles IgM in serum was considered a 
diagnosed case of measles, which has been confirmed by laboratory. WHO supplied Kits 
through the WHO/EPI country office. 
Polymerase Chain Reaction (PCR) was used to amplify viral genome in oral fluid, whole 
blood or serum samples collected from suspected measles patients. The full PCR standard 
operating procedure used for this study was attached in Chapter 4 as A4 (Appendix for 
Chapter 4). Sequencing of PCR products was carried out as previously described (Jin et 
al., 1996; Jin et al., 1997; Nigatu et al., 2001). Measles strains characterized were 
classified according to WHO nomenclature for wild-virus genotypes (WHO, 2001). A 
phylogenetic tree was constructed by analyzing either the 511 nucleotides (nt) of the H 
gene sequence or the 456 nt of the N gene sequence (Jin et al., 1998) using the Clustal 
method (Megalign Programme, DNASTAR). 
5.3. Results 
Over the period of 2000 - 2002, the MOH/EPI network was utilized to identify cases of 
measles-like infection across the country. Through the link, samples were collected from 
suspected measles outbreaks. The age distribution of laboratory confirmed measles cases 
are presented in Table5.1. Based on 119 suspected measles cases tested serologically the 
age group 0-1 contributed to 4.3% of the confirmed cases, 1-5 to 28%, 5-10 to 30.1%, 10- 
15 to 31.2% and the rest 6.5% was attributed to the age group 15 years and above. About 
93% of the cases were under 15 years of age. 
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Table 5.1. Age distribution of laboratory confirmed measles cases 
Age group 
(years) 
No. tested No. positive (%) Confirmed cases (%) 
<1 7 4(57.1) 4(4.3) 
1-4 31 26 (83.9) 26 (28.0) 
5-9 43 28 (65.1) 28 (30.1) 
10 - 14 32 29 (90.6) 29 (31.2) 
15+ 6 6(100) 6 (6.5) 
Total 119 93 (78.2) 93 
Table 5.2 below shows vaccination status of laboratory confirmed measles cases. In the 
108 unvaccinated children 90 cases (83.3%)were confirmed as measles IgM positive. Of 
the total vaccinated (11) children 3 cases (27.3%) had confirmed measles disease. 
Table 5.2. Vaccination status of laboratory confirmed measles cases. 
Result Vaccinated (%) Unvaccinated (%) 
Negative 8 (72.7) 18 (16.7) 
Positive 3 (27.3) 90 (83.3) 
Total 11 108 
The investigation of 17 suspected measles outbreaks is summarized in Table 5.3. The 
table shows a total of 150 serum/saliva specimens were collected from measles suspected 
patients. Of the total, 40 serum/oral fluid samples were collected from two measles 
outbreaks of western Shoa of the Oromia region. A further 52 were serum/oral-fluid 
samples collected from 5 measles outbreaks of Tigray region in northern Ethiopia. The 
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remaining 38,15 and 5 were serum samples collected from 10 suspected measles 
outbreaks of Amahara region, SNNPR and Diredawa town respectively. Samples of 14 
out of the 17 outbreaks were tested serologically, of which 13 (92.9%) outbreaks could be 
confirmed. A further 3 outbreaks for which there were no serum samples available for 
serological testing, outbreak samples (whole blood or oral fluid) were tested molecularly 
by PCR, and 2 were confirmed as measles outbreaks. All the 5 serum samples collected 
from Bahirdar town were serologically negative. Of these tested by RT-PCR one sample 
found positive. Of the total 16 laboratory confirmed (serologically and molecularly) 
outbreaks, 15 (94%) took place between January -August in the dry season. Of the 15,3 
occurred in the month of April and 5 in June. The remaining 1 occurred in November in 
the rainy season. 
The Behring ELISA detected measles IgM in 93 (78.2%) specimens. The RT-PCR 
amplification of the N nucleocapsid and H haemagglutinin genes were employed on 140 
of the 150 specimens (only 10 samples from the target outbreak investigation were 
excluded). The samples used for PCR were of mixed type (serum, oral fluid, and whole 
blood). Out of the total, measles virus specific DNA was detected in 54 (38.6%) 
specimens. Representative samples of 31 PCR positive specimens were selected from 14 
outbreaks for sequencing. Sequence analysis of 11 outbreaks revealed that the viruses 
were D4 genotype. Genotype B3 was identified from the 3 outbreaks of Wolkayet, 
Woreta and Bahirdar in North West part of the country (see Figure 5.2) 
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Table 5.3. Serological, PCR and genotype results for specimens collected from measles 
suspected patients during 2000 - 2002, stratified by geographical location. 
Region/ District Specimen type No. serolo No pos. Prop. No PCR No pos. Prop. No (; enoty 
Zone/ (Reported month) (No collected) gically (%) tested (%) sequen pe 
Town tested ced 
Oromia Gendebret Paired serum & 3 (n) 
(January, 00) oral fluid (24) 24 20 83.3 14 13 929 D4 
Nono Paired serum & 6 (3n, 
(November, 01) oral fluid (16) 16 13 81.3 16 8 50.0 3h) D4 
Tigray Atsibi Serum (7) 7 5 71.4 7 1 14.3 1 (n) D4 
(June, 01) 
Ganta Afeshume Whole blood 
(February, 01) (15) ND* - - 15 4 26.7 4 (n) D4 
Offla Serum (14) 14 12 85.7 14 3 21.4 3 (3h, D4 
(August, 01) In) 
Gulomakada Oral fluid (4) ND* - - 4 0 0 0 
(March, 02) 
Wolkayet Oral fluid (12) ND* - - 12 12 100 2 (h) B3 
(March, 02) 
Amahara Woreta Serum (9) 9 9 100 9 2 0 2 (h) B3 
(April, 02) 
Gondar town Serum (6) 6 2 33.3 6 0 0 0 
(April, 02) 
Ebinat(July, 02) Serum (6) 6 6 100 6 1 16.7 1 (n) D4 
Bahirdar town Serum (5) 5 0 0 5 1 0 1 (h) B3 
(June, 02) 
Woreillu Serum (5) 5 5 100 5 3 60.0 2 (n) D4 
(April, 02) 
Ankesha (Awl) Serum (7) 7 2 28.6 7 0 0 0 - 
(July, 02) 
SNNPR Sheko(May, 02) Serum (5) 5 5 100 5 1 20.0 1 (n) D4 
Lomma Serum (5) 5 5 100 5 2 40.0 2(n) D4 
(June, 02) 
Damot Gale Serum (5) 5 5 100 5 2 40.0 (n) D4 
(June, 02) 
Diredawa Diredawa town Serum (5) 5 4 80.0 5 1 20.0 1 (n) D4 
(June, 02) 
Total 150 119 93 78.2 140 54 38.6 31 
*= , Not 
done-no serum sample available jor testing 
** = Sequenced either for h haemaglutinin or n nucleocapsid gene 
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Figure 5.3 and 5.4 show genetic relationships between measles strains detected in 
Ethiopia during 2000-2002 and previously reported genotypes (in Ethiopia and 
worldwide) on the basis of the N gene (456 nt) (Figure 5.3) or H gene (511nt) (Figure 
5.4). MV strains reported in this study or that of Chapter 4 are indicated in circles and 
boxes. Both Figures show that D4 genotype is the most widely distributed in North, West 
and Southern parts of Ethiopia. B3 is distributed in specific areas of Amahra and Tigray 
regions. 
Figure 5.3. Genetic relationships between measles strains detected in Ethiopia during 
2000-2002 and previously reported genotypes. Unrooted tree diagram was constructed on 
the basis of the N gene (456 nt). 
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Figure 5.4. Genetic relationship between measles strains detected in Ethiopia during 
2000-2002 and previously reported genotypes. The unrooted tree diagram was 
constructed on the basis of the H gene (511nt) sequence. 
INddis Ababa-I 999 
h/ ff a-200 
01-201 
2% 
ETOO-206h anta es um- 2001 D4 
-6 ET01-17oh týsýbý-2001 
01-167h 
01-185h ono-20 1 
ET01-188h 
ET99-10h -13edelle-1999 
Erlan. DEU90-C2 
WTF. DEU92-C2 
Goet. DEU71-E 
Mad. SPA94ss-F 
Loss-A 
Mor-Vac 
Mont. CAN89-D4 
II1n. USA99-D7 
Vic. AUS85-D7 
anch. UNK94-D8 
ET99-54h is Aba a-1998 8 
Ban. THA93-D5 
PAIA. BlA93-D5 
Ilino. USA89-D3 
- Bristol. UNK74-D1 
JOHANNI. SOA88-D2 
NJ. USA94-D6 
Tokyo. JPN84-C1 
Ams. NET97-G2 
Vict. AUS99-G3 
Berk. USA83-G 1 
Hun. CHN93-H1 
Bj. CHN94-H2 
02-23h-B3 oreta -2002 
2-25h-e 
}B3 
ETO r3 air ar -2002 Ibadan. Ni iB3 
NY. USA/94-B3 
CAM83-B1 
Libreville/GAB84-B2 
5.4. Discussion 
Measles Outbreak Prevention is the strategy recommended for most of the Eastern 
African block countries where measles EPI coverage is 50 - 75% (WHO, 1997; WHO- 
Afro, 2000). Since the routine measles immunization coverage is low (<54%) in Ethiopia 
the strategy recommended for the country is the Measles outbreak Phase of the 
accelerated measles immunization control programme. The activities here include 
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improved surveillance to understand the changing epidemiology of the measles disease 
and identification of populations at higher risk. The data presented in Table 1 shows that 
the higher risk populations are less than 15 year children settled in Oromia, Amahara, 
SNNP and Tigray regions. This is consistent with the national measles cases data 
reported in the years 1997/98 - 2001/02 that indicates about 95% of cases were less than 
15 years of age (MOH, 2002). Table 5.1 also shows an increasing proportion (61.3%) of 
measles confirmed cases among older age groups, 5- 14 years. This result is consistent 
with epidemiological data collected for Tigray region that indicates an increasing 
proportion of measles cases among older children, 5- 14 years, over consecutive 7 years 
from 1994 compared to the children less than five years (Table 5.4). The national data 
collected on measles cases reported during 1997 - 2002 showed that the age group 5-14 
years contributed 40.8% of the cases (MOH, 2002). Both the national data and the data 
from Tigray region showed the shift of age in occurrence of measles cases from under 
five to above five years old. An increase in the average age at infection is an expected 
outcome of the reduced rate of measles transmission in a vaccinated population 
(Anderson and May, 1991) and is well documented (Bahn et al., 2003). The surveillance 
data and the present laboratory based findings suggest that the measles supplemental 
immunization should be delivered to all children 9m-14 years, ie an increased upper age 
from the current 59 months. 
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Table 5.4. Distribution of reported measles cases by age groups in Tigray region, 1991- 
2001* 
Year 
Age- 
groups 
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001** 
0-4 12,000 2,011 3,991 158 350 157 40 47 8 37 19 
5-14 5,625 897 1,703 28 467 137 100 214 166 326 113 
15+ 2,375 160 287 1 29 23 0 20 4 61 32 
Total 20,000 3,068 5,981 187 846 317 140 281 178 424 164 
*= Source: Epidemiology Division, Tigray Regional Health Bureau 
** = First six months report only. 
Based on Table 5.2 our study showed that the measles outbreaks in Ethiopia mainly 
involved unvaccinated children. Suspected vaccine failure contributed to 3.3% (3/93) of 
the total confirmed measles cases only. All 3 were vaccinated confirmed by recall. Thus, 
there is a clear indication that continued circulation of measles is due to low coverage and 
not vaccine failure. 
The distribution of measles outbreaks reported in Table 5.3 showed that the peak 
transmission season for measles is in the dry season (months of March-August) with an 
abrupt fall when the rainy season begins (months of late September-December). Only one 
outbreak occurred during the four months rainy season. Ten years data on the seasonal 
distribution of reported measles cases for Tigray region also showed that measles cases 
were occurred more frequently during the dry season of January, February and March 
(Table 5.5). 
130 
Table 5.5. Seasonal distribution of measles cases by months in Tigray region, 1991- 
2000* 
Months 
Year Jan Feb Mar Apr Ma June July Aug Sept Oct Nov Dec Total 
1991 5420 9451 2879 423 147 10 154 60 12 15 511 918 20,000 
1992 256 1102 1248 0 0 0 60 51 49 80 70 152 3,068 
1993 1203 1686 2641 72 0 0 44 5 2 17 112 199 5,981 
1994 44 40 27 13 0 0 15 8 3 0 0 30 180 
1995 27 56 94 35 0 307 0 26 0 154 0 147 846 
1996 20 39 10 0 0 0 0 0 12 105 72 59 317 
1997 72 20 8 0 0 0 0 0 1 0 2 37 140 
1998 38 2 0 0 0 185 0 0 0 0 0 56 281 
1999 0 0 0 0 0 78 61 0 39 0 0 0 178 
2000 0 0 183 0 32 20 61 0 0 128 0 0 424 
Total 7080 12396 7090 543 179 600 395 150 118 499 767 1598 31,415 
*= Source: Data collected from Epidemiology Division, Tigray Regional Health Bureau 
Associated information collected from this region indicates social activities such as 
weddings, church ceremonies, and soil and forest protection works undertaken at higher 
frequency during January-April of the dry season that may markedly influence the 
opportunities for transmission of the measles virus in crowded or congested conditions. 
An outbreak investigation study carried out at Nono district indicated that the measles 
outbreak occurred when the school opened during January. A study undertaken in 1998/9 
in Bedelle district (Nigatu et al., 2001) suggested the crowding of students into school, 
gathering of peoples in market places accompanied by greater movement of peoples 
promoted the exchange and spread of the measles virus to the adjacent communities and 
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villages. The link to school opening following vacation has been long documented (Fine 
and Clarkson, 1982). 
The national data shows an increase in number of measles cases as the immunization 
coverage increases through 1990-2000 (Figure 5.1). This may be attributed to the 
increased activities of the surveillance programme. As can be seen in Figure 5.2 and 
Table 5.3 most of the outbreaks occurred in North, North Western and South Western 
parts of the country. This may be accord with differences in surveillance, vaccine 
coverage and population density/isolation across the country. 
Measles is a disease well known to Ethiopian people especially in rural areas. Lindtjorn 
(1986) summarized the cultural beliefs or attitudes of Southwest Ethiopian about measles. 
These cultural factors were observed in areas where outbreaks were observed (Figure 
5.2). These attitudes are thought to have influenced the measles immunization control 
programmes. Cultural belief related to injections administered to the `measles sick child' 
was found to affect the collection of blood samples using needles for laboratory tests and 
drugs given by injection to control measles complications. The belief is " The sick child 
should not receive injection. If received an injection the disease is thought to aggravate 
resulting in serious illness and even death". Because of this cultural factor some of the 
outbreak communities in Tigray region declined to give blood samples for laboratory 
analysis. We found that the oral fluid collection devices were the better alternative for 
collecting specimen for measles testing. 
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An essential part of the accelerated measles control and surveillance program in Ethiopia 
is the diagnostic service given by the measles laboratory. Collecting blood specimens 
from measles patients has a cultural problem which impacts on the effective measles 
control in the country. The Central Public Health Laboratory (CPHL) is routinely using 
oral-fluid specimens for measles diagnostic tests in the UK measles surveillance program 
(Perry et al., 1993; Brown et al., 1994; Ramsay et al., 1997; Vyse et al., 2001; Ramsay et 
al., 2003). From this study it can be suggested that the establishment of this technique in 
Ethiopian measles laboratory and its integration into the surveillance system of the 
national EPI program would play a similarly important role. 
In the UK, USA and elsewhere molecular characterization of MV strains circulating in 
the country is part of the surveillance programme that assists to determine the pattern of 
measles outbreak transmission (Jin et al., 1997; Bellin and Rota, 1998; Chibo et al., 2000; 
Ramsay et al., 2003). The strain responsible for the 2000-2002 measles outbreaks 
reported from most of Tigray, Oromia, SNNP and Amhara regions was genotype D4. The 
measles strains from sporadic cases in Addis Ababa prior to 2000 (Nigatu et al., 2001), 
were identified as genotype D4 and D8. No further occurrence of D8 has been 
documented and it may presume that this was an imported case. Genotype D4 was 
reported from UK throughout 1995-2000, USA and Canada (Ramsay et al., 2003; Bellini 
and Rota, 1998). The genotype D8 was reported in 1999-2000 from UK, South Asia, the 
Middle East and the Balkans (Ramsay et al., 2003). The wide distribution of D4 genotype 
in the country and the presence of this genotype over a prolonged period through 1998- 
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2002 suggest this genotype to be the most important for sustainable indigenous 
transmission of measles in Ethiopia. 
Sequence analysis of two outbreaks, those which occurred in Gendebert and Nono of 
Western Shoa, revealed that the D4 genotype showed a transmission link between the two 
outbreaks, although each outbreak strains differ each other by 3 nt (nucleotide)/2 as 
(amino acids) over time within one year period. A detailed analysis of the relationship 
between the different outbreaks strains is required to see if there is link or association of 
transmission. 
Clade B viruses are predominantly found in Western and Central Africa. The Glade 
comprises B1, B2 and B3 genotypes where representatives of the Glade have been 
isolated in The Gambia, Cameroon, Gabon, Nigeria, Ghana, Zambia, Kenya and Sudan 
(Hanses et al., 1999; Troung et al., 1999; WHO, 2001; Mubarak et al., 2002; Kouomou et 
al., 2002). An importation of Glade B virus into the United States from Kenya was 
identified during 1995-1997 (Bellini and Rota, 1998). Analysis of isolates of Glade B 
showed the Sudanese isolates to be placed within the genotype B3, circulating 
indigenously in Khartoum over a3 years period through 1997-2000 (Mubarak et al., 
2002). Our investigation showed the presence of B3 genotype in North Western part of 
Ethiopia bordering Sudan. The similarity between our MV strains with those isolated in 
Sudan could be explained by the movements of infected peoples across the border of the 
two countries. However, a more comprehensive analysis of the relationship between the 
Sudan and the Ethiopia viruses is needed. As the B3 identified in Sudan linked to the 
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Northern Nigeria strain (Mubarak et al., 2002), the present studies show that this 
genotype has widened its distribution and now has become a cause of indigenous 
transmission of measles in Ethiopia. 
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CHAPTER 6 
EVALUATION OF A MEASLES VACCINE CAMPAIGN IN ETHIOPIA USING ORAL- 
FLUID ANTIBODY SURVEYS 
Summary 
Campaign vaccination is widely adopted in the accelerated control of measles. 
Measurements by which to evaluate and refine interventions are essential. The potential 
contribution of oral-fluid antibody prevalence data in this process has not been 
demonstrated. An evaluation was undertaken of a measles vaccine campaign in Ethiopia 
in 1999. In the town of Asela, southern Ethiopia, oral-fluid specimens were collected 
from 1928 children aged 9m - 5years attending for measles campaign vaccination. In 
June 2000, oral fluids were taken from 750 individuals aged 9m-19years, in the same 
location, from households selected by cluster surveys methods. Data on vaccine history in 
the households was recorded. Measles antibody status was determined by using 
Microlmmune EIA adjusted for known sensitivity and specificity relative to serum 
assays. Records from the pre-campaign data indicate that 73.6% of children in the target 
age received measles vaccine. Antibody prevalence in children attending for vaccination 
(pre-campaign) was 44% (26% in 9-11 month olds rising to 60% in 60-71 month olds). 
Post-campaign antibody prevalence was 80-90% in the target age group. The proportion 
negative in older children not targeted by vaccination was 39% in those 7-9 years of age, 
and 19% in those 10-14 years old. Comparison of antibody prevalence in the pre- and 
post-campaign children in the targeted age group suggests the campaign raised the 
immunity by 38-94% (average 77.5%) in proportion to pre-campaign levels (12-51%, 
average 36%, in absolute percentages). Following the campaign, significant levels of 
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susceptibility remain in the target ages, and, especially, in older children who were not 
targeted. These results highlight a need to identify prior susceptibility levels to define 
target age ranges, and suggest the upper age targeted was too young. The study made 
clear the problem of reliance on measles surveillance, which was not good enough to 
inform the decision on which age group to vaccinate in the campaign. The results raise 
concerns for continued circulation of measles and provide valuable information to health 
authorities for strategy refinement. 
6.1. Introduction 
Traditional methods of evaluating the effectiveness of an immunization programme have 
major limitations, particularly in the context of campaigns (Dietz and Cutts, 1997). These 
methods are based on estimating vaccine coverage, and case surveillance: reporting of 
clinical cases and analysis of trends in cases (epidemic/endemic behaviour). Reliability in 
resource poor countries may be undermined by inadequate communications, 
infrastructure and surveillance capacity. The percentage of the target population who 
receive vaccine, based on doses delivered and estimated denominator, is an indicator 
fraught with problems. Those receiving vaccine may be biased towards those accessible 
to services, and the denominator may exclude hard-to-reach groups (migrant, 
unregistered, and living in informal housing). Vaccine coverage surveys are likely to be 
less reliable in campaigns than for routine vaccination since vaccine certificates may not 
be issued or are less valued compared to `vaccination certificates' (eg. Road-in-Health 
Cards) issued by Health Centers, and will be based more on verbal histories with 
unknown reliability. Interpretation of case reports following campaigns may suffer from 
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inadequate reporting infrastructure, misdiagnosis where incidence is low and serological 
confirmation is absent, and premature interpretation of trends in case reports, i. e. 
insufficient time may have elapsed for a rebound epidemic to occur (Nokes and Swinton, 
1997). 
Inadequacy of traditional surveillance techniques in evaluating and for refining 
vaccination campaigns, suggest that serological surveys could play a larger role. The 
need for serological evaluation of immunization programs has long been recognized 
(Horstmann, 1973; Evans, 1980). 
Measles cross-sectional serological surveys could provide information as to whether the 
targeted, hard to reach and isolated populations are reached by vaccination, and identify 
what age groups should be included in immunization programmes (Babad et al., 1995; 
Gay et al., 1997a; Miller et al., 1977; Cox et al., 1998). Follow-up serological 
measurements in measles immunized persons has importance to determine the proportion 
developing immune responses, quality and extent of response, duration of response and 
level of protection against measles infection. From cross-sectional and follow-up 
serological surveys the risk of measles infection outbreak could be assessed. 
Experience in the UK shows the use of oral-fluid sampling and screening for the 
surveillance of measles, mumps and rubella (MMR) since 1994 (Ramsay et al., 1997; 
Vyse et al., 2001). Using oral-fluid collection in the UK surveillance system contributed 
and enhanced the MMR disease notification system. Data derived from such a system 
have been used to refine the MMR vaccination policy (Ramsay et al., 1997). Our recent 
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studies in rural Ethiopia clearly demonstrated the utility of oral-fluid surveys in 
determining measles specific IgG in a large community based study (Nokes et al., 2001). 
This non-invasive technology, which has low risk to operators and donors, was well 
accepted and we obtained in excess of 90% compliance with oral fluid collection, 
compared to only 60% in serological surveys in Ethiopia (Nokes et al., 1998b; Fontanet 
et al., 1998). The study utilised an enhanced GACELISA assay described earlier in 
Chapter 2. In another study we evaluated pre- and post-vaccine antibody in children 
attending for routine measles immunization in Addis Ababa. This utilised an oral-fluid 
MACELISA described in Chapter 3. This work clearly showed the promise of oral-fluid 
testing as an alternative to serum in estimating vaccine response and effectiveness. 
The present study assesses the effectiveness of a measles vaccination campaign in Asela 
town of Ethiopia using oral-fluid methods. The principal aim of the study is to 
demonstrate the application of oral-fluid sampling to evaluate a measles campaign. This 
was addressed through the following two process: 
" Assess `immune' status of children receiving vaccine in 1999 campaign in Ethiopia, 
i. e. identify what proportion of children attending for vaccination were already 
immune to measles. This would yield important information about the potential 
impact of the campaign, albeit within a selective sample. 
" Estimate post-campaign prevalence of measles IgG in the target age group (9m-59m) 
and older ages post-campaign (up to 20 yrs). This would generate information on the 
immunity level in the targeted age group and level of susceptibility in those outside 
the target group. Ideally a representative cross-sectional oral-fluid survey prior to the 
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campaign should have been conducted. However there was insufficient time available 
to carry this out. 
Information thus obtained would feed back to health authorities regarding campaign 
effectiveness and possible refinement to target age groups. During the survey, 
information was collected on knowledge and attitude of the study groups in relation to 
routine and campaign vaccinations. However, it was not relevant to this thesis and is not 
considered further here. 
This study adopts a refined measles specific GACELISA (Microimmune EIA) developed 
as a standardized kit form by the CPHL, UK. This kit has undergone extensive evaluation 
using set of 717 paired blood and oral-fluid specimens previously reported in this thesis 
(Chapter 2 Section 2.3.2). The samples derive from a population in the edge of the rift 
valley in Ethiopia. Compared to sensitive serum assay results the Microimmune EIA had 
a sensitivity and specificity of 92%. 
Ethical clearance was obtained from the National Ethical Committee at Ethiopian Science 
and Technology Commission (Ref. No. RDHE/84-31/2000) and Coventry Research 
Ethics Committee, Coventry, UK. Support letter (Ref. No. QEFAIO/2-7/1745) was 
obtained from The Council of Regional State of Oromiya Health Bureau, Arsi Zonal 
Health Department that involved with polio NID and measles campaign. 
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6.2. Materials and Methods 
6.2.1. Study setting and population 
The study site selected was Asela town with a population size of 50,000 (1994 census) 
and situated 180 km south of Addis Ababa on edge of rift valley in Arssi Zone, Oromia 
Region. All other Zones targeted for the 1999 measles campaign through the National 
Immunization Days (NID) of polio were over 300km from Addis Ababa. The NID 
utilised static immunization sites; these included regular static (a hospital and a health 
center) and outreach immunization sites, 14 `kebele' offices. The population size of 9- 
59m was 6,375 for Asela during the campaign. Pre- and post-campaign selected `kebeles' 
for the study are shown in Figure 6.1. The selection criteria are presented in the A6 
(Appendix to Chapter 6). Measles routine vaccination in Asela was started in 1987. Since 
1987 up to 1995 vaccination coverage of the town was reported together with Tiyo 
district where Asela is located and serving as the capital of the district. During 1999, the 
time when the campaign was undertaken, routine measles vaccination coverage of the 
town was 64.3%. No measles cases had been reported in Asela town since 1994 except a 
month old child was detected as measles suspected case in the hospital in 2000. 
6.2.2. Survey methods 
Full details of the survey methods including questionnaires used are given in the A6. In 
summary the survey methods were as follows: 
" Collect oral fluid (OF) from children (9m to 5 years) at vaccination posts in Asela 
town at the time they present for measles campaign vaccination (during Polio NID). 
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Figure 6.1. Pre- and post-campaign selected `kebeles' for Asela town measles 
immunization evaluation surveys conducted in 1999-2000. 
Pre-campaign 
selected 'Kebeles' 
Post-campaign selected 
'Kebeles' 
  Pro- and post-campaign 
solocted 'Kebelos' 
0 Conduct a cluster sample survey (i. e. representative of' the population) oI' I)ni-II)yr 
olds in Asela Town post-campaign (see A6 for how the study design was 
implemented and the sample size determined). 
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100 200 1000m 
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" Screen using Microimmune OF assay (characteristics: 92% sensitive and 92% 
specific relative to serum assay) 
6.2.3. Pre-campaign survey 
The NID measles campaign was carried out between December 3-5`h 1999. Vaccine was 
delivered through different stations over the three days period. From the total 14 'kebele' 
office stations, 7 were randomly selected for the study. During the measles campaign, 
children aged 9-59 months visiting the 7 vaccination stations for measles vaccine 
provided OF samples for the study. Each site was supported by two study staff who 
enrolled children (parents/guardian), and collected and labeled specimens. In order not to 
hinder the throughput of children receiving vaccine, minimal questionnaire details were 
obtained (see questionnaire 1 A6). Data was available that was routinely collected at the 
time of measles/polio campaign, including household location, child age in months, sex, 
together with prior history of EPI vaccinations. 
6.2.4. Post-campaign survey 
The post-campaign community cluster survey was conducted six months after the pre- 
campaign NIDs between June 9`h and July 10`h 2000, involving 29 staff. These comprised 
7 teams of 3 members to visit households, 3 supervisors, 2 laboratory assistants from 
Asela Health Centre to process samples for transport, and 3 support staff from the 
Ethiopian Health Nutrition Research Institute (EHNRI). Staff received training in sample 
collection, questionnaire delivery, and sample processing prior to the survey. Supervisors 
monitored work and checked questionnaire completion daily. 
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Seven clusters or Kebeles were selected out of the total of 14 in the town by probability 
proportional to population size (PPS) (See A6, appendix attached to this Chapter). The 
1994 Government census (CSA, 1998) figures were used for the selection of Kebeles. 70 
households were selected from each cluster by simple random sampling using the 
household registers held at each Kebele (see A6). All individuals from a household aged 
9 months to <20 years of age were eligible. 750 individuals were recruited into this study 
providing questionnaire details and saliva samples. For each eligible individual details 
were collected on measles vaccination history, history of measles disease, EPI vaccine 
history, reasons for not receiving vaccines, and knowledge of vaccine preventable 
diseases (see questionnaire 3 and 4 in A6). For children under 15 years of age an 
appropriate adult respondent completed the questionnaire. Verbal consent was obtained 
before samples were taken. 
6.2.5. Sample size estimation 
6.2.5.1. Pre-campaign 
The primary aim is to determine, with a set level of precision, the proportion, p, of 
measles antibody negative individuals attending vaccination centers who are susceptible 
at the time of the campaign. Based on measles surveys in urban and rural Ethiopia 
(Enquselassie et al., in prep; Nokes et at., 2001) it was estimated that 50% of individuals 
9m-2 years, and 30% aged 3-5 years would be seronegative. Based on standard sampling 
theory for precision of prevalence estimates the required sample sizes for each groups 
were 340 and 560 individuals, respectively, to yield 95% CI for the proportion 
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seronegative in age class 9m-2 years and 3-5 years of 0.5 +/-0.054 and 0.3 +/-0.038, 
respectively. 
6.2.5.2. Post-campaign 
It was assumed that 10% of individuals 9m-<5 years, 15% aged 5-<10 years and 5% aged 
10-<20 years would be seronegative in the post-campaign, respectively, with defined 
95% CI of +/-0.04,0.05, and 0.03. The required sample sizes for each groups were, 
therefore, 196,195,203 people, respectively. Based upon the population age-distribution 
of 10% <5,12% 5-9, and 32% 10-19 years (1994 census), and an average household size 
of 5 (i. e. at least one child in each of the two younger age groups should be observed in 
every other HH), then a sample of 400 HHs should be adequate, or 440 HHs assuming 
10% refusal. 
6.2.6. Sample collection and processing 
Each eligible individual was requested to provide an oral-fluid specimen, using the 
ORACOL device. Samples were labeled with a unique identifier and transported in 
stoppered tubes in cooled icebox to the local Health Center laboratory for processing. All 
samples were processed the same day of collection as described previously (Nokes et al, 
1998b) and stored frozen at -10°C. At the end of the field surveys samples were returned 
to EHNRI and stored at -20°C. 
6.2.7. Laboratory methods 
Survey samples were transferred to CPHL packed in polystyrene cool boxes with dry ice. 
Samples were screened using the Microimmune in-house kit developed at CPHL. This 
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IgG antibody capture ELISA has been developed for commercial application. The kit has 
been evaluated using 717 paired serum/oral-fluid samples collected from Ethiopia; the 
paired serum of which had previously been tested by the Behring Enzygnost rubeolla IgG 
test (Behring Diagnostics, Marburg, Germany) (see Chapter 1 of this thesis). Sensitivity 
and specificity relative to serological results for this series was found to be 91.7 and 
91.9% respectively, results as yet unpublished (Dr D. Samuel, CPHL, personal 
communication). The principles of the test in brief are as follows. Anti-human IgG coated 
microwells binds IgG in the test sample. After washing the wells, recombinant measles 
virus nucleoprotein (rMVN) antigen is added and will bind to wells when there is 
captured measles specific IgG antibodies. A monoclonal anti-measles antibody linked to 
HRP is then added to detect the immobilised recombinant measles antigen. After 
washing, the binding of anti-measles-HRP is visualised by adding TMB substrate. The 
presence of specific IgG results in HRP oxidising the colorless TMB substrate to an 
intense blue oxidised product, the signal of which is enhanced by adding a stopping 
solution, which changes the color to yellow. The optical density of the yellow 
chromogen is measured at 450/620nm. All components of the assay, apart from the 10 x 
wash buffer are provided as ready-to-use reagents. The assay incorporates color-coded 
reagents for monitoring sample addition steps and can be completed within 2h. 
Specimens were identified as measles specific IgG positive, negative and equivocal 
results based on optical density (OD) readings as OD > NC (negative control) x 1.25, OD 
< NC x 1.1, and OD < NC x 1.25 and > NC x 1.1, respectively. 
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6.2.8. Data management and statistical analysis - clusters, conversion from oral- 
fluid prevalence to 'true' prevalence 
Data from the questionnaires was double entered and validated using Epi-Info 6.04. 
Suitable entry checks were coded and data entered into 4 data entry programs (see A6). 
The laboratory results were entered into an Excel spreadsheet. Both Epi-Info files and 
Excel files were converted into Stata file format. Cleaning and statistical analysis were 
carried out using STATA V7. 
Prevalence estimates were calculated using `svy' commands in STATA to adjust the 
confidence intervals for the clustering effect. The oral-fluid prevalence of immunity 
estimates and confidence intervals were scaled, using an Excel spreadsheet, to adjust for 
the sensitivity (92%) and specificity (92%) of the oral-fluid assay compared to the serum 
assay as described previously (Nokes et al., 1998b). The observed age-prevalence profile 
from oral fluid can be transformed to the `true' profile given the following relationship, 
P. = Ps +a (1 - PS) -ß PS, 
where, P. is the proportion oral-fluid ('test') positive, P. the proportion serum ('true') 
positive, 0 the probability of a false negative (with sensitivity 1- ß), and a the probability 
of a false positive (with specificity 1- a). Thus, given a and ß, and community estimates 
of prevalence obtained through an oral-fluid survey only, then it is possible to calculate 
the `true' antibody prevalence from the above equation by rearranging as follows: 
PS= PY-a 
1- (a+ß). 
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6.3. Results 
6.3.1. Sampling and population studies 
The following two Tables show information on routine vaccination coverage, and the 
proportions of vaccine eligible and vaccine recipient children sampled in the pre- and 
post-campaign measles surveys of Asela town. The latter informs on how well the under 
5 years children were covered in the campaign, and also on the sampling intensity of the 
pre- and post-campaign surveys. Table 6.3 shows the proportion of eligible children 
sampled stratified by age groups, in the pre- and post-campaign. 
Table 6.1. Routine measles vaccination coverage in Asela town, 1996-2001a 
Year Estimated <1 year 
children 
Vaccinated Coverage (%)b 
1996 1234 437 35.4 
1997 1267 730 57.6 
1998 1300 844 64.9 
1999 1333 857 64.3 
2000 1367 805 58.9 
2001 1401 883 63.0 
= Routine vaccination was started in February 1987. Since 1979 up to 1995 vaccination coverage of 
Asela town was reported together with Tiyo district. 
b= Computation of coverage based on the assumption that all the <lyear children born within that year are 
supposed to be vaccinated for measles in the routine EPI activities. 
Table 6.1 shows the reported vaccination coverage by year in Asela town, 1996-2001. 
Over this period coverage increased from 35.4% in 1996 to 63% in 2001. The trend 
shows that after 1997 the coverage does not seem to markedly increase in the following 
consecutive years. This proportion may be an underestimate if significant numbers of 
children receive vaccine in the second year of life. 
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Table 6.2. Proportion of vaccine eligible and vaccine recipient children sampled in the 
pre- and post-campaign measles surveys, Asela town, 1999-2000, stratified by kebele 
Vaccine 
site 
Total 
popn' 
<5years Eligible 
for 
vacc. 
(9- 
59m) 
Eligible 
& vacc. 
recipient 
% Pre- 
sampled 
(9-59m) 
% Post- 
sampled 
(9-59m) 
% Vacc. 
received 
(60- 
71 m)° 
Kebele A B C D E=D/C F G=F/D H I=H/C J 
01 1481 230 205 147 71.7 - - 22 10.7 0 
02 3472 538 463 280 60.5 229 81.8 - - 45 
03 4255 659 568 511 90.0 - - 24 4.2 17 
04 5173 801 690 383 55.5 - - 26 3.8 15 
05 4345 673 566 325 57.4 216 66.5 - - 3 
06 4079 632 551 339 61.5 315 92.9 21 3.8 69 
07 5636 874 747 598 80.1 396 66.2 34 4.6 0 
08 2507 389 333 185 55.6 - - - - 17 
09 5632 873 780 882 113 - - 30 3.8 0 
10 3137 486 429 316 73.7 - - - - 4 
11 1684 261 224 170 75.9 132 77.6 30 13.4 2 
12 2207 342 297 187 63.0 - - - - 0 
13 1055 164 152 118 77.6 93 78.8 - - 1 
14 2728 423 372 254 68.3 186 73.2 - - 8 
Grand 
total 
47391 7345 6377 4695 73.6 1567 75.2 187 5.0` 181 
= Based on the population for 1999 derived by projecting the 1994 government census. Projection 
rovided by Arisi Zone EPI Office. ý= 
Total vaccinated population of 7 sampled kebeles was 2084 
`= Total population of 7 sampled kebeles was 3764 d 
= Data from Arisi Zone EPI Office 
Table 6.2 show the sample size of the vaccinated population enrolled in the pre-campaign 
survey. It also shows the proportion of vaccine eligible children that were sampled in the 
post-campaign survey. Of the total 6375 measles vaccine eligible children (9-59m) 4695 
(73.6%) were vaccinated in the campaign. Of the vaccinated children in the seven 
selected `kebeles' (total population= 2084) 1567 (75.2%) were sampled in the pre- 
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campaign. Of the total vaccine eligible in the seven selected 'kebeles' (total population= 
3764) 187 (5%) of them were selected in the post-campaign. 
Table 6.3. Proportion of eligible children sampled by age groups, Asela town pre- and 
post-campaign measles surveys, 1999-2000. 
Age group 
(month)a 
Population Pre-vaccine 
sample 
Proportion 
(%) 
Post-vaccine 
sample 
Proportion 
(%) 
A B B/A C C/A 
9-11 272 94 34.6 6 2.2 
12-23 1220 304 24.9 31 2.5 
24-35 1423 367 25.8 41 2.9 
36-47 1482 386 26.0 46 3.1 
48-59 1980 416 21.0 63 3.2 
Sub total 6377 1567 24.6 187 2.9 
60-71 1569 361 23.0 29 1.8 
Total 7946 1928 24.3 216 2.7 
'= Although the 'eligible' age was 9-59m a significant proportion of children age 5years ie 6 -71 months 
did come for vaccination, and therefore were sampled in our study. Note that at vaccination posts, the age 
category of children receiving vaccine was not recorded accurately. 
b= Based on the population for 1999 derived by projecting the 1994 government census. Projection 
provided by Arsi Zone EPI office. 
Table 6.3 shows ranges of 21-35% (average of 24.6%) of the eligible children were 
sampled in the age groups between 9-59 months in the pre-campaign survey. Ranges of 
2-3% (average of 2.9%) of the eligible children were sampled in the age groups between 
9-59 months in the post-campaign survey. 
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6.3.2. Measles Immunity in pre- and post-campaign surveys 
Table 6.4. Measles immunity prevalence (observed /`true') in a target age group of pre- 
campaign survey of Asela town, 1999. 
Age Positive / Observed 95% CI `True' 95% CI 
group Total prevalence [unadjusted / prevalence [unadjusted 
adjusted] adjusted] 
(months) 
9-11 28/94 0.298 0.214-0.398 / 0.259 0.160-0.379 / 
0.216-0.395 0.162-0.375 
12-23 108/304 0.355 0.303-0.414 / 0.328 0.265-0.394 / 
0.291-0.425 0.251-0.411 
24-35 161/367 0.439 0.389-0.490 / 0.427 0.368-0.488 / 
0.368-0.512 0.343-0.514 
36-47 180/386 0.466 0.417-0.516 / 0.460 0.401-0.519 / 
0.381-0.553 0.358-0.563 
48-59 235/416 0.565 0.517-0.612 / 0.577 0.520-0.633 / 
0.520-0.609 0.524-0.630 
60-71 210/361 0.582 0.530-0.632 / 0.597 0.536-0.657 / 
0.501-0.658 0.501-0.688 
Total 922/1928 0.478 0.474 
Table 6.4 shows measles IgG prevalence of 1928 samples in age groups 9-11 months to 
60-71 months (ie inclusive of 5 years olds). The Table provides an estimate of the 
prevalence of measles immunity in children prior to receiving vaccine. 95% CIs are 
presented as unadjusted and adjusted for clustering effects. The results suggest that 26% 
(9-11m) to 60% (5 years olds) of children (average of 47%) already had measles antibody 
prior to the campaign ('true' prevalence). 
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Table 6.5. Measles immunity prevalence (observed /`true') by age group in a post- 
campaign survey of Asela town, 2000. 
Age Positive / Observed 95% CI `True' 95% CI 
group Total prevalence [unadjusted / prevalence [unadjusted 
adjusted] adjusted] 
(months) 
9-11 2/6 0.333 0.084-0.733 / 0.301 0.005-0.777 / 
0.118-0.652 0.045-0.681 
12-23 19/31 0.613 0.434-0.766 / 0.635 0.421-0.817 / 
0.454-0.751 0.445-0.799 
24-35 32/41 0.780 0.629-0.882 / 0.834 0.654-0.955 / 
0.627-0.883 0.651-0.956 
36-47 39/46 0.848 0.713-0.926 / 0.914 0.754-1.007 / 
0.632-0.948 0.657-1.033 
48-59 50/63 0.794 0.676-0.876 / 0.850 0.710-0.948 / 
0.653-0.887 0.682-0.961 
60-71 24/29 0.828 0.646-0.927 / 0.890 0.674-1.008/ 
0.732-0.894 0.776-0.969 
Total 166/216 0.769 0.820 
Table 6.5 shows measles IgG prevalence of 216 samples in age groups 9-11 months to 
60-71 months (i. e. inclusive of 5 years olds). The Table provides an estimate of the 
prevalence of measles immunity in children 6 months after the measles campaign of 
December 1999. The results suggest that 30% - 63%, in age classes 9-11m and 12-23m, 
respectively, and 83% - 91% in age classes 24-35m to 60-71m (average of 82%) had 
measles antibody at this time. Note that by July 2000, all children 9-11 months and a 
significant proportion of those aged lyear would have been too young to be offered 
vaccine in the 1999 campaign. Similarly a significant proportion of children aged 6 years 
(outside the vaccination target age range) would have been aged 5 years at time of the 
campaign (i. e. within the target age range). Hence the relatively low proportion positive 
in the 0-1 yr olds and the relatively high proportion positive in the 6 years olds. 
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Figure 6 . 2. Post-campaign measles antibody prevalence by age group (years) for the <20 
Years old. Asela toti n. 2000 
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Figure 6 
.2 shows the prevalence of measles specific 
IgG in individuals Irum U-IO scars 
collected in early July 2000. Black bars indicate OF prevalence and open bars 'true' 
prevalence. The proportion negative in older children was 39%rß in those 7-9 years o(' age, 
and 19(7 in those 10-14 years old. 
Table 6.6. Prevalence of measles immunity by age group and sex in post-camp ait'n 
survey of Asela town, 2000. 
Age ! Aale Female Bot h sexes 
group 
(years) 
Pos. /lot. Percentage I'os. /Tot. Percentage Pos. /'lot. Percentage 
0-4 71/98 72.45 71/89 79.78 142/187 75.93 
5-9 65/85 76.47 62/89 69.66 127/174 72.98 
10-14 93/112 83.04 105/133 78.95 198/245 80.81 
15-19 47/52 90.38 81/92 88.04 128/144 88.88 
Total 276/347 79.54 319/403 79.16 595/750 711.33 
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Table 6.6 suggest no marked sex difference in measles immunity prevalence (79.5% for 
male vs 79.2% for female) in the post-campaign survey based on 750 individuals of < 20 
year olds. Aggregation into 5 years age groups masks the underlying pattern seen in 
Figure 6.2. The 15-19 years age group appears to have higher prevalence than other age 
bands. 
Table 6.7. Impact of the measles immunization campaign on measles `immunity' of 
target age groups of Asela town, 1999-2000a 
Pre-campaign survey Post-campaign survey Changes 
Age group 
(months)b 
`True' 
prevalence 
A 
Age group 
(months) 
`True' 
prevalence 
Difference 
Prevalence 
B 
Susceptibility 
reduction 
B/(1-A)% 
9-11 0.259 15-17 0.381 0.122 16.5 
12-23 0.328 18-29 0.836 0.508 75.6 
24-35 0.427 30-41 0.935 0.508 88.7 
36-47 0.460 42-53 0.852 0.392 72.6 
48-65 0.593 54-71 0.872 0.279 67.4 
Overall 0.481 0.863 0382 73.6 
'= Note that the 9m and 65m old children pre-campaign were aged 15m and 71m by the time of the post 
campaign survey was undertaken. 
b= Note that the oldest child in the pre-campaign age classes is 65 months, hence upper age for post- 
campaign comparison is 71 months. 
Table 6.7 compares the estimated true prevalence of measles 'immunity' in 9m-65m olds 
in the pre-campaign with that of 15-71m old children in the post-campaign. This provides 
a rough estimate of the effectiveness of the campaign at reducing susceptibility to 
measles in the target population. Overall, it is estimated that within the target age range 
9m-65m, there was a rise in `true' prevalence of 48% to 86%, or a susceptible prevalence 
reduction of 74% (Table 6.7). An absolute prevalence increment of between 12% (9-11 
month group) to 51% (12-35 month age class) were observed. Reduction in the 
proportion susceptible was least (16.5%) in the 9-11 month group, and between 67% and 
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89% in all other group. In the target age range 12m-65m (18-71m post-campaign) 
measles antibody prevalence was estimated to be between 84-94%. 
Table 6.8. Prevalence of pre- and post-campaign measles immunity by selected `kebeles', 
1999-2000. Adjusted for specificity and sensitivity and 95%CI (adjusted for clustering). 
`Kebeles' Pre-campaign (9m-71m) Post-campaign (9m 
to <20 ears 
Changes 
Pos/Tot % Pos/Tot % Difference 
% 
% reduction in 
susceptibility 
01 - - 79/98 80.6 
02 120/273 44.0 
03 - - 73/88 83.0 
04 - - 102/123 82.9 
05 131/254 51.6 - 
06 176/394 44.7 87/113 77.0 32.3 58.4 
07 250/484 51.7 76/102 74.5 22.8 51.6 
08 - - - - 
09 - - 96/125 76.8 
10 - - - - 
11 85/166 51.2 82/101 81.2 30.0 61.5 
12 - - - - 
13 55/115 47.8 - - 
14 105/242 43.4 - - 
Total 922/1928 47.8 595/750 79.3 31.5 60.3 
The prevalence of pre- and post-campaign measles immunity by selected 'kebeles' is 
given in Table 6.8. The highest prevalence of measles immunity (about 51%) was 
observed in `kebeles' 05,07 and 11 in the pre-campaign and in 'kebeles' 01,03,04 and 
11(about 80%) in the post-campaign. The lowest prevalence observed in `kebele' 14 
(43%) in the pre-campaign and `kebele' 07 (75%) in the post-campaign. Comparison of 
measles immunity between the pre- and post-simultaneously selected 'kebeles' shows 
measles immunity raised from 45% (06 `kebele'), 52% (07 'kebele') and 51% (11 
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`kebele') in pre-campaign to 77%, 75% and 81% in the post-campaign respectively. The 
resultant reduction in proportion susceptible in each 'kebele' was 52-62% (average 60%). 
6.3.3. Measles vaccination status 
Data from the pre-campaign survey (Table 6.9) shows that 78% of children had a history 
of routine measles vaccination (card or recall). Of these children 49-62% were measles 
antibody positive, which compared with 21% in those without history of vaccination. 
Table 6.10 presents descriptive statistics of 606 children under 15 years of age enrolled in 
the post-campaign survey. Around 86% of these children had a history of routine measles 
vaccination. In these children who would have been of eligible age for vaccination during 
the campaign, 88% had a history of routine measles vaccination. In these groups, between 
83% and 88% were measles positive. Children without a history of routine vaccination 
had marginally lower seroprevalence (77-80%). Of children aged 12-23 months 74% had 
a history of routine measles vaccination in whom measles seroprevalence was between 
66-80%. This compared with only 35% seropositivity in children of this group with no 
routine vaccination. 
In Table 6.10 comparison is made of routine vaccination history and seroprevalence in 
children of eligible age who did or did not attend for campaign measles vaccination. The 
proportion without history of measles vaccination is slightly lower in those who did not 
attended for campaign vaccination (16%). Measles antibody prevalence in children 
vaccinated during the campaign was 89-100%. In children of eligible age who did not 
receive measles vaccination in the campaign, measles seroprevalence was between 60% 
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(no history of routine measles vaccination) and 72-85% (history of routine measles 
vaccination). 
Table 6.9. Descriptive statistics for the pre-campaign measles survey 
Results 
n% Positive 'OF' % 'True' % 
Measles vaccination 
Yes card 25 1.3 15 60.0 61.9 
Yes recall 1482 76.9 729 49.2 49.0 
No 147 7.6 38* 25.4 20.7 
Unknown 194 10.1 91 46.9 46.3 
Missing 80** 4.2 49 61.3 63.5 
*= Of the 38 children 3 (7.9%) of them reported to have history of measles infection 
** = 97.5% of these children were above 3 old years (36m-71m) 
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Table 6.10. Descriptive statistics on vaccine uptake from the post-campaign measles 
survey (for children <15 years) 
n % Positive 
Results 
'OF' % 'True' % 
Measles vaccination status 
Card 84 13.9 67 79.8 85.5 
Recall 434 71.6 336 77.4 82.6 
None 88 14.5 64 72.7 77.0 
Total 606 100 467 77.1 82.3 
Routine measles vaccination in elig ible children* 
Card 46 23.0 37 80.4 86.2 
Recall 130 65.0 106 81.5 87.5 
None 24 12.0 18 75.0 79.8 
Total 200 100 161 80.5 86.3 
Routine measles vaccination in children 12-23 months of age 
Card 11 35.5 7 63.6 66.2 
Recall 12 38.7 9 75.0 79.8 
None 8 25.8 3 37.5 35.1 
Total 31 100 19 61.3 63.5 
Routine measles vaccination in eligible children who reported for measles vaccination in the 
campaign. 
Card 30 24.4 26 86.7 93.7 
Recall 81 65.9 67 82.7 88.9 
None 12 9.8 11 91.7 99.6 
Total 123 100 104 84.6 91.2 
Routine measles vaccination in eligible children who did not report for measles vaccination in the 
campaign. 
Card 16 20.8 11 68.8 72.4 
Recall 49 63.6 39 79.6 85.2 
None 12 15.6 7 58.3 59.9 
Total 77 100 57 74.0 78.6 
*= Eligible children are those between 9-59m age group described in Table 6.2. 
6.4. Discussion 
The objective of this study was to evaluate a measles vaccination campaign in an urban 
developing country population and demonstrate a transferable oral-fluid methodology for 
this purpose. Thus the present work highlights the potential of oral-fluid methods to 
evaluate the effect of the vaccination campaign on population immunity to measles. 
158 
The pre-survey is a biased sample in so far as children attending for vaccination may 
differ in some important characteristics from those who do not attend. For example, we 
don't know what was the proportion measles positive in children who did not turn up for 
vaccination. However, nearly three quarters of all children of eligible age did attend for 
vaccination, and of these vaccinated children within a random sample of 7 vaccination 
centers three quarters were sampled and immunity tested. Therefore the pre-campaign 
survey provides a precise estimate of immunity in those receiving vaccine, which in turns 
constitutes the vast majority of the eligible population. 
The post-campaign provided an opportunity to compare routine vaccine uptake in those 
who attend for campaign vaccination with those who did not. The survey revealed (Table 
6.10) little difference between the two groups; children of eligible age attending the 
campaign 24% had card evidence and 66% recall of routine measles vaccination, as 
compared with 21% and 64%, respectively. This supports the assertion that the pre- 
campaign survey provides a reasonably accurate estimate of measles immunity in the 
community as a whole against which to compare post-vaccination survey data. 
Furthermore, the post-vaccine survey comprised a simple random sample of households 
within clusters selected with probability proportion to size. Prevalence estimates in the 
pre-campaign survey were weighted for different target population sizes covered by each 
vaccination center (`kebele') and confidence intervals for both pre- and post-surveys 
were adjusted for clustering of observations within 'kebeles', (i. e. to take account of the 
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possibility of reduced variability in immune status of individuals within clusters). We 
consider estimates of prevalence for such survey to be representative of the community. It 
should be noted however, that selection of vaccination centers (`kebele' offices) should 
ideally have been made using PPS sampling. However, household registration data at that 
time was not available. 
An indication of the impact of the campaign is thus provided by comparison of the pre- 
and post-campaign surveys. This suggests campaign vaccination to have elevated 
immunity in the target age groups by as much as 50% in some age groups, and an average 
of 36% in the target age group as a whole. A more useful measure of impact is the 
estimate of the fraction of susceptibles that become immune through the campaign (Table 
6.7). This suggests that in age groups 12-23m to 48-65m 67-89% of susceptibles acquired 
immunity, or an average in the target age group of 74%. If we assume 90% vaccine 
efficacy, then we might estimate the coverage in the target group was approximately 
70%. These estimates of the reduction in susceptible proportion compare well with the 
estimated proportion of 74% of Asela town eligible children receiving vaccine. No 
measles infection was reported in the six months period elapsed between the pre- and 
post-campaign survey as the data from the Health Center and Hospital indicated, and 
other than one case in 2000, no measles cases were seen in Asela since 1994 (Source: 
Arsi Zonal Health Bureau, 2001). However, these data may not accurately reflect the rate 
of natural infection in this period since the community in Southern Ethiopia do not have 
positive beliefs and attitudes towards seeking health services for the 'measles sick child' 
(Lindtjorn, 1986). 
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One of the important factors that influence the success of vaccination campaigns is the 
age range vaccinated (Nokes and Swinton, 1997; Cutts and Steinglass, 1998). The post- 
campaign survey suggests that there remains relatively high prevalence of susceptibility 
in older age groups, e. g. 39% of 7-9 years olds, and 19% of 10-14 years olds. The lower 
immunity levels in the older age groups may be due to historically low routine 
immunization coverage when these groups were eligible and reduced transmission of 
measles virus in the community due to moderate immunization coverage. Records of 
measles coverage of Asela town were reported together with Tiyo district between 1987- 
1995 and cannot be disaggregated. However, we know that in 1990 the national measles 
immunization coverage was 9%. Some of the children aged between 12-14 years were 
not reached by the routine immunization as the Asela routine measles immunization was 
started in 1987. In future, the effectiveness of campaigns might be increased by an 
increase in the age range targeted for supplemental immunization (e. g. up to age 9 or 14 
years). The overall measles immunity in the under 5 years was found to be 77.5% after 
the post-campaign survey. The routine and supplemental immunization activities need to 
be strengthened to increase population immunity in order to establish the protective herd 
immunity Ro -> 93% (Anderson and May, 1991). 
Pre-campaign immunity was 26% in the 9-11 month olds, rising to 59% in 48-65m age 
group. This low level of immunity (average - 48%) in the pre-vaccine age group appears 
not to be due to mothers with recent memory of their child attending for routine measles 
vaccination preferentially deciding not to get them vaccinated in the campaign. In fact 
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routine measles vaccination history was slightly higher in children attending for 
campaign vaccination than those not (Table 6.10). Alternatively, the estimated low-level 
immunity might arise from problems associated with the sensitivity of the assay, for 
example, in vaccinees with lower levels of measles antibody. Finally, it may be that 
vaccine coverage data is unreliable or vaccine is not effectively administered. However, 
our surveys pre- and post-immunization provided estimates of routine vaccination 
coverage of 78% and 74-88%, respectively; somewhat higher than official coverage 
statistics (60-65%). While vaccine failure cannot be ruled out, it would appear than in the 
campaign at least vaccine efficacy was high (- 90%). Further studies to investigate the 
performance of the Microimmune assay in highly vaccinated populations; persons of 
lower vaccine history and in different age groups are required. 
The post-campaign survey shows a lower level of immunity in those who did not attend 
the campaign (79%) compared to those who attended the campaign, which is 91% (Table 
6.10). The pre-vaccine survey shows that 78% of the children did have a history of 
routine vaccination by card and recall (Table 6.9). Similarly in the post-campaign survey 
85.5% of the children had a history of routine vaccination by card and recall (Table 6.10). 
However, in the pre-campaign, of those who said they had been vaccinated (78%), only 
-55% were found to have measles immunity. Official coverage data (Table 6.1) shows 
60-65% through 1997-2001. It is interesting that the post-campaign prevalence of 
immunity in campaign non-attenders (79%) was considerably higher than those of the 
pre-campaign children who attended for campaign vaccination (48%). The explanation 
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for the lower level of immunity observed in the pre-campaign could be due to vaccine 
delivery and efficacy or the assay, as mentioned above. 
An issue to be addressed in evaluating the effectiveness of mass immunization campaigns 
is to assess whether the hard to reach and isolated populations are reached by vaccination 
(Dietz and Cutts, 1997). In this study these groups are not addressed due to the absence of 
community census information. 
Measles, mumps and rubella surveillance based on oral fluid has been routinely 
undertaken in the UK (Ramsay, Brugha and Brown, 1997). The primary role, however, 
remains the confirmation of measles diagnosis by detecting measles specific IgM. This 
study presents a new model to evaluate a measles vaccination campaign using oral-fluid 
antibody surveys. There is only one previous example of a study undertaken to assess 
immunity prevalence using OF following a vaccination campaign, which was a study of 
rubella in Brazil (Azevedo Neto et al., 1995). However, that study used GACRIA, which 
is not easily transferred to developing country laboratories. The present study was 
designed and performed in such a way as to be applicable to the developing country 
context. In essence it uses a simple transferable oral-fluid method (Microimmune OF kit) 
for determining measles specific IgG antibody that opens the way for widespread use in a 
surveillance capacity. An obstacle to the widespread use of OF samples for surveillance 
has been the lack of commercial tests optimised in a ready-to-use kit form. The 
Microimmune IgG capture EIA has been optimised for such purpose. The details of the 
measles survey work activities (see appendix A6) presented in this thesis provide a basis 
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for guidelines for field application of oral-fluid methods. With this regard a generic 
protocol designed to be prepared for the uses of oral fluid in measles vaccine programme 
evaluation would be timely by which to accelerate future application of these methods. 
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A6 (APPENDIX TO CHAPTER 6) 
MEASLES SURVEYS WORK ACTIVITIES 
1. General 
The survey teams played an important role in the success of the study. Each survey team 
comprised 3 members to visit households who received training in sample collection and 
questionnaire delivery. Survey teams who were visiting the household should first 
introduce themselves and obtain informed consent from the head of the household by 
explaining: 
" Title of the research project 
" Basic information about the disease and objective of the study 
" Information about coordinators of the project-they need to describe that although the 
study was coordinated by EHNRI and University of Warwick it was not possibly 
realized without the support of health authorities at regional, zonal and local levels. 
" Information about how the work was carried out 
The interviewers were instructed to pay the maximum effort to obtain the correct answers 
for each question. 
2. Pre-campaign survey and questionnaire 
Prior to the surveys of the campaign visits were made to Asela town to present the study 
plan to local health officials and to administrative officials of the 'kebeles' (urban 
dwellers associations). During these visits effort was made to identify the vaccine 
delivery sites. Local 'kebele' offices were used as vaccine delivery stations over the three 
days period. Of the total 14 stations 7 were selected by simple random sampling (i. e. 
each had equal probability of selection) for the study purpose. At each site we based 2 
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study staff, that were local nurses, who enrolled children (parents/guardian), filled 
questionnaires and collected and labeled specimens. 
In order not to hinder the throughput of children receiving measles vaccine, brief 
questionnaire details were obtained. The one page questionnaire was administered to each 
child prior taking the measles vaccine. Information such as address, name and number of 
vaccination site, number and code of the child, date and lab number were available to the 
survey teams prior administering the questionnaire for each child (includes information 
routinely collected by measles vaccine staff at site). The additional information collected 
on each child including age, sex, parental education level, history of measles infection 
and measles vaccination (see questionnaire 1). 
3. Post-campaign survey and questionnaire 
The sampling frame comprised the register of households at each `kebele'. In Asela town 
there were 14 `kebeles' each with different population size. Seven clusters or `kebeles' 
were selected out of the total 14 by probability proportional to population size (PPS). 
Any individuals from a household aged 9 months to <20 years were eligible for inclusion. 
4. Methods of sample collection 
The last Government census was carried out in 1994 (CSA, 1998). A more recent 
population estimate from 1999 was available, collated by the health center, during active 
surveillance of households before the NIDs. Unfortunately, this more recent surveillance 
was thought to be an underestimate on the basis that it was not performed in a way 
planned for population census. It was therefore thought necessary to use the official 1994 
statistics. The census was then projected for 1999 for the selection of `kebeles' (clusters) 
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with PPS. The process of selection of clusters is described in Table 1 below. The 
population for each `kebele' (column 2) was accumulated (Column 3). The sampling 
interval was calculated from the cumulative total divided by the number of clusters 
required (i. e. 47391/7 = 6770). The starting individual number within the first sampling 
interval was selected by random number table (i. e. random number between 1 and 6770). 
The random number selected for the starting point was 639, i. e. selection of 'kebele' 1. A 
further 6 `kebeles' were selected by sequentially adding the sampling interval to the 
starting number (column 4), i. e. `kebeles' 3,4,6,7,9,11 (column 5).. 
For the household selection within chosen `kebeles', the household registers for each 
kebele were used (Table 1, column 6). Each register lists the number of households with 
a named head of household, number of household members, by sex, number in household 
<5yrs, by sex, and house number. Since there was no community census information 
about the hard to reach population (such as migrants, those living in informal housing, 
etc) it was not possible to include this important group in our study. 
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Table A6.1. Process of selection of 7 clusters from 14 `kebeles' of Asela using PPS. 
Kebele Population Cumulative 
population 
Numbers 
for 
selecting 
clusters 
Cluster Registered 
number of 
household 
s 
1 1481 1481 639 1 280 
2 3472 4953 
3 4255 9208 7409 2 926 
4 5173 14381 14179 3 829 
5 4345 18726 
6 4079 22805 20949 4 652 
7 5636 28441 27719 5 988 
8 2507 30948 
9 5632 36580 34489 6 684 
10 3137 39717 
11 1684 41401 41259 7 319 
12 2207 43608 
13 1055 44663 
14 2728 47391 
Total 47391 
5. Selection of households 
Seventy households were to be selected from each `kebele' using the `kebele' registers. 
The registers were not listed in sequential order as different health workers had 
completed different sections. Each household in each register from a selected 'kebele' 
was given a new number starting at 1. This way the number of households per 'kebele' 
was checked and the households listed suitably for a random selection. Random number 
lists of 70 households were generated using Stata after calculating the proportion of 
households in each `kebele' to be selected. 
6. Household information form 
This form (attached in this appendix) was designed to help organise the field work and 
provide a method of monitoring numbers of samples and questionnaires collected and 
number of households visited. From the `kebele' registers the name of the household and 
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house number were identified and entered by supervisors onto the form created for each 
team of field workers for data collection on households selected. When visiting the 
household it was thought necessary to obtain information on those eligible/ineligible, if 
consent is given, where necessary, and reasons if unavailable. For practical purposes it 
was also useful to note whether samples were collected and questionnaires completed for 
those eligible and if they were not available at the time to note when they would be 
available for revisit. 
7. Questionnaire 3 and 4 for children who participated in the survey 
Questionnaire 3 was for <15 years old children for whom the parents/guardian responded. 
Questionnaire 4 was for children >=15 years, who responded for themselves with or 
without parents. The two questionnaires are similar except the <15 questionnaire asked 
some more information about the history and vaccination status of the children (where it 
was though there would be less recall bias). For some children who were <15 at the time 
of the measles campaign but outside the target age range, some of the questions specific 
to participating in the campaign were not relevant. 
8. Discussion of questionnaires 
The following questions were discussed with the survey teams. 
" Misreporting of age is a common problem in Ethiopia. Very few parents keep record 
of date of birth of their children or issuance of birth certificate is uncommon as most 
births take place at home. In view of these it was discussed to take the necessary 
considerations to avoid misreporting age. Age was therefore imputed either by the 
respondents and/or enumerators on the basis of linking the probable age with some 
presumably known events. 
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" BCG scar: It was decided that it would be useful to check for BCG scar where there 
was only verbal response to whether or not an individual had received the vaccine. 
The interviewers were familiar with what a BCG scar was as they all work in the 
Health Centers. This was the case when the interviewers were asked at the training 
, meeting. 
9. Staffing for the survey 
Three health staffs supervised the survey. Two laboratory personnel from EHNRI, Addis 
Ababa, processed samples. Another 2 laboratory technicians from the Health Center gave 
assistance in the sample processing. Seven teams of 3 (1 for each `kebele') carried out the 
post-campaign survey. Each team had 2 staff from the Health Center and one person 
from the `kebele' office to show the interviewers to the selected houses. Many staffs 
from the Health Center were involved with previous pre-campaign survey so have 
experience both in interviewing and with collecting saliva samples. The health workers 
were known in the community; thus the compliance was likely to be high as families tend 
to be more co-operative with people they know working at health center. 
10. Training session with interviewers from the Health Center 
Distributing consent form, household form and questionnaires to the trainees supported 
training. General explanation was made on each questionnaire and detail on each 
question in the questionnaires was also discussed. The Health Center staffs had a briefing 
before starting the survey that they covered: 
" Establishing those in the household eligible/ineligible (household member defined as 
excluding visitors/live-in helpers of <6 months, as given in Qu. 15 of the <15yrs 
questionnaire) 
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" Verbal consent to be obtained before samples are taken 
" Completion of household information on form 
" Indicating on the form that all is completed for a household or when it may be 
possible to return and finish 
" Collection and labeling of samples. A demonstration of taking a sample was given 
and each interviewer was given a swab to use. Careful labeling was discussed. The 
ID on the sample will be `kebele' number/house number/individual number within 
household. This ID number was entered on the questionnaire, later a separate 
laboratory number will be given to the samples and put on the questionnaires. 
" Each question on the <15 yrs questionnaire was explained and questions answered. 
11. Field work 
7 teams (1 per `kebele') were sent out with questionnaires, household lists, swabs and 
icebox. Transport was co-coordinated to deliver and collect interviewers from the field. 
Supervisors assigned were visited the teams in the field. 
On return 
1. Household forms checked 
2. Samples placed in racks 
3. Questionnaire laboratory specimen number checked with the specimens. Samples and 
questionnaires matched (household members together) and samples put in rack in order 
of questionnaires. 
4. Samples given laboratory number (001 onwards) and the laboratory number was 
written on the front of the corresponding questionnaire. The laboratory number and 
individual household number will be entered with the questionnaire data. 
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5. The questionnaires are then checked by supervisor and the samples processed. 
6. Labels for the sample vials prepared with lab specimen ID ('kebele' number/house 
number/individual number) laboratory number (001 onwards) and date of collection. 
7. Specimens processed and kept at -10°C ready for transport to Addis. 
Initially, on return from the field the supervisors discussed both the household form and 
all questionnaires with the interviewers to check for errors and sort out any problems. 
There were some problems with a few questions initially but by the third round of 
fieldwork most problems were resolved. 
12. Monitoring of fieldwork 
Each day the supervisors visited the survey teams in the field. On return the survey 
teams had the opportunity to discuss problems with the supervisors. 
13. Checking of questionnaire data 
During the survey the questionnaires were not systematically checked. However, once 
the bulk of the fieldwork was completed the supervisors check each questionnaire 
thoroughly and raise any problems with the relevant fieldworkers. It was thought 
essential to check as much as possible in Asela. All questionnaires were checked with 
particular attention given to the first set of questionnaires completed where there were 
some problems with interpretation of the questions. 
14. Completion of survey 
Overall the survey was well organised and well co-coordinated. The interviewers were 
experienced health workers, with knowledge of the community, who worked together 
well. The laboratory staffs were well organised and there were no problems with the 
processing of samples. 
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15. Data Entry 
Epi-Info (Epi-Info version 6.04) was used for data entry. Data was then double entered. 
Two data clerks entered the data from the pre-campaign survey (questionnaire 1) and the 
post-campaign (questionnaires 3 and 4, and household data form. See attached in this 
appendix). Four data entry programs, with check files to assist data entry, have been 
written: 
preform. ges and preform. chk - pre-campaign survey questionnaire 
forml. qes and forml. chk - post-campaign survey questionnaire - <15 years 
form2. qes and form2. chk - post-campaign survey questionnaire - >=15 years 
hhform. ges and hhform. chk - post-campaign survey - household information form 
16. Management of data entry 
Separate pathways were set up for each data entry clerk containing the necessary files for 
data entry. There were two disks with identical data entry files. One set have 'a' in front 
of the file names and the other set V. This should avoid any confusion of files between 
data entry clerks. 
Reliable systems of backup were used. Each data entry clerk, in rotation, used at least 2 
backup disks, so that at worst only work from one entry session would be lost. 
17. Laboratory results 
The laboratory results were entered into an Excel spreadsheet. 
18. Data Analysis 
Epi-Info duplicate files were compared using the 'merge' procedure, and all 
inconsistencies checked. Epi-Info 6 files and Excel files were converted into Stata file 
format and the files were merged for analysis. 
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QUESTIONNAIRE 1 
PRE-CAMPAIGN QUESTIONNAIRE 
Lab. number 
1. Name of static vaccination site Date (GC) 
Number of static vaccination site (IDI) 
2. Child number 
3. Child code (IDI child) 
4. First name of child 
Family name of child _ 
5. Address: 
Woreda 
Kebele 
House no. 
6. Sex 
7. Age in years and months 
8. Parental education 
9. Measles vaccination 
10. If yes to Qu. 9, age at routine measles vaccination (mths) 
11. History of measles infection 
12. Age when measles infection occurred in years and months 
13. Number of children less than 5 years old 
14. How many of these children are receiving vaccine in the campaign 
15. Child received measles vaccine in this campaign 1. Yes 2. No 
Comment 
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QUESTIONNAIRE 2 
HOUSEHOLD INFORMATION FORM 
1. Kebele 
2. Cluster no. 
3. Name of interviewer 
4. Serial no. 
5. Name of household 
6. House no. 
7. Number non-eligible 
8. Number eligible 
9. Number of eligible consented 
10. Reason if not available 
11. Remarks 
Comment 
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QUESTIONNAIRE 3 
QUESTIONNAIRE FOR MEASLES CAMPAIGN EVALUATION 
CHIILDREN LESS THAN 15 YEARS (PARENT RESPOND) 
1. Date of interview (GC)T/ / Name of Interviewer 
2. Zone Woreda Kebele/PA II/No. 
3. Lab. Specimen No 
4. Age of in Months if less than 5 years Age in years if 5 or over 
5. Place of birth : 
1. In Assela town 
6. Born at : 
1. Home 
7. Gender: 
2. Elsewhere (specify) 
2. Hospital 
1. Male 
8. Details of immunization card: 
1. Original 2. Replacement 
9. Vaccination status : 
3. Other (specify) 
2. Female 
3. Lost 4. Never had 
Card: write date Verbal Histor : Y/N 
Routine Campaign Routine Campaign 
BCG 
OPV1 
DPTI 
OPV2 
DPT2 
OPV3 
DPT3 
Booster polio 
doses 
Measles 1 
Measles 2 
Other (specify) 
10. What was the age at vaccination (months) 
11. If yes (vaccinated) to above (9) was the vaccine given in Assella town ? 
1. Yes 2. No 
12. How long lived in Assela town (yrs) 
(0= <1 year, 88= all life) 
13. Is there History of measles disease ? 
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1. Yes 2. No 3. Unknown 
14. If Yes to above (13), What was the age at time of measles infection in months? 
15. Family size (exclude visitors <6 months and helpers (e. g. maid) 
16. Number sleep in same bed (inclusive, i. e. answer must be 1 or more) 
17. Mothers' education level (care taker) : 
1. Unable to read and write 
2. Able to read and write 
3. From 1-6 grade 
4. From 7-12 
5. Above high School 
18. Father's education level : 
1. Unable to read and write 
2. Able to read and write 
3. From 1-6 grade 
4. From 7-12 
5. Above high School 
19. What do you think is the most dangerous disease of children in this area ? 
1.2.3. 
20. EPI disease mentioned in first 3: 
1. Yes 2. No 
21. What diseases are prevented by vaccines? 
Circle number of EPI diseases mentioned 
0123456 
22. What were the vaccines given in the campaign ? 
Polio Y/N 
D PT Y/N 
Anti-TB Y/N 
Measles Y/N 
Other (specify) Y/N 
23. Do you Know of any children who had an abscess after vaccination ? 
1. Own child 2. Neighbour's child 3. Relative's child 4. Other S. None 
24. If yes to above (23) , was this after vaccination 
in the routine program or 
vaccination in the campaign ? 
1. In routine vaccination 2. Campaign vaccination 
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25. If a child has been vaccinated against measles, do you think he/she will later 
catch this disease ? 
1. Yes 2. No 3. Don't know 
26. If yes to above (25), will the illness be equal to, more severe or less severe than in 
unvaccinated child ? 
1. Equal 2. Worse 3. Mild 
27. Has it ever happened that you took your child to be vaccinated but for sonic 
reason the health staff did not vaccinate him ? 
1. Yes 2. No 
28. Did you know about the last national immunization day(s) for polio/measles? 
1. Yes 2. No 
29. If yes to above(28), how did you receive the information? 
1. Neighbor 2. School child 3. Public meeting 
4. Radio 5. Newspaper 6. Posters 
7. Health staff 8. Other 9. More than one of the above 
30. Did you receive prior advice about where to take your child for vaccination 
during last NIDs? 
1. Yes 2. No 
31. How many times did you attend the NIDs last year (circle one)? 
0123 >3 
32. If you didn't take child for vaccination on NIDs, why not? 
1. Away from area 2. No information 3. Inconvenient time 
4. Mother (self) ill 5. Child ill 
Comment 
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QUESTIONNAIRE 4 
QUESTIONNAIRE FOR MEASLES CAMPAIGN EVALUATION 
CHILDREN OVER 15 YEARS OF AGE 
1. Date of interview (G. C)-/ / Name of Interviewer 
2. Zone Woreda Kebele/PA 
3. Lab. Specimen No 
4. Age in years if 15 years or over, 
5. Place of birth : 
1. In Assela town 
6. Born at: 
1. Home 
7. Gender 
2. Elsewhere (specify) 
2. Hospital 
1. Male 
8. Received measles vaccine during last campaign? 
1. Yes 2. No 3. Unknown 
2. Female 
9. Received measles vaccination in the routine EPI Program? 
1. Vaccinated(card) 2. Vaccinated (remember) 3. Not vaccinated 
4. Unknown 
10. What was the age at vaccination (months) 
11. If yes (vaccinated) to above (9) was the vaccine given in Assella town ? 
1. Yes 2. No 
12. How long lived in Assela town (yrs) 
(0= <1 year, 88= all life) 
13. Is there History of measles disease ? 
1. Yes 2. No 3. Unknown 
14. If Yes to above (13), What was the age at time of measles infection in months? 
15. Family size (exclude visitors <6 months and helpers (e. g. maid) 
16. Number sleep in same bed (inclusive, i. e. answer must be 1 or more) 
17. What do you think is the most dangerous disease of children in this area ? 
1.2.3. 
18. EPI disease mentioned in first 3: 
1. Yes 2. No 
H/No. 
3. Other (specify) 
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19. What diseases are prevented by vaccines? 
Circle number of EPI diseases mentioned 
0123456 
20. What were the vaccines given in the campaign ? 
Polio Y/N 
DPT Y/N 
Anti-TB Y/N 
Measles Y/N 
Other (specify) 
21. Do you know of any children who had an abscess after vaccination ? 
1. Own child 2. Neighbor's child 3. Relative's child 
4. Other 
22. If yes to above (21) , was this after vaccination in the routine program or vaccination in the campaign ? 
1. In routine vaccination 2. Campaign vaccination 
23. If a child has been vaccinated against measles, do you think he/she will later catch this 
disease ? 
1. Yes 2. No 3. Don't know 
24. If yes to above (23), will the illness be equal to, more severe or less severe than in 
unvaccinated child ? 
1. Equal 2. Worse 3. Mild 
25. Has it ever happened that you go to be vaccinated but for some reason the health staff 
did not vaccinate you ? 
1. Yes 2. No 
26. Did you know about the last national immunization day(s) for polio/measles? 
1. Yes 2. No 
27. If yes to above(26), how did you receive the information? 
1. Neighbour 2. School child 3. Public meeting 
4. Radio 5. Newspaper 6. Posters 
7. Health staff 8. Other 9. More than one of the above 
180 
CHAPTER 7 
FUTURE DEVELOPMENTS AND APPLICATIONS IN MEASLES ORAL-FLUID 
METHODS 
7.1 Future technical developments 
The low concentration of IgG/IgM antibodies in oral fluid relative to other diagnostic 
specimens such as plasma (Mortimer and Parry, 1988) demanded the development of an 
enhanced immuno assays and of diagnostic techniques based on nucleic acid 
amplification. 
Promotion of the use of oral fluid as viral diagnostic fluid requires that immunological 
assays have higher sensitivity. The development of antibody capture assays, either 1251 
labeled (RIA) or ELISA, that are able to generate higher signals by capturing the 
proportion of specific to the total immunoglobulin (present in the oral fluid), enabled 
saliva to be used for successful immunological assays (Duermeyer et al., 1979; Flehmig 
et al., 1979). Capture ELISA is better for wide-scale use in many laboratories but less 
sensitive than radioimmuno assays. Hence sensitivity enhancement is required to make 
best advantage of ELISA. In this study we developed FITC/anti-FITC enhanced capture 
ELISA that can be used for population and vaccine surveys. 
The production of measles antigen for measles diagnosis, such as the one we used for 
GAC- and MAC-ELISA (see in Chapter 2 and 3), benefited from tissue culture. 
However, production of purified measles antigens in tissue culture can be difficult. The 
capture format has been revolutionised by the raising of purified antigen and monoclonal 
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antibodies for use in oral-fluid measles diagnostics. Cloning and expression of measles 
genes provides a relatively straightforward alternative approach (Hummel et al., 1992; 
Bouche et al., 1998), simplifying purification and enabling large-scale production for 
improvement in measles oral-fluid diagnostic assays. 
Kits based on the use of recombinant antigens such as the Light Diagnostic kit 
(Chemicon Temecula, CA, USA) benefited from the cloning and expression approach. 
More recently IgG and IgM kits specific to measles have been developed based on such 
an alternative approach by Microimmune Ltd (Brentford, Middlesex, UK) for both oral- 
fluid and serum samples. However, there are problems associated with the use of 
recombinant antigens associated with the production of 'incorrectly' processed antigens 
by most expression systems (Hummel et al., 1992; Bouche et al., 1998) and the problem 
of using a single cloned antigen to detect a measles antigen that may vary between 
isolates. This may be resolved by cloning and expressing the most conserved region of 
the measles gene identified from sequence data of different isolates. Notwithstanding this 
problem measles antibody assays that are increasingly based on the use of cloned proteins 
will continue to play a prominent role in oral-fluid diagnostic development. Such 
immuno-assays may be useful in the future when they become better suited to use with 
automated systems that are capable of handling all stages of testing from specimen 
preparation to issuing of diagnostic results. 
Microimmune assays are observed to be easy to use, but have not yet been evaluated 
under a wide range of conditions such as in highly vaccinated populations. Studies of 
rubella revealed problems of sensitivity in enhanced GACELISA in older age groups. 
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This appears to be due to decay in the level of specific antibody in serum and in oral fluid 
(Vyse et al., 1999; Nokes et al., 1998; 2001). Age-related variation in sensitivity was not 
seen as a big problem in measles assays here and previously (Nigatu et al., 1999; Nokes 
et al., 2001). However, low-level measles antibodies resulting from vaccine-induced 
immunity is a feature of many communities, particularly those with high-level routine 
immunizations coverage. Future work is required to evaluate the performance of newly 
developed kit assays in such settings. 
Assays of measles nucleic acid are fundamentally different from those of measles 
antibodies, since they detect a component of the measles virus itself, rather than 
serological evidence of its past presence. Among the several techniques used to detect 
viral nucleic acids the Polymerase Chain Reaction (PCR) is the one widely used for 
detection of measles nucleic acid (Shimizu et al., 1993; Nakagomi et al., 1995; Jin et at, 
1996). In contrast to direct hybridisation, whose application is restricted to where high 
concentration of the virus is present, PCR amplifies the probe signal by means of a 
sequential series of secondary, tertiary, etc. stages. The signal amplification thus 
increases the sensitivity of detection to a range where it can detect viruses at low 
concentration in various specimens (Jin et al., 1996). PCR is suitable for the detection of 
the low concentration of measles virus present in oral fluid. Actually oral fluid is better 
for nucleic acid extraction than serum or blood because of the absence of PCR inhibitors, 
such as haem or porphyrin, in the former (Jin et al., 1996). In addition, oral fluid 
specimens do not need pre-treatment for nucleic acid extraction. In future developments 
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of measles oral-fluid diagnosis based on the nucleic acid amplification systems are likely 
to play an increasing part. 
The new tool developed by Roche Molecular Biochemicals, MagNA Pure LC DNA 
isolation kit, for the isolation of nucleic acid from various types of specimen including 
oral fluid, is a breakthrough that has shortened the tedious manual RNA extraction 
process in measles nucleic acid detection. This is now practised in many laboratories of 
industrialized countries but may be restricted to laboratories that have specialised 
requirements and too costly for most developing countries. The developments of kit- 
based measles oral-fluid molecular diagnostic assays, like the ARMS-EIA (Amplification 
Refractory Mutation System-Enzyme-immunoassay), which is under development at 
CPHL, may place oral-fluid testing within the reach of most diagnostic laboratories. 
ARMS-EIA is a non-sequencing genotyping method for discriminating between closely 
related measles strains. It is as easy as PCR and EIA, and compared to PCR it is time 
saving and does not need interpretation of bands on gels (Dr. Dhan Samuel personal 
communication). 
IgG can be measured in terms of its functional binding avidity. The binding strength 
between the IgG and the virus antigen is supposed to be low in primary infection and 
changes to high in past infection. This avidity can be measured by disrupting the 
interaction using protein denaturants such as urea or diethylamine (Thomas and Morgan- 
Capner, 1991). Diagnosis of primary infection by IgG avidity assay using serum samples 
has got relevance for the diagnosis of viral infection such as rubella (Redman and 
Seppala, 1988; Thomas and Morgan-Capner, 1988). The detection of antibody with low 
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or high avidity enables a more accurate diagnosis in differentiating primary infection 
from past infection. 
IgG avidity is useful when the IgM assay result is indeterminate. It may also help in 
distinguishing primary and secondary ('boosting') response to measles vaccine. Future 
development of IgG avidity in oral-fluid measured by GACELISA may allow specific, 
sensitive and accurate diagnosis of primary infection. Our studies (see Chapter 3) show 
the problem of MACELISA in detecting IgM in oral-fluid samples collected at early onset 
of measles rash. The future development of IgG avidity that can determine IgM in early- 
collected oral fluid samples makes MACELISA better use. 
Another interesting area to look at in the future is the differentiation between antibodies 
resulting from vaccine strain and wild type measles virus. This assists in defining vaccine 
uptake and estimating continued measles transmission. It may be difficult to explain the 
technical development at this stage. However, it is an area for future research. 
Evaluation of a new diagnostic test has the potential sources of bias introduced by the 
study design. The test's discriminatory ability, sensitivity, and specificity depend upon 
the composition of the study population. The study design we used for evaluation of the 
present measles oral- fluid diagnostic assays (see Chapter 2 and 3) is an area that can be 
followed in the future for other viral diagnostic test evaluation. 
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7.2 Future wider applications of oral-fluid methods 
Table 7.1. Setting and details of specific role for non-invasive methods 
Setting for country/district 
Low /Med uptake High uptake routine Campaign 
routine 
Methods: community As previous As previous plus. 
surveys of IgG across Methods: Post-campaign surveys 
wide age range. of IgG and perhaps IgM. 
Population Including hard-to-reach Purpose: IgG - Identify 
survey groups, informal immunity levels post-campaign. 
settlements. Susceptibility in target age group 
Purpose: immunity and outside target group. IgM - 
profiles. Identifies indicator of impact ie proportion 
susceptibility gaps and responding to vaccine. 
age range for Implications: Age-range for 
campaigns. future campaigns; locate 
Implications: increase problems of vaccine efficacy 
in coverage, need for 
and age range for 
A li campaigns pp cat Methods: Vaccine As previous As previous plus. 
clinic samples pre- and Methods: IgG survey of 
ions of Vaccinee post vaccination. IgM 
individuals attending vaccine 
and/or IgG testing. clinics. 
oral- surveys Purpose: Assess Purpose: Identify proportion able 
efficacy of routine to respond to vaccine. 
vaccination. Implications: Assess potential fluid Implications: Identify effectiveness, and suggest 
cause of low efficacy. alternative method for delivery 
methods eg hard-to-reach groups. 
Not indicated while Method: IgM testing on As previous 
Diagnosis measles incidence demand. 
remains high Purpose: Confirmation of 
clinical diagnosis 
Case Not indicated while Method: System of As previous 
surveillan measles transmission reporting and 
OF sampling 
ce: serolog remains 
high from sporadic cases and 
outbreaks. IgM and ical and Genotyping 
genetic Purpose: verify cases, and 
monitor distribution of 
virus and endemicity 
Implications: need for 
additional control measures 
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The application of oral-fluid methods to population surveys, vaccine surveys, diagnosis 
of clinical cases, and case surveillance for different vaccine uptake settings of a 
country/district are illustrated in Table 7.1. 
The following is a description of some of the applications of oral-fluid methods. 
A. Population surveys 
Measles antibody population surveys can used to define the proportions of susceptible 
and immune in the population. Population immunity may result from natural measles 
infection or/and measles routine and campaign vaccination. Current methods cannot 
distinguish between the two. Population immunity surveys can identify in which age 
groups large pockets of susceptibles remain in unvaccinated populations, in a population 
with routine immunization, and before and after a vaccine campaign. This would provide 
valuable information on the age groups to target for vaccination and effectiveness of the 
routine or campaign vaccination, and clues to where future outbreaks might arise. 
Similarly, through such surveys hard-to-reach groups in rural/urban under different 
geographical settings can be reached. 
Population surveys may be appropriate at all stages of vaccination programmes, in 
country/settings of vaccine uptake for low to high, with or without campaigns/accelerated 
measures. Predominantly, such surveys could assess specific antibody status. However, 
post-campaigns there might be a role for IgM testing in community survey to establish 
what proportion of the population actually responded to vaccine. Based on surveys 
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cluster sampling techniques, as for EPI vaccine cluster sampling, and using of the-shelf 
EIA kits, the surveys would be rapid and simple to effect. 
B. Vaccine surveys 
Vaccine surveys assess the level of population immunity attending vaccine clinic to a 
measles routine vaccination. It can identify the responses to routine vaccine in pre- and 
post-vaccinated children. The widespread use of serological determinants of vaccine 
responsiveness is limited by the need to carry out follow up of vaccinees at 2 (IgM) <4 
(IgG) weeks. OF sampling will not improve greatly up on this situation, except that 
compliance for second samples is likely to be greater than if blood samples are required. 
However, the future development of oral-fluid IgG avidity measurement cannot be ruled 
out that may improve this situation. 
C. Diagnosis 
Measurement of measles antibody present in oral-fluid samples provides information on 
the status of current and past infection by use of tests for IgG and IgM antibody. 
Laboratory diagnosis of suspected measles clinical cases can assist in (i) confirmation of 
the occurrence of measles clinical illness (ii) capability of physicians to diagnose illness 
and (iii) reporting of the infection to health department. The usefulness of oral fluid in 
this capacity is at present hindered by the relatively low sensitivity of IgM assays in 
samples taken early after onset of rash. Delay in collecting a sample may be impractical. 
Improved sensitivity of assays remains a need. 
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D. Case surveillance 
The recognition and identification of measles outbreaks and sporadic cases using a 
system of reporting and oral-fluid sampling is established in the UK (Perry et al., 1993; 
Brown et al.; 1994; Ramsay et al., 2003). For measles epidemic investigation in 
Ethiopia, where infrastructure is poor and locations of the remote, oral-fluid sampling 
was found to be appropriate. Especially in the situations where community beliefs or 
attitudes like " measles sick should not get injection" are present, in which communities 
declined to give blood specimens, oral-fluid specimens are preferable. Provided 
reasonable storage conditions while in transit or awaiting transit to the laboratory are 
made, oral-fluid is a robust sample for IgG testing and IgM testing (UK surveillance and 
in these studies in Ethiopia) (Nigatu et al., 1999; Morris M et al., 2002). However, further 
stability studies of OF at different temperature in field conditions are required in the 
future. 
Another area of increasing importance is the application of sequence data obtained from 
oral-fluid nucleic acid amplification techniques. Genetic information is valuable, in 
combination with other traditional epidemiological data, to enhance the ability to 
determine measles transmission pathways and to assess the success of measles control 
strategies (WHO, 2001). 
The practical utility of oral-fluid methods (antibody and genetic) in evaluating and 
refining measles immunization programmes would, additionally, provide support for a 
national surveillance initiative. The utility of OF in a population survey is demonstrated 
189 
in Chapter 6. The use OF in a vaccine sero-conversion study is shown in Chapter 3. OF 
application in molecular epidemiological use is presented in Chapter 4 and 5. In 
summary, in this thesis work it has been possible to demonstrate the utility of oral fluid in 
sero-epidemiological and molecular investigations for measles immunization control 
programs in Ethiopia. It is to be hoped that this work will assist in the wider uptake and 
acceptance of OF methodology, most particularly in the developing country situation, 
within the Africa region and elsewhere. There is a strong case and imperative for the 
promotion of OF methods by WHO in its global programme of control/eradication of 
measles over the coming decade. 
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